<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95887</article-id><article-id pub-id-type="doi">10.7554/eLife.95887</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.95887.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Heterozygous variants in <italic>PLCG1</italic> affect hearing, vision, cardiac, and immune function</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ma</surname><given-names>Mengqi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7345-575X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zheng</surname><given-names>Yiming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Mingxi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Shenzhao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3117-3900</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Xueyang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4453-4971</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Xi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1941-2318</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Etoundi</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li-Kroeger</surname><given-names>David</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6473-7691</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Worley</surname><given-names>Kim C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Burrage</surname><given-names>Lindsay C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Blieden</surname><given-names>Lauren S</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Allworth</surname><given-names>Aimee</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="pa2">§</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Wei-Liang</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="pa3">#</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Merla</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mandriani</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Otten</surname><given-names>Catherine E</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Blanc</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rosenfeld</surname><given-names>Jill A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5664-7987</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Dutta</surname><given-names>Debdeep</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0989-7013</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa4">¶</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Shinya</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2172-8036</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wangler</surname><given-names>Michael F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Glass</surname><given-names>Ian A</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jingheng</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Blue</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Prontera</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rosain</surname><given-names>Jeremie</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Marlin</surname><given-names>Sandrine</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lalani</surname><given-names>Seema R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bellen</surname><given-names>Hugo J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5992-5989</contrib-id><email>hbellen@bcm.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con29"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author"><collab>Undiagnosed Diseases Network</collab><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Molecular and Human Genetics, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05cz92x43</institution-id><institution>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Neurology, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>The Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00md77g41</institution-id><institution>Laboratory of Regulatory &amp; Functional Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza</institution></institution-wrap><addr-line><named-content content-type="city">San Giovanni Rotondo</named-content></addr-line><country>Italy</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05290cv24</institution-id><institution>Department of Molecular Medicine &amp; Medical Biotechnology, University of Naples Federico II</institution></institution-wrap><addr-line><named-content content-type="city">Naples</named-content></addr-line><country>Italy</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/027ynra39</institution-id><institution>Department of Interdisciplinary Medicine, University of Bari &quot;Aldo Moro&quot;</institution></institution-wrap><addr-line><named-content content-type="city">Bari</named-content></addr-line><country>Italy</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01njes783</institution-id><institution>Department of Neurology, University of Washington and Seattle Children’s Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pg5jh14</institution-id><institution>SeqOIA Genomics Platform, Assistance Publique–Hôpitaux de Paris (AP-HP)</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Division of Genetic Medicine, Department of Pediatrics, University of Washington School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03jxvbk42</institution-id><institution>Brotman Baty Institute</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Institute for Public Health Genetics, University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff14"><label>14</label><institution>Medical Genetics and Rare Diseases Unit, Hospital of Perugia</institution><addr-line><named-content content-type="city">Perugia</named-content></addr-line><country>Italy</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05tr67282</institution-id><institution>Laboratory of Human Genetics of Infectious Diseases, Imagine Institute, Necker Hospital for Sick Children</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f82e368</institution-id><institution>Center for the Study of Immune Deficiencies, Necker-Enfants Malades Hospital, AP-HP Centre, University of Paris</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rq3rb55</institution-id><institution>Genetics of Rare Ophthalmological, Auditory and Mitochondrial Disorders, Inserm UMR_S1163, Imagine Institute</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f82e368</institution-id><institution>Reference Center for Genetic Deafness, Department of Genomic Medicine for Rare Diseases, Necker-Enfants Malades Hospital, AP-HP Centre, University of Paris</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nahmad</surname><given-names>Marcos</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/009eqmr18</institution-id><institution>Center for Research and Advanced Studies of the National Polytechnic Institute</institution></institution-wrap><addr-line><named-content content-type="city">Mexico City</named-content></addr-line><country>Mexico</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Desplan</surname><given-names>Claude</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0190ak572</institution-id><institution>New York University</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Invitae Corporation, San Francisco, United States</p></fn><fn fn-type="present-address" id="pa3"><label>#</label><p>Children's National Medical Center and George Washington University, Washington DC, United States</p></fn><fn fn-type="present-address" id="pa4"><label>¶</label><p>Department of Biological Sciences &amp; Bioengineering, and Mehta Family Centre for Engineering in Medicine, Indian Institute of Technology Kanpur, Uttar Pradesh, India</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>27</day><month>08</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP95887</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-02-05"><day>05</day><month>02</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-01-09"><day>09</day><month>01</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.01.08.23300523"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-19"><day>19</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95887.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-07-23"><day>23</day><month>07</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95887.2"/></event></pub-history><permissions><copyright-statement>© 2024, Ma, Zheng et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Ma, Zheng et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-95887-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-95887-figures-v1.pdf"/><abstract><p>Phospholipase C isozymes (PLCs) hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) into inositol 1,4,5-trisphosphate (IP<sub>3</sub>) and diacylglycerol (DAG), important signaling molecules involved in many cellular processes including Ca<sup>2+</sup> release from the endoplasmic reticulum (ER). <italic>PLCG1</italic> encodes the PLCγ1 isozyme that is broadly expressed. Hyperactive somatic mutations of <italic>PLCG1</italic> are observed in multiple cancers, but only one germline variant has been reported. Here, we describe seven individuals with heterozygous missense variants in <italic>PLCG1</italic> [p.(Asp1019Gly), p.(His380Arg), p.(Asp1165Gly), and p.(Leu597Phe)] who present with hearing impairment (5/7), ocular pathology (4/7), cardiac septal defects (3/6), and various immunological issues (5/7). To model these variants <italic>in vivo</italic>, we generated the analogous variants in the Drosophila ortholog, <italic>small wing</italic> (<italic>sl</italic>). We created a null allele <italic>sl<sup>T2A</sup></italic> and assessed its expression pattern. <italic>sl</italic> is broadly expressed, including wing discs, eye discs, and a subset of neurons and glia. <italic>sl<sup>T2A</sup></italic> mutant flies exhibit wing size reductions, ectopic wing veins, and supernumerary photoreceptors. We document that mutant flies also exhibit a reduced lifespan and age-dependent locomotor defects. Expressing wild-type <italic>sl</italic> in <italic>sl<sup>T2A</sup></italic> mutant flies rescues the loss-of-function phenotypes, whereas the variants increase lethality. Ectopic expression of an established hyperactive <italic>PLCG1</italic> variant, p.(Asp1165His) in the wing pouch causes elevated Ca<sup>2+</sup> activity and severe wing phenotypes. These phenotypes are also observed when the p.(Asp1019Gly) or p.(Asp1165Gly) variants are overexpressed in the wing pouch, arguing that these are gain-of-function variants. However, the wing phenotypes associated with p.(His380Arg) or p.(Leu597Phe) overexpression are either mild or only partially penetrant. Our data suggest that the heterozygous missense variants reported here affect protein function differentially and contribute to the clinical features observed in the affected individuals.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Phospholipase C</kwd><kwd><italic>Drosophila</italic></kwd><kwd>phenotypic heterogeneity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>D. melanogaster</italic></kwd><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100017236</institution-id><institution>Huffington Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Bellen</surname><given-names>Hugo J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000179</institution-id><institution>Office of the Director</institution></institution-wrap></funding-source><award-id>R24 OD031447</award-id><principal-award-recipient><name><surname>Bellen</surname><given-names>Hugo J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>U54 NS093793</award-id><principal-award-recipient><name><surname>Bellen</surname><given-names>Hugo J</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000051</institution-id><institution>National Human Genome Research Institute</institution></institution-wrap></funding-source><award-id>U01 HG010233</award-id><principal-award-recipient><institution>Undiagnosed Diseases Network</institution></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>U01 NS134355</award-id><principal-award-recipient><institution>Undiagnosed Diseases Network</institution></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000051</institution-id><institution>National Human Genome Research Institute</institution></institution-wrap></funding-source><award-id>U01 HG007709</award-id><principal-award-recipient><institution>Undiagnosed Diseases Network</institution></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000051</institution-id><institution>National Human Genome Research Institute</institution></institution-wrap></funding-source><award-id>U01 HG007942</award-id><principal-award-recipient><institution>Undiagnosed Diseases Network</institution></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Clinical, genetic, and model organism data collectively define <italic>PLCG1</italic> as a disease-associated gene with diverse missense variants contributing to phenotypic heterogeneity.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The inositol lipid-specific phospholipase C (PLC) isozymes are key signaling proteins that play critical roles in transducing signals from hormones, growth factors, neurotransmitters, and many extracellular stimuli (<xref ref-type="bibr" rid="bib9">Berridge and Irvine, 1984</xref>; <xref ref-type="bibr" rid="bib25">Exton, 1996</xref>; <xref ref-type="bibr" rid="bib5">Balla, 2013</xref>). The PLCs selectively hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) into inositol 1,4,5-trisphosphate (IP<sub>3</sub>) and diacylglycerol (DAG) (<xref ref-type="bibr" rid="bib65">Nishizuka, 1984</xref>; <xref ref-type="bibr" rid="bib60">Majerus et al., 1986</xref>). PIP2 functions as a membrane anchor for numerous proteins and affects membrane dynamics and ion transport (<xref ref-type="bibr" rid="bib38">Hilgemann et al., 2001</xref>; <xref ref-type="bibr" rid="bib39">Hilgemann, 2007</xref>; <xref ref-type="bibr" rid="bib89">Suh and Hille, 2008</xref>). The two products, IP<sub>3</sub> and DAG, are important intracellular second messengers involved in Ca<sup>2+</sup> signaling regulation and protein kinase C signaling activation, respectively (<xref ref-type="bibr" rid="bib66">Nishizuka, 1992</xref>; <xref ref-type="bibr" rid="bib10">Berridge, 1993</xref>). Hence, PLC orchestrates diverse cellular processes and behaviors, including cell growth, differentiation, migration, and cell death (<xref ref-type="bibr" rid="bib102">Yang et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Cocco et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Gomes et al., 2021</xref>; <xref ref-type="bibr" rid="bib3">Asano et al., 2022</xref>). There are at least 13 PLC isozymes grouped in 6 classes (β, δ, ε, γ, η, ζ) in mammals with similar enzymatic function, but each PLC has its own spectrum of activators, expression pattern, and subcellular distribution (<xref ref-type="bibr" rid="bib90">Suh et al., 2008</xref>; <xref ref-type="bibr" rid="bib45">Kadamur and Ross, 2013</xref>; <xref ref-type="bibr" rid="bib47">Katan and Cockcroft, 2020</xref>).</p><p><italic>PLCG1</italic> [MIM: 172420] encodes the PLCγ1 isozyme. PLCγ1 can be directly activated by receptor tyrosine kinases (RTKs) as well as cytosolic receptors coupled to tyrosine kinases (<xref ref-type="bibr" rid="bib33">Gresset et al., 2012</xref>). Upon tyrosine phosphorylation, PLCγ1 undergoes conformational changes that release its autoinhibition upon which it associates with the plasma membrane to bind and hydrolyze its substrates (<xref ref-type="bibr" rid="bib32">Gresset et al., 2010</xref>; <xref ref-type="bibr" rid="bib36">Hajicek et al., 2019</xref>; <xref ref-type="bibr" rid="bib68">Nosbisch et al., 2022</xref>). There is a second PLCγ isozyme, PLCγ2, encoded by <italic>PLCG2</italic> [MIM: 600220]. Although these two isozymes have similar protein structure and activation mechanism, they are differentially expressed and regulated, and play non-redundant roles (<xref ref-type="bibr" rid="bib40">Homma et al., 1989</xref>; <xref ref-type="bibr" rid="bib77">Regunathan et al., 2006</xref>). <italic>PLCG2</italic> is mostly expressed in cells of the hematopoietic system and mainly functions in immune response, causing human diseases associated with immune disorders (<xref ref-type="bibr" rid="bib103">Yu et al., 2005</xref>; <xref ref-type="bibr" rid="bib70">Ombrello et al., 2012</xref>; <xref ref-type="bibr" rid="bib104">Zhou et al., 2012</xref>; <xref ref-type="bibr" rid="bib64">Neves et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">Baysac et al., 2024</xref>). However, <italic>PLCG1</italic> is ubiquitously expressed and is enriched in the central nervous system (CNS) (<xref ref-type="bibr" rid="bib34">GTEx Consortium, 2015</xref>). <italic>P</italic>lcg1 is essential in mice, and a null allele causes embryonic lethality with developmental defects in the vascular, neuronal, and immune system (<xref ref-type="bibr" rid="bib44">Ji et al., 1997</xref>; <xref ref-type="bibr" rid="bib53">Liao et al., 2002</xref>). <italic>PLCG1</italic> has emerged as a possible driver for cell proliferation, and increased expression levels of <italic>PLCG1</italic> have been observed in breast cancer, colon cancer, and squamous cell carcinoma (<xref ref-type="bibr" rid="bib2">Arteaga et al., 1991</xref>; <xref ref-type="bibr" rid="bib67">Noh et al., 1994</xref>; <xref ref-type="bibr" rid="bib72">Park et al., 1994</xref>; <xref ref-type="bibr" rid="bib101">Xie et al., 2010</xref>). Moreover, hyperactive somatic mutations of <italic>PLCG1</italic> have been observed in angiosarcomas and T cell leukemia/lymphomas (<xref ref-type="bibr" rid="bib8">Behjati et al., 2014</xref>; <xref ref-type="bibr" rid="bib49">Kunze et al., 2014</xref>; <xref ref-type="bibr" rid="bib95">Vaqué et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Kataoka et al., 2015</xref>). However, the genotype-phenotype association of germline <italic>PLCG1</italic> variants has yet to be explored.</p><p>Here, we reported seven individuals carrying heterozygous variants in <italic>PLCG1</italic> (GenBank: NM_002660.3) who exhibit partially overlapping clinical features including hearing impairment (5/7), ocular pathology (4/7), cardiac defects (3/6), abnormal brain MRI findings (2/3), and immunological issues with diverse manifestations (5/7). Utilizing <italic>Drosophila</italic> to model the variants <italic>in vivo</italic>, we provide evidence that the missense <italic>PLCG1</italic> variants are toxic and affect protein function to varying degrees. We argue that these variants contribute to the clinical symptoms observed in the affected individuals.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Individuals with heterozygous missense variants in <italic>PLCG1</italic> exhibit hearing impairment, cardiac defects, ocular pathology, and immune dysregulation</title><p>Seven individuals with heterozygous missense variants in <italic>PLCG1</italic> were recruited through the Undiagnosed Diseases Network (UDN) (<xref ref-type="bibr" rid="bib87">Splinter et al., 2018</xref>) (Individuals 1–2) and GeneMatcher (<xref ref-type="bibr" rid="bib85">Sobreira et al., 2015</xref>) (Individuals 3–7). Individual 1 [c.3056A&gt;G, p.(Asp1019Gly)], Individual 2 [c.1139A&gt;G, p.(His380Arg)] and Individual 3 [c.3494A&gt;G, p.(Asp1165Gly)] are <italic>de novo</italic> cases from unrelated families. Individuals 4–7 are from the same family, and all carry the <italic>PLCG1</italic> variant [c.1789C&gt;T p.(Leu597Phe)]. The phenotypes of the individuals partially overlap but show a spectrum of clinical manifestations.</p><p>Briefly, Individual 1 is an 18-year-old male who presented with multiple joint contractures, stiffness, and difficulty with gait. He was also diagnosed with pyloric stenosis, congenital mild hearing loss, bilateral posterior embryotoxon with Axenfeld anomaly, and ventricular septal defect (VSD). Brain MRI revealed stable mild diffuse cerebral and cerebellar volume loss and stable multifocal gliosis within the supratentorial white matter. Spine MRI was consistent with mild caudal regression syndrome. He had gross motor delay, partly related to multiple joint contractures since infancy.</p><p>Individual 2 is a 14-year-old female with left congenital microphthalmia and a right-sided optic nerve hypoplasia. At the age of 11 years, she presented with a slowly progressive relapsing inflammatory encephalomyelitis with optic neuritis and a leukoencephalopathy that was rapidly responsive to corticosteroid treatment but was unable to be withdrawn from the treatment. Her brain MRI showed progressive strikingly symmetric changes, consisting of primarily white matter swelling, persistent diffuse T2 FLAIR, and confluent hyperintensities within the frontoparietal lobes bilaterally. Apart from a slightly reduced NK cell CD56 level (58; normal range 76–800), there was no obvious immunodeficiency identified.</p><p>Individual 3 is a 9-year-old male with a history of intrauterine growth retardation. He had a mild to moderate sensorineural deafness from birth. He also presented with a small subaortic VSD and a wide atrial septal defect (ASD) with left-to-right shunt. He had recurrent pulmonary infections in the first year of life and had an absolute T lymphocytopenia, with normal absolute B lymphocytes. He presented with some facial dysmorphism, such as left eyelid ptosis, downturned mouth, long and flat philtrum, anteverted nostrils, prognathism, and evident veins of the scalp.</p><p>Individual 4 is an 11-year-old female. She presented with bilateral congenital and progressive sensorineural hearing loss, mild motor delay, and a unilateral posterior embryotoxon. She also had a history of joint inflammation, tarsal synovitis, recurrent respiratory and lung infections, as well as inflammatory lymphadenopathy with normal hemato-immunologic tests.</p><p>Individual 5 is the mother of Individual 4. She is 42 years old and had a severe immunologic history starting at the age of 6 years with immune thrombocytopenic purpura, polyarthritis, autoimmune pulmonary fibrosis, pneumococcal sepsis with chronic thrombocytopenia and IgA and IgG2 deficiency. She also presented with congenital ventricular septal defect and a high myopia since adolescence. She experienced sudden bilateral hearing loss during corticosteroid therapy, and by the age of 42 years, she had moderate bilateral sensorineural hearing loss.</p><p>Individual 6 is the brother of Individual 4. He is 13 years old and has a history of recurrent upper respiratory and lung infections due to a mild IgA and IgG2 deficiency. His hearing is normal.</p><p>Individual 7 is the maternal grandfather of Individual 4. He is 66 years old and has moderate bilateral hearing loss starting in adulthood with no other clinical finding.</p><p>A summary of the clinical findings is shown in <xref ref-type="table" rid="table1">Table 1</xref> and detailed case reports are included in Appendix 1.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Clinical features of the affected individuals.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Individual 1</th><th align="left" valign="bottom">Individual 2</th><th align="left" valign="bottom">Individual 3</th><th align="left" valign="bottom">Individual 4</th><th align="left" valign="bottom">Individual 5</th><th align="left" valign="bottom">Individual 6</th><th align="left" valign="bottom">Individual 7</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2"><bold><italic>PLCG1</italic> variants</bold></td><td align="left" valign="bottom">c.3056A&gt;G</td><td align="left" valign="bottom">c.1139A&gt;G</td><td align="left" valign="bottom">c.3494A&gt;G</td><td align="left" valign="bottom">c.1798C&gt;T</td><td align="left" valign="bottom">c.1798C&gt;T</td><td align="left" valign="bottom">c.1798C&gt;T</td><td align="left" valign="bottom">c.1798C&gt;T</td></tr><tr><td align="left" valign="bottom">p.(Asp1019Gly)</td><td align="left" valign="bottom">p.(His380Arg)</td><td align="left" valign="bottom">p.(Asp1165Gly)</td><td align="left" valign="bottom">p.(Leu597Phe)</td><td align="left" valign="bottom">p.(Leu597Phe)</td><td align="left" valign="bottom">p.(Leu597Phe)</td><td align="left" valign="bottom">p.(Leu597Phe)</td></tr><tr><td align="left" valign="bottom"><bold><italic>Inheritance pattern</italic></bold></td><td align="left" valign="bottom"><italic>de novo,</italic> Sanger confirmed</td><td align="left" valign="bottom"><italic>de novo</italic>, Sanger confirmed</td><td align="left" valign="bottom"><italic>de novo</italic>, Sanger confirmed</td><td align="left" valign="bottom">Inherited</td><td align="left" valign="bottom">Inherited</td><td align="left" valign="bottom">Inherited</td><td align="left" valign="bottom">Unknown</td></tr><tr><td align="left" valign="bottom"><bold>Gender</bold></td><td align="left" valign="bottom">Male</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Male</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">Male</td><td align="left" valign="bottom">Male</td></tr><tr><td align="left" valign="bottom"><bold>Age at evaluation</bold></td><td align="char" char="." valign="bottom">18 years</td><td align="char" char="." valign="bottom">14 years</td><td align="char" char="." valign="bottom">9 years</td><td align="char" char="." valign="bottom">11 years</td><td align="char" char="." valign="bottom">42 years</td><td align="char" char="." valign="bottom">13 years</td><td align="char" char="." valign="bottom">66 years</td></tr><tr><td align="left" valign="bottom"><bold>Age of onset</bold></td><td align="left" valign="bottom">Hearing loss since birth; other congenital anomalies recognized in infancy</td><td align="left" valign="bottom">Congenital microphthalmia/optic atrophy; episodic steroid-responsive inflammatory encephalomyelitis/optic neuritis from 11 years</td><td align="left" valign="bottom">Congenital hearing loss and heart defects</td><td align="left" valign="bottom">Congenital</td><td align="char" char="." valign="bottom">6 years</td><td align="left" valign="bottom">Childhood</td><td align="left" valign="bottom">Adulthood</td></tr><tr><td align="left" valign="bottom"><bold>Developmental milestones</bold></td><td align="left" valign="bottom">Motor delays due to joint contractures; speech delay due to hearing loss</td><td align="left" valign="bottom">Developmental history limited; started walking at ~2 yo, articulation from 4 years</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Motor delays</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom"><bold>Hearing</bold></td><td align="left" valign="bottom">Mild hearing loss</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Mild-moderate sensorineural hearing loss</td><td align="left" valign="bottom">Sensorineural bilateral, congenital progressive, profound hearing loss</td><td align="left" valign="bottom">Moderate bilateral sudden and progressive sensorineural hearing loss</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Mild-moderate bilateral sensorineural hearing loss</td></tr><tr><td align="left" valign="bottom"><bold>Vision</bold></td><td align="left" valign="bottom">Axenfeld anomaly bilaterally; posterior embryotoxon</td><td align="left" valign="bottom">Bilateral but variable congenital eye malformation</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Unilateral posterior embryotoxon</td><td align="left" valign="bottom">High myopia</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Normal</td></tr><tr><td align="left" valign="bottom"><bold>Heart</bold></td><td align="left" valign="bottom">Cardiac septal defects (closed spontaneously)</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Ventricular septal defect; atrial septal defect</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Ventricular septal defect</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom"><bold>Brain MRI abnormality</bold></td><td align="left" valign="bottom">Stable mild diffuse cerebral and cerebellar vermian volume loss, stable multifocal gliosis within the supratentorial white matter</td><td align="left" valign="bottom">Relapsing steroid-responsive inflammatory encephalomyelitis and progressive symmetrical white matter changes with swelling, and persistent diffuse T2 hyperintensities (deep and periventricular white matter), and bilateral frontoparietal lobe confluent hyperintensities</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom"><bold>Immunological issues</bold></td><td align="left" valign="bottom">No concerns reported</td><td align="left" valign="bottom">Symmetric steroid-responsive neuroinflammation</td><td align="left" valign="bottom">Lymphocytopenia (T lymphocytes), frequent infections during the first year of life</td><td align="left" valign="bottom">Episodes of joint inflammation, tarsal synovitis, recurrent upper respiratory and lung infections, and inflammatory lymphadenopathy<break/>Routine immunological evaluations revealed no biological abnormalities</td><td align="left" valign="bottom">Mild B lymphopenia, IgG2 severe deficit, splenectomy, post-vaccination sepsis septicemia, several autoimmune clinical manifestations, ITP (immune thrombocytopenic purpura)</td><td align="left" valign="bottom">Normal lymphocytes, IgA and IgG2 mild deficits; frequent oropharynx and lung infections</td><td align="left" valign="bottom">No concerns reported</td></tr><tr><td align="left" valign="bottom"><bold>Skin disorders</bold></td><td align="left" valign="bottom">Multiple lentigines, keratosis pilaris</td><td align="left" valign="bottom">Striae seen over lower abdomen and bilateral inner thighs, possibly secondary to steroid use</td><td align="left" valign="bottom">Thin skin, prominent veins of the scalp</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td></tr><tr><td align="left" valign="bottom"><bold>Joint</bold></td><td align="left" valign="bottom">Joint stiffness/contractures; bilateral coxa profunda; trigger finger, cubitus valgus</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Articular inflammations, tarsus synovitis episodes</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">Normal</td><td align="left" valign="bottom">NA</td></tr><tr><td align="left" valign="bottom"><bold>Dysmorphisms</bold></td><td align="left" valign="bottom">Relative macrocephaly</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Relative macrocephaly, facial dysmorphism</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td></tr><tr><td align="left" valign="bottom"><bold>Short stature</bold></td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td></tr><tr><td align="left" valign="bottom"><bold>Other potential variants</bold></td><td align="left" valign="bottom">Intragenic <italic>PSD3</italic> duplication, paternally inherited</td><td align="left" valign="bottom"><italic>ERAP2</italic> and <italic>SEMA3G</italic> (compound heterozygous variants for both)</td><td align="left" valign="bottom"><italic>de novo</italic> heterozygous missense variant in <italic>PKP2</italic></td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr></tbody></table><table-wrap-foot><fn><p>Individual 1 carries an intragenic duplication in<italic> PSD3</italic>. <italic>PSD3</italic> has not been associated with a Mendelian disorder but is potentially associated with an autosomal dominant arthrogryposis (<xref ref-type="bibr" rid="bib6">Bayram et al., 2016</xref>). Hence, it may underlie the joint defects observed in individual 1.</p></fn><fn><p>Individual 2 has compound heterozygous missense variants in <italic>ERAP2</italic> and <italic>SEMA3G</italic>. <italic>ERAP2</italic> [MIM: 609497] has not been associated with a Mendelian disorder. It encodes an ER-residential metalloaminopeptidase that functions in the major histocompatibility class I antigen presentation pathway. Some variants in <italic>ERAP2</italic> are associated with a susceptibility to autoimmune diseases such as ankylosing spondylitis and Crohn’s disease (<xref ref-type="bibr" rid="bib28">Franke et al., 2010</xref>; <xref ref-type="bibr" rid="bib16">Cortes et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">Ebrazeh et al., 2021</xref>; <xref ref-type="bibr" rid="bib96">Venema et al., 2024</xref>). Given that individual 2 exhibits neuroinflammation and encephalitis, these phenotypes may be associated with the <italic>ERAP2</italic> variants. <italic>SEMA3G</italic> (Semaphorin 3G) has not been associated with a Mendelian disorder. However, a homozygous missense variant in <italic>SEMAG3</italic> was observed in two affected siblings from a consanguineous family. The siblings exhibited dysmorphic features as well as developmental delay (<xref ref-type="bibr" rid="bib69">Oleari et al., 2021</xref>).</p></fn><fn><p>Individual 3 carries a <italic>de novo</italic> missense variant in <italic>PKP2</italic> [MIM: 602861]. <italic>PKP2</italic> encodes Pakophilin-2 and has been associated with dominant arrhythmogenic right ventricular dysplasia 9 [MIM: 609040] (<xref ref-type="bibr" rid="bib30">Gerull et al., 2004</xref>; <xref ref-type="bibr" rid="bib17">Dalal et al., 2006</xref>; <xref ref-type="bibr" rid="bib37">Hakui et al., 2022</xref>). However, this individual was born with septal defects.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>The missense <italic>PLCG1</italic> variants affect conserved protein domains and are predicted to be deleterious</title><p><italic>PLCG1</italic> is predicted to be tolerant to loss-of-function alleles with a pLI (probability of being loss-of-function intolerant) score (<xref ref-type="bibr" rid="bib52">Lek et al., 2016</xref>) of 0.16, suggesting that loss of one copy of the gene is unlikely to cause haploinsufficiency in humans, consistent with the presence of many protein truncating variants in gnomAD (<xref ref-type="bibr" rid="bib46">Karczewski et al., 2020</xref>). However, the missense constraint Z score (<xref ref-type="bibr" rid="bib52">Lek et al., 2016</xref>) of <italic>PLCG1</italic> is 3.69, suggesting that it is intolerant to missense variants. Consistently, all variants are located within regions or stretches depleted in missense variants according to scores such as regional missense constraint (RMC) (<xref ref-type="bibr" rid="bib14">Chao et al., 2024</xref>) or missense tolerance ratio (MTR) (<xref ref-type="bibr" rid="bib91">Sun et al., 2024</xref>). In addition, the prediction based on the DOMINO algorithm indicates that <italic>PLCG1</italic> variants are likely to have a dominant effect (<xref ref-type="bibr" rid="bib75">Quinodoz et al., 2017</xref>). Several other in-silico pathogenicity predictions also suggest that these variants are likely to be pathogenic (<xref ref-type="table" rid="table2">Table 2</xref>) based on MARRVEL (<xref ref-type="bibr" rid="bib100">Wang et al., 2017</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Pathogenicity prediction of the proband variants.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Individual 1</th><th align="left" valign="bottom">Individual 2</th><th align="left" valign="bottom">Individual 3</th><th align="left" valign="bottom">Individual 4–7</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold><italic>PLCG1</italic> variants (NM_002660.2</bold>)</td><td align="left" valign="bottom">c.3056A&gt;G (p.Asp1019Gly)</td><td align="left" valign="bottom">c.1139A&gt;G (p.His380Arg)</td><td align="left" valign="bottom">c.3494A&gt;G (p.Asp1165Gly)</td><td align="left" valign="bottom">c.1789C&gt;T<break/>(p.Leu597Phe)</td></tr><tr><td align="left" valign="bottom"><bold>CADD</bold></td><td align="char" char="." valign="bottom">34</td><td align="char" char="." valign="bottom">26.3</td><td align="char" char="." valign="bottom">34</td><td align="char" char="." valign="bottom">25.7</td></tr><tr><td align="left" valign="bottom"><bold>M-CAP</bold></td><td align="left" valign="bottom">Damaging, 0.7070</td><td align="left" valign="bottom">Damaging, 0.8303</td><td align="left" valign="bottom">Damaging, 0.7607</td><td align="left" valign="bottom">Damaging, 0.5872</td></tr><tr><td align="left" valign="bottom"><bold>PolyPhen2 hDiv</bold><break/>(<bold>rare allele</bold>)</td><td align="left" valign="bottom">Probably Damaging, 0.9120</td><td align="left" valign="bottom">Probably Damaging, 0.7456</td><td align="left" valign="bottom">Probably Damaging, 0.9120</td><td align="left" valign="bottom">Probably Damaging, 0.9058</td></tr><tr><td align="left" valign="bottom"><bold>PolyPhen2 hVar (Mendelian Disease</bold>)</td><td align="left" valign="bottom">Probably Damaging, 0.8948</td><td align="left" valign="bottom">Probably Damaging, 0.6982</td><td align="left" valign="bottom">Probably Damaging, 0.9756</td><td align="left" valign="bottom">Probably Damaging, 0.9737</td></tr><tr><td align="left" valign="bottom"><bold>Mutation Taster</bold></td><td align="left" valign="bottom">Disease Causing</td><td align="left" valign="bottom">Disease Causing</td><td align="left" valign="bottom">Disease Causing</td><td align="left" valign="bottom">Disease Causing</td></tr><tr><td align="left" valign="bottom"><bold>Count in gnomAD</bold></td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td><td align="left" valign="bottom">Absent</td></tr></tbody></table></table-wrap><p>The four variants identified from the affected individuals map to different conserved protein domains of PLCγ1, and each variant affects an amino acid residue that is conserved from flies to humans (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). The p.(Asp1019Gly) and p.(His380Arg) variants map to the catalytic core domains (X and Y regions, respectively), the p.(Asp1165Gly) variant is in the C-terminal C2 domain and the p.(Leu597Phe) variant is in the nSH2 domain. The latter is part of the PLCγ-specific regulatory array composed of a split PH domain (sPH), two Src homology 2 (nSH2 and cSH2) domains, and a Src homology 3 (SH3) domain. PLCγ1 also contains other conserved domains including an N-terminal pleckstrin homology (PH) domain and four EF hand motifs.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The <italic>PLCG1</italic> ortholog is <italic>small wing</italic> (<italic>sl</italic>) in Drosophila.</title><p>(<bold>A</bold>) Schematic of human PLCG1 and fly Sl protein domains and positions of the variants identified in the affected individuals. Domain prediction is based on annotation from NCBI. (<bold>B</bold>) Alignment of protein domains near variants of PLCG1 and PLCG2 with PLCG1 from other species. The variants are marked with boxes. All the variants affect conserved amino acids (labeled in red). Isoforms for alignment: Human PLCG1 NP_877963.1; Human PLCG2 NP_002652.2; Mouse Plcg1 NP_067255.2; Zebrafish plcg1 NP_919388.1; Fly sl NP_476726.2. (<bold>C</bold>) Schematic of fly <italic>sl</italic> genomic span, transcript, alleles, and the 92 kb genomic rescue (GR) construct. Loss-of-function alleles of <italic>sl</italic> including <italic>sl</italic><sup>2</sup> (13 bp deletion, <xref ref-type="bibr" rid="bib93">Thackeray et al., 1998</xref>), <italic>sl<sup>KO</sup></italic> (CRISPR-mediated deletion of the gene span; <xref ref-type="bibr" rid="bib94">Trivedi et al., 2020</xref>), and <italic>sl<sup>T2A</sup></italic> (T2A cassette inserted in the first intron; <xref ref-type="bibr" rid="bib50">Lee et al., 2018</xref>) are indicated. The T2A cassette in <italic>sl<sup>T2A</sup></italic> is flanked by FRT sites and can be excised by Flippase to revert loss-of-function phenotypes. GAL4 expression in <italic>sl<sup>T2A</sup></italic> is driven by the endogenous <italic>sl</italic> promoter, allowing assessment of <italic>sl</italic> gene expression pattern with a <italic>UAS-mCherry.nls</italic> reporter line. This system also allows <italic>in vivo</italic> modeling of proband-associated variants by crossing with human <italic>PLCG1</italic> cDNAs or corresponding fly <italic>sl</italic> cDNAs. The primer pair used for real-time PCR is indicated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Human PLC genes and orthologs in Drosophila.</title><p>In humans, at least 13 genes encoding Phospholipase C isozymes have been identified and classified into 6 protein families, whereas in Drosophila, 2 PLCβ genes and 1 PLCγ gene have been identified. The <italic>small wing</italic> (<italic>sl</italic>) gene is the fly ortholog of human <italic>PLCG1</italic> and <italic>PLCG2</italic>.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-95887-fig1-figsupp1-data1-v1.xls"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Real-time PCR reveals that <italic>sl<sup>T2A</sup></italic> is a loss-of-function allele causing severely reduced mRNA expression of <italic>sl</italic>.</title><p>Relative <italic>sl</italic> mRNA expression levels are &lt;5% and&lt;1% in <italic>sl<sup>T2A</sup></italic> and <italic>sl<sup>KO</sup></italic> mutant larvae when compared to controls (<italic>w<sup>1118</sup></italic>). The primers used for real-time PCR are shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref>. Each dot represents a replicate per genotype. Unpaired t test, ***p&lt;0.001, mean ± SEM.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95887-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig1-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>The <italic>small wing</italic> (<italic>sl</italic>) is the fly ortholog of human <italic>PLCG1</italic></title><p>Flies have three genes encoding PLC isozymes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Among them, <italic>small wing</italic> (<italic>sl</italic>) is predicted to be the ortholog of <italic>PLCG1</italic> with a DIOPT (DRSC Integrative Ortholog Prediction Tool) score of 17/18 (DIOPT version 9.0; <xref ref-type="bibr" rid="bib41">Hu et al., 2021</xref>). The encoded proteins share 39% identity and 57% similarity and are composed of similar conserved domains (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The <italic>sl</italic> gene is also predicted to be the ortholog of <italic>PLCG2</italic> with a DIOPT score of 12/18. These data suggest that <italic>sl</italic> corresponds to two human genes encoding the PLCγ isozymes. To obtain information about the nature of the <italic>PLCG1</italic> variants, we utilize Drosophila to model them <italic>in vivo</italic> using the binary GAL4 system (<xref ref-type="bibr" rid="bib13">Brand and Perrimon, 1993</xref>). We generated transgenic flies carrying the <italic>UAS-human PLCG1</italic> cDNAs for both the reference (<italic>UAS-PLCG1<sup>Reference</sup></italic>) and the variants (<italic>UAS-PLCG1<sup>D1019G</sup></italic>, <italic>UAS-PLCG1<sup>H380R</sup></italic>, <italic>UAS-PLCG1<sup>D1165G</sup></italic>, and <italic>UAS-PLCG1<sup>L597F</sup></italic>). Given the high level of protein sequence homology and the conservation of the affected amino acids (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), we also generated transgenic flies for the reference and analogous variants in the fly <italic>sl</italic> cDNA, namely <italic>UAS-sl<sup>WT</sup></italic> and <italic>UAS-sl<sup>variants</sup></italic> (<italic>UAS-sl<sup>D1041G</sup></italic>, <italic>UAS-sl<sup>H384R</sup></italic>, <italic>UAS-sl<sup>D1184G</sup></italic>, and <italic>UAS-sl<sup>L630F</sup></italic>).</p><p>In Drosophila, <italic>sl</italic> is on the X chromosome, and several alleles of <italic>sl</italic> have been isolated or previously generated, including <italic>sl<sup>2</sup></italic>, <italic>sl<sup>KO</sup></italic>, and <italic>sl<sup>T2A</sup></italic> (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). <italic>sl<sup>2</sup></italic> carries a 13 bp deletion in the third exon that leads to a frameshift and early stop gain (<xref ref-type="bibr" rid="bib93">Thackeray et al., 1998</xref>). <italic>sl<sup>2</sup></italic> is a strong loss-of-function allele that causes small wing size, ectopic wing veins and extra R7 photoreceptors (<xref ref-type="bibr" rid="bib93">Thackeray et al., 1998</xref>). <italic>sl<sup>KO</sup></italic> was generated by CRISPR-mediated genomic editing that removes nearly the entire gene (<xref ref-type="bibr" rid="bib94">Trivedi et al., 2020</xref>). <italic>sl<sup>T2A</sup></italic> allele was generated by inserting an FRT-SA-T2A-GAL4-polyA-FRT cassette as an artificial exon into the first coding intron of <italic>sl</italic> (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; <xref ref-type="bibr" rid="bib20">Diao et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Lee et al., 2018</xref>). The polyA arrests transcription, and <italic>sl<sup>T2A</sup></italic> is a strong loss-of-function allele (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). The T2A viral sequence triggers ribosomal skipping and leads to the production of GAL4 proteins (<xref ref-type="bibr" rid="bib22">Donnelly et al., 2001</xref>; <xref ref-type="bibr" rid="bib19">Diao and White, 2012</xref>) that are expressed in the proper spatial and temporal pattern of <italic>sl</italic>. This allows us to assess the expression pattern of <italic>sl</italic> by driving the expression of a <italic>UAS-fluorescent protein</italic> (<xref ref-type="bibr" rid="bib50">Lee et al., 2018</xref>), or to assess the function of variants by expressing the human <italic>UAS-reference/variant cDNAs</italic> (<xref ref-type="bibr" rid="bib42">Huang et al., 2022a</xref>; <xref ref-type="bibr" rid="bib43">Huang et al., 2022b</xref>; <xref ref-type="bibr" rid="bib55">Lu et al., 2022a</xref>; <xref ref-type="bibr" rid="bib56">Lu et al., 2022b</xref>; <xref ref-type="bibr" rid="bib57">Ma et al., 2023</xref>; <xref ref-type="bibr" rid="bib71">Pan et al., 2023</xref>). In addition, the cassette is flanked by two FRT sites and can therefore be excised from the cells that express the gene in the presence of <italic>UAS-Flippase</italic> to revert the mutant phenotypes (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; <xref ref-type="bibr" rid="bib50">Lee et al., 2018</xref>).</p><p>We first assessed the expression pattern of <italic>sl</italic> by driving <italic>UAS-mCherry.nls</italic> (an mCherry that localizes to nuclei) with <italic>sl<sup>T2A</sup></italic>. <italic>sl</italic> is expressed in the 3<sup>rd</sup> larval wing discs and eye discs (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), consistent with the loss-of-function phenotypes observed in the wings and eyes (<xref ref-type="bibr" rid="bib93">Thackeray et al., 1998</xref>). The expression pattern of <italic>sl</italic> in the wing discs is not homogenous. Higher expression levels are observed in the anterior compartment and along both the anterior/posterior and dorsal/ventral compartment boundaries (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The hemizygous <italic>sl<sup>T2A</sup>/Y</italic> male flies and the trans-heterozygous <italic>sl<sup>T2A</sup>/sl<sup>2</sup></italic> or <italic>sl<sup>T2A</sup>/sl<sup>KO</sup></italic> female flies show reduced wing size and ectopic wing veins (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), as well as additional photoreceptors in the eye (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). These phenotypes can be rescued by <italic>UAS-Flippase</italic> or by introducing a genomic rescue construct (<italic>Dp(1;3)DC313</italic>; <xref ref-type="bibr" rid="bib98">Venken et al., 2010</xref>, <xref ref-type="fig" rid="fig1">Figure 1C</xref>) that covers the <italic>sl</italic> locus (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). These data show that all the observed phenotypes in <italic>sl<sup>T2A</sup></italic> mutants can be attributed to the loss of <italic>sl</italic>.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>sl<sup>T2A</sup></italic> is a loss-of-function allele that affects fly wing and eye development.</title><p>(<bold>A</bold>) <italic>sl</italic> expression in wing and eye discs. Expression of <italic>UAS-mcherry.nls</italic> (red) was driven by <italic>sl<sup>T2A</sup></italic> to label the nuclei of the cells that expressed <italic>sl. sl</italic> is expressed in the 3rd instar larval wing disc (left) and eye disc (right). A higher magnification image of the wing disc pouch region indicated the by dashed rectangle is shown. The posterior/anterior and dorsal/ventral compartment boundaries are indicated by dashed lines in yellow. Scale bars, 100 μm. (<bold>B</bold>) <italic>sl<sup>T2A</sup></italic> cause a wing size reduction and ectopic veins (arrow) in hemizygous mutant male flies. The wing phenotypes can be rescued by introduction of a genomic rescue (GR) construct or the expression of Flippase. Scale bars, 0.5 mm. The quantification of adult wing size is shown in the right panel. Each dot represents the measurement of one adult wing sample. Unpaired t test, ∗∗∗∗p&lt;0.0001, mean ± SEM. (<bold>C</bold>) <italic>sl<sup>T2A</sup></italic> causes extra photoreceptors (arrows) in the hemizygous mutant flies. The eye phenotype can be rescued by introduction of a genomic rescue (GR) construct. The photoreceptor rhabdomeres stain positive for phalloidin labeling F-actin. Scale bars, 10 μm. The quantification is shown in the right panel. Each dot represents the measurement of one retina sample. Unpaired t test, ****p&lt;0.0001, mean ± SEM.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2B and C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95887-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Trans-heterozygous <italic>sl</italic> mutant flies exhibit defects in wing and eye development.</title><p>(<bold>A</bold>) Representative images showing that <italic>sl<sup>T2A</sup></italic>/<italic>sl<sup>2</sup></italic> trans-heterozygous mutant flies have smaller wing and ectopic veins (indicated by arrow). Scale bars, 0.5 mm. (<bold>B</bold>) Representative images showing that <italic>sl<sup>T2A</sup></italic>/<italic>sl<sup>KO</sup></italic> trans-heterozygous mutant flies have extra photoreceptors (indicated by arrows). The schematic of the section of a normal ommatidia presenting seven photoreceptors (the R8 photoreceptor is not visible in such section) is shown. The photoreceptor rhabdomeres stain positive for phalloidin labeling F-actin. Scale bar, 10 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>The <italic>sl</italic> gene is expressed in the fly CNS and loss of <italic>sl</italic> causes longevity and locomotion defects</title><p>Given that human <italic>PLCG1</italic> is highly expressed in the CNS (<xref ref-type="bibr" rid="bib34">GTEx Consortium, 2015</xref>) and that the affected individuals present with neurologic phenotypes including hearing or vision deficits (<xref ref-type="table" rid="table1">Table 1</xref>), we investigated the expression pattern and the cell type specificity of <italic>sl</italic> in the CNS of flies. <italic>sl</italic> is expressed in the larval CNS as well as the adult brain, and co-staining with the pan-neuronal marker Elav (<xref ref-type="bibr" rid="bib79">Robinow and White, 1991</xref>) and glial marker Repo (<xref ref-type="bibr" rid="bib82">Sepp et al., 2001</xref>) shows that <italic>sl</italic> is expressed in many neurons and glia cells in the CNS (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We therefore assessed the longevity and climbing of <italic>sl<sup>T2A</sup></italic> flies. Compared to the wild-type <italic>w<sup>1118</sup></italic> flies, <italic>sl<sup>T2A</sup>/Y</italic> hemizygous mutant flies show a shortened lifespan and a progressively reduced climbing ability. These phenotypes can be rescued by expression of the wild-type <italic>sl</italic> cDNA (<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>WT</sup></italic>; <xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>sl</italic> is expressed in a subset of neurons and glia in the CNS, and loss of <italic>sl</italic> causes behavioral defects.</title><p>(<bold>A</bold>) Expression pattern of <italic>sl</italic> in the central nervous system observed by <italic>sl<sup>T2A</sup></italic>-driven expression of <italic>UAS-mCherry.nls</italic> reporter (red). In either larval or adult brain, <italic>sl</italic> is expressed in a subset of fly neurons and glia, which were labeled by pan-neuronal marker Elav (green, upper panel) and pan-glia marker Repo (green, lower panel). Higher magnification images of the regions indicated by dashed rectangles are shown. Scale bars, 20 μm in the magnified images, 50 μm in other images. (<bold>B</bold>) Loss of <italic>sl</italic> causes defects in longevity and locomotion. <italic>sl<sup>T2A</sup></italic> hemizygous flies have a shorter lifespan than <italic>w<sup>1118</sup></italic> control flies. The median lifespan of <italic>sl<sup>T2A</sup></italic> and <italic>w<sup>1118</sup></italic> flies is 40 days and 62 days, respectively. The shorter lifespan of <italic>sl<sup>T2A</sup></italic> flies can be rescued by a UAS transgene that expresses the wild-type <italic>sl</italic> cDNA (<italic>sl<sup>WT</sup></italic>). Fly locomotion was assessed by climbing assay (see Materials and methods). <italic>sl<sup>T2A</sup></italic> flies at the age of 7 days show reduced locomotion and become almost immotile at the age of 35 days. The reduced locomotion ability in <italic>sl<sup>T2A</sup></italic> flies can be fully rescued by <italic>sl<sup>WT</sup></italic>. For lifespan assay, Longrank test, ****p&lt;0.0001; sample size n=114, 115, and 125 for <italic>w</italic><sup><italic>1118</italic></sup>, <italic>sl<sup>T2A</sup></italic>, and <italic>sl</italic><sup><italic>T2A</italic></sup>&gt;<italic>sl</italic><sup><italic>WT</italic></sup> flies, respectively. For climbing assay, each dot represents a measurement of one vial containing 17–22 flies for test. Unpaired t test, ****p&lt;0.0001, mean ± SEM.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95887-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig3-v1.tif"/></fig></sec><sec id="s2-5"><title>Functional assays in flies indicate that the <italic>PLCG1</italic> variants are toxic</title><p>To assess the impact of the variants, we expressed the <italic>sl</italic> variant cDNAs in the <italic>sl<sup>T2A</sup>/Y</italic> hemizygous mutant males (<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>variants</sup></italic>) and compared their rescue ability with the wild-type <italic>sl</italic> (<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>WT</sup></italic>). As shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref> (middle panel), the <italic>sl<sup>T2A</sup>/Y</italic> mutant flies (or the ones expressing a <italic>UAS-Empty</italic> control construct) have a slightly reduced eclosion rate, but expression of the <italic>sl<sup>WT</sup></italic> cDNA fully rescues the percentage of eclosing progeny as measured by the Mendelian ratio. In contrast, expression of <italic>sl<sup>L630F</sup></italic> (<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>L630F</sup></italic>) reduced the percentage of hemizygous male progeny from the expected 25% to approximately 17%, while expression of <italic>sl<sup>H384R</sup></italic> causes a severe reduction in the number of eclosing flies, with only a few escapers (<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>H384R</sup></italic>). Expression of the <italic>sl<sup>D1041G</sup></italic> or <italic>sl<sup>D1184G</sup></italic> leads to 100% lethality. These data clearly indicate that these variants are toxic but at different levels.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The human and corresponding fly variants are toxic when expressed in flies.</title><p>(<bold>A</bold>) Summary of the viability associated with expression of <italic>sl</italic> cDNAs in <italic>sl<sup>T2A</sup></italic> mutant or heterozygous flies. Cross strategy: heterozygous <italic>sl<sup>T2A</sup></italic> female flies were crossed to male flies carrying <italic>UAS-cDNAs</italic> or control (<italic>UAS-Empty</italic>) constructs, or crossed to the <italic>y w</italic> males as an extra control. The percentages of hemizygous <italic>sl<sup>T2A</sup>/Y</italic> male progeny (red) or <italic>sl<sup>T2A</sup>/yw</italic> heterozygous female progeny (blue) that express different <italic>UAS-cDNA</italic> constructs were calculated. The expected Mendelian ratio is 0.25 (indicated by the green line in the graph). The fly analogue variants of the proband-associated variants were tested. Each dot represents one independent replicate. Unpaired t test, ****p&lt;0.0001, **p&lt;0.01, *p&lt;0.05, ns: not significant, mean ± SEM. (<bold>B</bold>) Summary of the viability associated with the expression of <italic>PLCG1</italic> cDNAs in <italic>sl<sup>T2A</sup></italic> mutant (red, males) or heterozygous (blue, females) flies. The same cross strategy and progeny ratio measurement described in (<bold>A</bold>) was applied. The proband-associated variants, as well as three previously reported <italic>PLCG1</italic> variants were assessed. We also included the <italic>PLCG2</italic> reference cDNA. Each dot represents one independent replicate. Unpaired t test, **p&lt;0.01, *p&lt;0.05, ns: not significant, mean ± SEM.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4">Figure 4A and B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95887-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Proband-associated variants exhibit deleterious impacts in adults.</title><p>(<bold>A</bold>) Cross strategy of the temperature shifting assay to express <italic>UAS-sl</italic> cDNAs only in the adult stages. GAL80<sup>ts</sup> is a temperature-sensitive inhibitor of GAL4, which allows temporal control of <italic>UAS-</italic> transgene expression by temperature manipulation. <italic>GAL80<sup>ts</sup></italic> represses GAL4 activity at the permissive temperature (18°C) but becomes inactive at restrictive temperature (29°C), thereby allowing GAL4 to activate expression of <italic>UAS-transgenes</italic>. In this assay, <italic>Tub-GAL4, Tub-GAL80<sup>ts</sup></italic> driver was used to express wild-type or variant <italic>sl cDNAs</italic> specifically in adult flies by shifting the temperature after eclosion. (<bold>B</bold>) Adult-stage expression of <italic>sl</italic> variants induces lifespan reduction. The adult flies with expression of <italic>sl<sup>D1184G</sup></italic> mostly die within 1 week after eclosion. The flies expressing <italic>sl<sup>D1041G</sup></italic> or <italic>sl<sup>H384R</sup></italic> have median lifespans of approximately 21 days and 26 days, respectively, both shorter than those expressing <italic>sl<sup>WT</sup></italic>, which have a median lifespan of 31 days. The sample size for each genotype is indicated (n). Longrank test, ****p&lt;0.0001. (<bold>C</bold>) Adult-stage expression of <italic>sl<sup>D1041G</sup></italic> induces some locomotion defect. Flies aged to 20 days were assessed for locomotor ability using a climbing assay. The expression of <italic>sl<sup>H384R</sup></italic> did not induce significant difference compared to <italic>sl<sup>WT</sup></italic>. We did not test <italic>sl<sup>D1184G</sup></italic> as the flies are short-lived. Each dot represents the measurement of one fly. Unpaired t test, *p&lt;0.05, ns: not significant, mean ± SEM. These results suggest that the two strong variants (<italic>sl<sup>D1041G</sup></italic> and <italic>sl<sup>D1184G</sup></italic>) contribute to both developmental and acute effects while the <italic>sl<sup>H384R</sup></italic> variant mainly contributes to developmental stages.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95887-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>The toxicity of human <italic>PLCG1</italic> cDNAs in flies correlates with expression levels.</title><p>(<bold>A</bold>) Summary of the eclosion rate of animals expressing <italic>sl</italic> cDNAs in <italic>sl<sup>T2A</sup></italic> mutant (left panel) or heterozygous (right panel) flies at 22°C. The phenotypes are similar to, but slightly milder compared to the same assays performed at 25°C (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> caused lethality in both conditions, whereas expression of <italic>PLCG1<sup>Reference</sup></italic>, <italic>PLCG1<sup>H380R</sup></italic>, or <italic>PLCG1<sup>L597F</sup></italic> led to reduced eclosion rate in mutant hemizygous but not in heterozygous flies. Each dot represents one independent replicate. Unpaired t test, ****p&lt;0.0001, ***p&lt;0.001, *p&lt;0.05, ns: not significant, mean ± SEM. (<bold>B</bold>) Summary of the viability of expressing <italic>PLCG1<sup>Reference</sup></italic> ubiquitously using <italic>Tub-GAL4</italic>. Expression levels of the <italic>UAS-PLCG1<sup>Reference</sup></italic> transgenes can be manipulated at different temperatures. (<bold>C</bold>) Summary of the viability of expressing <italic>PLCG1</italic> reference and variant cDNAs using a weak ubiquitous driver <italic>da-GAL4</italic>. Expression levels of the <italic>UAS- PLCG1<sup>Reference</sup></italic> transgenes can be manipulated at different temperatures. (<bold>D</bold>) Representative images of the pupae of <italic>da-GAL4&gt;UAS-PLCG1 cDNAs</italic> flies at 25°C. Expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> caused reduced pupal size. Scale bars, 0.5mm.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95887-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Expressing human <italic>PLCG1</italic> does not rescue wing or eye phenotypes associated with <italic>sl<sup>T2A</sup></italic>.</title><p>Representative images showing the adult wings (upper panel) and the photoreceptors (lower panel) expressing <italic>PLCG1<sup>Reference</sup></italic> or <italic>sl<sup>WT</sup></italic>. Expression of <italic>sl<sup>WT</sup></italic> rescues the loss-of-function phenotypes including wing size reduction, ectopic veins (indicated by red arrows) and extra photoreceptors (indicated by yellow arrows), whereas expression of the <italic>PLCG1<sup>Reference</sup></italic> or <italic>UAS-Empty</italic> shows no rescue. Scale bars, 0.5 mm for the wing images and 10 μm for the photoreceptor images. The photoreceptor rhabdomeres stain positive for phalloidin labeling F-actin. Quantification of the wing size (upper right panel) and the photoreceptors (lower right panel) is shown. Each dot represents a measurement of one wing or retina sample, respectively. Unpaired t test, ***p&lt;0.001, *p&lt;0.05. ns: not significant.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95887-fig4-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig4-figsupp3-v1.tif"/></fig></fig-group><p>Since the <italic>sl<sup>T2A</sup>/Y; UAS-cDNA</italic> hemizygous males lack the endogenous <italic>sl<sup>+</sup>,</italic> we tested <italic>sl<sup>T2A</sup>/yw; UAS-cDNA</italic> heterozygous female flies that carry a copy of wild-type <italic>sl<sup>+</sup></italic> while simultaneously expressing <italic>UAS-cDNAs</italic> driven by the <italic>sl<sup>T2A</sup></italic> driver in the cells that endogenously express <italic>sl</italic> (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, right panel). The eclosion rates of heterozygous female progeny expressing <italic>sl</italic> variants were significantly reduced compared to those expressing <italic>sl<sup>WT</sup></italic>. Expression of <italic>sl<sup>H384R</sup></italic> or <italic>sl<sup>L630F</sup></italic> in the heterozygous progeny reduced the expected 25% proportion to approximately 10% and 20%, respectively, whereas expression of <italic>sl<sup>D1041G</sup></italic> or <italic>sl<sup>D1184G</sup></italic> resulted in complete lethality in heterozygous flies. These results suggest that the missense variants exert a dominant toxic effect. Additionally, we observed that the toxicity may have both developmental and acute effects in adults, with varying severity among the different variants (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), indicating that <italic>sl</italic> function is required in adult flies, implying that <italic>PLCG1</italic> variants may cause long-term deficits in affected individuals.</p><p>To compare the <italic>sl</italic> and <italic>PLCG1</italic>-associated phenotypes, we conducted similar assays using human <italic>PLCG1</italic> cDNAs (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Expression of <italic>PLCG1<sup>Reference</sup></italic> in the <italic>sl<sup>T2A</sup>/Y</italic> mutant flies (<italic>sl<sup>T2A</sup>/Y; UAS-PLCG1<sup>Reference</sup></italic>) reduces viability by 80%, and expression of the other PLCγ coding gene, <italic>PLCG2</italic>, is also toxic and causes similar viability reduction compared to <italic>PLCG1<sup>Reference</sup></italic>. This suggests that expression of human PLCγ genes is toxic in flies. This toxicity appears to be associated with expression level (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), and the survivals of <italic>sl<sup>T2A</sup>/Y; UAS-PLCG1<sup>Reference</sup></italic> did not show rescue of the loss-of-function phenotypes in the wings or eyes (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Expression of <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic> in the <italic>sl<sup>T2A</sup>/Y</italic> mutant flies (<italic>sl<sup>T2A</sup>/Y; UAS-PLCG1<sup>H380R</sup></italic> or <italic>sl<sup>T2A</sup>/Y; UAS-PLCG1<sup>L597F</sup></italic>) leads to a significant but very modest increase in lethality when compared to <italic>PLCG1<sup>Reference</sup></italic>, whereas expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> results in 100% lethality (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, left panel). When the reference and variants are assayed in the presence of a wild-type copy of <italic>sl<sup>+</sup>,</italic> the heterozygous female progeny expressing the reference cDNA of <italic>PLCG1</italic> or <italic>PLCG2</italic> exhibited normal eclosion rate, as did the ones expressing <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic>, suggesting that the presence of a wild-type copy of <italic>sl<sup>+</sup></italic> combined with the reduced expression levels (typically 50% due to dosage compensation for the genes on X chromosome) masks some of the potential toxicity. However, expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> still resulted in complete lethality in the females (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, right panel). In summary, expression of the <italic>PLCG1</italic> variants and the corresponding fly <italic>sl</italic> variants exhibits greater toxicity than the reference or wild-type proteins with varying degrees of severity, suggesting that the variants are likely to be gain-of-function or neomorphic alleles. Among them, the <italic>PLCG1<sup>D1019G</sup></italic> and <italic>sl<sup>D1041G</sup></italic>, as well as <italic>PLCG1<sup>D1165G</sup></italic> and <italic>sl<sup>D1184G</sup></italic>, are very strong toxic alleles, whereas <italic>PLCG1<sup>H380R</sup>, PLCG1<sup>L597F</sup>,</italic> and their fly analogues are mild variants.</p></sec><sec id="s2-6"><title>The p.(Asp1019Gly) and p.(Asp1165Gly) variants are hyperactive</title><p>To assess whether the variants act as gain-of-function alleles that enhance the enzymatic activity of the PLCγ1 isozyme, we tested them using a Ca²<sup>+</sup> reporter assay. Since one of the products of the PLCγ1 isozyme, IP₃, binds to receptors on the endoplasmic reticulum to trigger Ca²<sup>+</sup> release (<xref ref-type="bibr" rid="bib27">Foskett et al., 2007</xref>), intracellular Ca²<sup>+</sup> levels can serve as a proxy of the PLCγ1 enzymatic activity. We expressed the <italic>CaLexA</italic> (calcium-dependent nuclear import of LexA) reporter (<xref ref-type="bibr" rid="bib62">Masuyama et al., 2012</xref>) in the wing disc pouch region using a specific GAL4 driver (<italic>nub-GAL4&gt;UAS-CaLexA.GFP</italic>) while simultaneously expressing <italic>UAS-PLCG1</italic> cDNAs. We first assessed three control variants: <italic>PLCG1<sup>H380A</sup>, PLCG1<sup>D1165H</sup>,</italic> and <italic>PLCG1<sup>S1021F</sup></italic>. Substitution of His380 with Ala (H380A) has been reported to suppress PIP<sub>2</sub> hydrolysis and IP<sub>3</sub> production (<xref ref-type="bibr" rid="bib84">Smith et al., 1994</xref>; <xref ref-type="bibr" rid="bib99">Wada et al., 2022</xref>), acting as an enzymatic-dead loss-of-function allele. On the other hand, the p.(Asp1165His) (D1165H) variant was previously identified as a strong gain-of-function somatic variant in adult T cell leukemia/lymphoma (<xref ref-type="bibr" rid="bib48">Kataoka et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Hajicek et al., 2019</xref>; <xref ref-type="bibr" rid="bib83">Siraliev-Perez et al., 2022</xref>), and has been documented to cause a dramatic increase in phospholipase activity <italic>in vitro</italic> (<xref ref-type="bibr" rid="bib36">Hajicek et al., 2019</xref>; <xref ref-type="bibr" rid="bib83">Siraliev-Perez et al., 2022</xref>). The p.(Ser1021Phe) variant was reported recently in a <italic>de novo</italic> case and was characterized as a gain-of-function germline variant (<xref ref-type="bibr" rid="bib92">Tao et al., 2023</xref>). As shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>, the GFP signal of the <italic>CaLexA.GFP</italic> reporter was low in wing discs expressing <italic>PLCG1<sup>H380A</sup></italic>, whereas the signal was significantly enhanced in those expressing <italic>PLCG1<sup>D1165H</sup> or PLCG1<sup>S1021F</sup></italic>, showing that this is a robust assay for detecting increased enzymatic activity. We next tested the variants of the affected individuals. As shown in <xref ref-type="fig" rid="fig5">Figure 5A</xref>, expression of <italic>PLCG1<sup>Reference</sup></italic> did not induce obvious GFP signals, suggesting that the protein is not enzymatically active, possibly because of autoinhibition. Similarly, expression of <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic> did not significantly alter the GFP signal, suggesting that they are not constitutively active. However, expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> markedly increased the GFP signal, similar to the <italic>PLCG1<sup>D1165H</sup></italic> and <italic>PLCG1<sup>S1021F</sup></italic> positive controls (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). The same observations were made with the fly <italic>sl</italic> variants (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). These results indicate that the <italic>PLCG1<sup>D1019G</sup></italic> and <italic>PLCG1<sup>D1165G</sup></italic> variants are hyperactive, whereas the <italic>PLCG1<sup>H380R</sup></italic> and <italic>PLCG1<sup>L597F</sup></italic> variants are not hyperactive based on this assay.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Ectopic expression of <italic>PLCG1</italic> variants causes variable phenotypes.</title><p>(<bold>A</bold>) The Ca<sup>2+</sup> reporter <italic>CaLexA.GFP</italic> was expressed in the wing disc pouch, simultaneously with the <italic>PLCG1</italic> cDNAs. Expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> caused elevated CaLexA.GFP signal (green), indicating increased intracellular Ca<sup>2+</sup> levels, indicating that these variants are hyperactive. Nuclei were labeled with DAPI (blue). Scale bars, 100 μm. (<bold>B</bold>) Representative images of the adult wing blades showing the morphological phenotypes caused by wing-specific expression of <italic>PLCG1</italic> cDNAs. Expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> caused severe wing morphology defects including notched margin (arrows) and fused/thickened veins (arrowheads). Expression of <italic>PLCG1<sup>L597F</sup></italic> exhibited partial penetrance. Expression of <italic>PLCG1<sup>H380R</sup></italic> exhibited very mild phenotypes, comparable to <italic>PLCG1<sup>Reference</sup></italic>. Scale bars, 0.5 mm. (<bold>C</bold>) Representative images showing that eye-specific expression of <italic>PLCG1<sup>Reference</sup></italic> or <italic>PLCG1<sup>H380R</sup></italic> causes an ~15% eye size reduction compared to the <italic>UAS-Empty</italic> control construct, and expression of <italic>PLCG1<sup>L597F</sup></italic> further reduced eye size. Expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> causes a severe size reduction by ~30%. Scale bars, 100 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Intracellular Ca<sup>2+</sup> reporter assay suggests that the p.(Asp1019Gly) and p.(Asp1165Gly) are hyperactive variants.</title><p>(<bold>A</bold>) Three previously reported <italic>PLCG1</italic> variants (<italic>PLCG1<sup>H380A</sup></italic>, <italic>PLCG1<sup>D1165H</sup></italic>, and <italic>PLCG1<sup>S1021F</sup></italic>) were tested as controls. The Ca<sup>2+</sup> reporter <italic>CaLexA.GFP</italic> was co-expressed with <italic>PLCG1</italic> cDNAs in the wing disc pouch region. Expression of <italic>PLCG1<sup>D1165H</sup></italic> or <italic>PLCG1<sup>S1021F</sup></italic> caused elevated CaLexA.GFP signal (green), whereas expression of <italic>PLCG1<sup>H380A</sup></italic> did not. Nuclei were labeled with DAPI (blue). Insets show merged images of DAPI and GFP channels. Scale bars, 100 μm. (<bold>B</bold>) The fly variants were analyzed using the <italic>CaLexA.GFP</italic> reporter. Expression of <italic>sl<sup>D1041G</sup></italic> or <italic>sl<sup>D1184G</sup></italic> caused elevated CaLexA.GFP signal (green), similar to the corresponding <italic>PLCG1</italic> variants. Note that the wing discs expressing <italic>sl<sup>D1184G</sup></italic> are morphologically aberrant and have a diminished GFP signal. Nuclei were labeled with DAPI (blue). Insets show merged images of DAPI and GFP channels. Scale bars, 100 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Wing and eye phenotypes associated with ectopic expression of <italic>PLCG1</italic> variants.</title><p>(<bold>A</bold>) Quantification of the wing blade size in non-notched wings from the samples overexpressing <italic>PLCG1<sup>Reference</sup></italic> or <italic>sl<sup>WT</sup></italic>. Wing-specific expression of <italic>PLCG1<sup>Reference</sup></italic> or <italic>sl<sup>WT</sup></italic> caused an approximate 15% wing size reduction compared to the <italic>UAS-Empty</italic> control construct. Each dot represents one measured adult wing. Unpaired t test, ****p&lt;0.0001, mean ± SEM. (<bold>B</bold>) Quantification of the percentage of adult wings with margin notching phenotype. Wing-specific expression of <italic>PLCG1<sup>Reference</sup></italic> caused ~10% wings to display a notched margin. Expression of <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic> caused approximately 18% and 23% of the wings to display notched margins, respectively. Expression of the enzymatic-dead <italic>PLCG1<sup>H380A</sup></italic> caused less than 10% wings with notched margin, whereas expression of the hyperactive <italic>PLCG1<sup>S1021F</sup></italic> is not significantly different from <italic>PLCG1<sup>Reference</sup></italic>. Each dot represents one independent replicate. The total number of flies (N) was counted per genotype. Unpaired t test, ***p&lt;0.001, **p&lt;0.01, ns: not significant, mean ± SEM. (<bold>C</bold>) Representative images of adult wing blades showing morphological phenotypes caused by wing-specific expression of <italic>sl</italic> cDNAs. Expression of <italic>sl<sup>D1041G</sup></italic> caused severe wing defects including notched margins (arrows). Expression of <italic>sl<sup>H384R</sup></italic> or <italic>sl<sup>L630F</sup></italic> exhibited partial penetrance. Expression of <italic>sl<sup>D1184G</sup></italic> caused lethality before eclosion. Scale bars, 0.5 mm. (<bold>D</bold>) Quantification of eye size with expression of <italic>PLCG1</italic> cDNAs. Eye size were normalized to the size of the <italic>ey-GAL4&gt;UAS-Empty</italic> control. Each dot represents the measurement of one adult eye. Unpaired t test, ****p&lt;0.0001, *p&lt;0.05, ns: not significant, mean ± SEM. (<bold>E</bold>) Representative images showing that wing-specific expression of <italic>PLCG1<sup>D1165H</sup></italic> caused similar but more severe morphological phenotypes compared to <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic>. Expression levels of <italic>UAS-cDNA</italic> can be manipulated by raising the animals at different temperatures. Scale bars, 0.5 mm. (<bold>F</bold>) Representative images showing the phenotypes associated with ectopic expression of the control <italic>PLCG1</italic> variants. Expression of <italic>PLCG1<sup>H380A</sup></italic> or <italic>PLCG1<sup>S1021F</sup></italic> did not induce obvious morphological phenotypes in adult wings or eyes compared to <italic>PLCG1<sup>Reference</sup></italic>, whereas no eclosed adults were collected when overexpressing <italic>PLCG1<sup>D1165H</sup></italic> at 29°C in these contexts. Scale bars, 0.5 mm for wing images, 100 μm for eye images.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95887-fig5-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig5-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-7"><title>The <italic>PLCG1</italic> variants affect size and morphology of wings and eyes</title><p>To further assess the impact of the <italic>PLCG1</italic> variants on normal development, we analyzed the morphology of the adult wings upon wing-specific expression of <italic>PLCG1</italic> or <italic>sl</italic> cDNAs (<italic>nub-GAL4&gt;UAS-cDNAs</italic>). Interestingly, ectopic expression of either <italic>PLCG1<sup>Reference</sup></italic> or <italic>sl<sup>WT</sup></italic> in the wing disc leads to an ~10% reduction in adult wing size when compared to the <italic>UAS-Empty</italic> control (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>). This observation, together with the reduced wing size seen in the loss-of-function context (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), suggests that both reduced and elevated levels of PLCγ1 can impair wing growth. This implies a dosage-dependent regulation on wing growth by the PLCγ1 isozymes, while the underlying mechanism is unknown. Additionally, as shown in <xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>, approximately 10% of the wings expressing <italic>PLCG1<sup>Reference</sup></italic> exhibit notching along the wing margin, a phenotype not observed in wings expressing <italic>sl<sup>WT</sup></italic>. Expression of <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic> caused notched wings in approximately 18% and 23% of the flies, respectively (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>), whereas expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> results in severe wing phenotypes characterized by notched wing margins, fused/thickened veins, and reduced wing sizes with &gt;95% penetrance (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Notably, expression of fly <italic>sl<sup>variants</sup></italic> could lead to similar morphological defects as their corresponding human variants, arguing that these wing phenotypes are due to alterations of PLCG1 or Sl protein function (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2C</xref>).</p><p>We also assessed the effect of expression of human <italic>PLCG1</italic> on eye development using the <italic>eyeless-GAL4</italic> (<italic>ey-GAL4</italic>). Expression of <italic>PLCG1<sup>Reference</sup></italic> or <italic>PLCG1<sup>H380R</sup></italic> in fly eyes leads to a mild reduction in eye size when compared to <italic>UAS-Empty</italic> control (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2D</xref>). However, expression of <italic>PLCG1<sup>L597F</sup></italic> results in rough eyes that are reduced in size, whereas overexpression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> leads to a more severe eye phenotype (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). In summary, the eye data are consistent with the wing data, showing that <italic>PLCG1<sup>D1019G</sup></italic> and <italic>PLCG1<sup>D1165G</sup></italic> are more toxic than <italic>PLCG1<sup>Reference</sup></italic>. On the other hand, the toxicity of <italic>PLCG1<sup>H380R</sup></italic> and <italic>PLCG1<sup>L597F</sup></italic> is stronger than the <italic>PLCG1<sup>Reference</sup></italic> but not as severe as <italic>PLCG1<sup>D1019G</sup></italic> and <italic>PLCG1<sup>D1165G</sup></italic>. Interestingly, the morphological defects in wings or eyes caused by ectopic expression of <italic>PLCG1</italic> cDNAs correlate with the expression level (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2E</xref>), but do not directly correlate with the phospholipase enzymatic activity. For example, expression of <italic>PLCG1<sup>S1021F</sup></italic> does not cause obvious morphological defects when compared to <italic>PLCG1<sup>Reference</sup></italic> (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B and F</xref>), even though <italic>PLCG1<sup>S1021F</sup></italic> is hyperactive and induces significantly elevated intracellular Ca<sup>2+</sup> in the CaLexA reporter assay (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we report seven individuals who carry heterozygous missense variants in <italic>PLCG1</italic> which encodes the phospholipase C γ1 isozyme. The individuals present with partially overlapping clinical features including hearing impairment, eye abnormality, heart defects, and immune phenotypes. We show that the fly ortholog, <italic>small wing</italic> (<italic>sl</italic>), is widely expressed in wings and eyes, as well as in the central nervous system. Consistent with its expression pattern, we report that <italic>sl</italic> not only regulates wing and eye development, as previously documented, but also plays critical roles in the nervous system and affects locomotion and longevity. Furthermore, we assessed the function of the variants in the context of the human and fly cDNAs and show that their expression induces variable levels of toxicity when compared to the reference <italic>PLCG1</italic> or wild-type <italic>sl</italic>. Two of the variants are clearly hyperactive, and all the variants exhibit neomorphic effects (discussed in Appendix 1 as Figure Notes). These observations show that the variants impair the normal function <italic>in vivo</italic> and suggest that they contribute to the symptoms observed in the affected individuals. Similarly to inborn error caused by the paralogous <italic>PLCG2</italic> (<xref ref-type="bibr" rid="bib7">Baysac et al., 2024</xref>), germline variants in <italic>PLCG1</italic> can be pathogenic and dominant by different mechanisms.</p><sec id="s3-1"><title>Structural analysis of the PLCG1 variants</title><p>Previously, studies based on biochemical assays and protein structures provided insights into how the variants studied here may affect the enzymatic activity of PLCγ1 (the protein structure of full-length rat Plcg1 is shown in <xref ref-type="fig" rid="fig6">Figure 6A</xref>). In its basal state, the PLCγ-specific regulatory array (sPH-nSH2-cSH2-SH3) forms autoinhibitory interfaces with the catalytic domains. Upon activation by the RTKs through binding with nSH2, PLCγ1 is phosphorylated, which induces the dissociation of the inhibitory cSH2 domain from the C2 domain. This triggers conformational rearrangements, allowing the enzyme to associate with the membrane and to expose the catalytic domains to allow hydrolysis of PIP2 (<xref ref-type="bibr" rid="bib32">Gresset et al., 2010</xref>; <xref ref-type="bibr" rid="bib36">Hajicek et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Liu et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Le Huray et al., 2022</xref>; <xref ref-type="bibr" rid="bib68">Nosbisch et al., 2022</xref>). As shown in <xref ref-type="fig" rid="fig6">Figure 6A</xref>, the proband-associated variants map to conserved domains of the protein, either within the catalytic domains or at intramolecular and intermolecular interfaces. The p.(Asp1019Gly) and p.(Asp1165Gly) variants impact key residues involved in autoinhibition, leading to increased enzymatic activity. Specifically, the p.(Asp1019Gly) variant affects a conserved residue within the hydrophobic ridge of the Y box (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), which is important for interaction with the sPH domain. This interaction is critical for the autoinhibition by blocking the membrane engagement of the catalytic core domain prior to enzymatic activation (<xref ref-type="bibr" rid="bib24">Ellis et al., 1998</xref>; <xref ref-type="bibr" rid="bib36">Hajicek et al., 2019</xref>). Notably, a substitution at the same position (Asp1019Lys, D1019K) has been demonstrated to enhance basal phospholipase activity <italic>in vitro</italic> (<xref ref-type="bibr" rid="bib35">Hajicek et al., 2013</xref>), supporting its regulatory importance. Similarly, another hotspot somatic variant, p.(Ser345Phe), located in the corresponding hydrophobic ridge within the X box, is also hyperactive (<xref ref-type="bibr" rid="bib95">Vaqué et al., 2014</xref>; <xref ref-type="bibr" rid="bib61">Manso et al., 2015</xref>). On the other hand, the p.(Asp1165Gly) variant affects a residue situated within a loop of the C2 domain (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). The Asp1165 residue plays a key role in stabilizing the interaction between the cSH2 domain and the C2 domain to maintain the autoinhibited state (<xref ref-type="bibr" rid="bib18">DeBell et al., 2007</xref>). As mentioned above, the somatic variant p.(Asp1165His) leads to significantly elevated phospholipase activity <italic>in vitro</italic> (<xref ref-type="bibr" rid="bib54">Liu et al., 2020</xref>; <xref ref-type="bibr" rid="bib83">Siraliev-Perez et al., 2022</xref>), and results in severe phenotypes <italic>in vivo</italic> (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2E and F</xref>). Molecular dynamics simulation data consistently indicate that autoinhibition is likely disrupted by the p.(Asp1019Gly) and p.(Asp1165Gly) variants (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). In contrast, the p.(His380Arg) variant impacts the His380 residue within the X box, situated near a Ca<sup>2+</sup> ion in the catalytic core (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). His380 plays a role in coordination of the phosphate group at the 1-position of IP<sub>3</sub> (<xref ref-type="bibr" rid="bib51">Le Huray et al., 2022</xref>). While this residue may not be key to autoinhibition, it is important for the phospholipase activity. Substitution of His380 with Phe or Ala (H380F, H380A) has been reported to suppress PIP<sub>2</sub> hydrolysis and IP<sub>3</sub> production (<xref ref-type="bibr" rid="bib84">Smith et al., 1994</xref>; <xref ref-type="bibr" rid="bib99">Wada et al., 2022</xref>). Hence, substitution of the His380 with Arg by the p.(His380Arg) variant may create a more basic environment, impacting the lipase activity. On the other hand, the p.(Leu597Phe) variant affects a residue within the nSH2 domain, which is part of the PLCγ-specific regulatory array (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). The nSH2 domain mediates interactions with phosphorylated tyrosine residues on RTKs to initiate activation (<xref ref-type="bibr" rid="bib4">Bae et al., 2009</xref>). Leu597 is located near the phosphotyrosine-binding pocket, and this variant may therefore alter receptor specificity or induce novel protein interactions. Additionally, we utilized the DDMut platform (<xref ref-type="bibr" rid="bib105">Zhou et al., 2023</xref>) to predict protein stability and folding of the variants, which are discussed in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>. In summary, our <italic>in vivo</italic> data are consistent with previous reports and <italic>in silico</italic> analyses, showing that the affected amino acids map to critical residues and strengthening the conclusion that the variants are pathogenic and likely impact the protein function through distinct mechanisms.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>PLCG1</italic> variants affect important residues.</title><p>(<bold>A</bold>) 3D structure of full-length rat Plcg1 (rat Plcg1 shares 97% amino acid identity with human PLCG1). The conserved protein domains are labeled with different colors. Two major intracellular interfaces are circled by dashed lines: 1-The hydrophobic ridge between the sPH domain and the catalytic core (X-box and Y-box); and 2-The interface between the cSH2 domain and the C2 domain. The four amino acids affected by the variants are shown as bolded black and indicated by yellow balls. (<bold>B</bold>) Enlarged views of the Asp1019 residue within the autoinhibition interface between sPH domain and the Y box. The potential interactions with nearby residues are indicated. (<bold>C</bold>) Enlarged view of the Asp1165 residue within the autoinhibition interface between the cSH2 domain and the C2 domain. The potential interactions with nearby residues are indicated. (<bold>D</bold>) Enlarged view of the His380 residue within the X-box catalytic domain, in proximity to the Ca<sup>2+</sup> cofactor. (<bold>E</bold>) Enlarged view of the Leu597 and nearby residues in the nSH2 domain. Structural analysis was performed via UCSF Chimera (<xref ref-type="bibr" rid="bib73">Pettersen et al., 2004</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title><italic>In silico</italic> analyses of <italic>PLCG1</italic> variants.</title><p>(<bold>A</bold>) Molecular dynamics simulations for the p.(Asp1019Gly) and p.(Asp1165Gly) variants. These variants exhibit increased disorganization with a higher root mean square deviations (RMSD) compared to the reference PLCG, similar to the hyperactive p.(Asp1165His) variant. Color code: PLCG1 reference - red; p.(Asp1019Gly) - green; p.(Asp1165Gly) - cyan; p.(Asp1165His) - purple. (<bold>B</bold>) Prediction of the effects of PLCG1 variants on protein stability and folding using DDMut. DDMut is a platform designed to predict protein stability based on the Gibbs Free Energy change (ΔΔG), and larger ΔΔG indicates a more pronounced impact on protein stability. The protein structure of rat Plcg1 [Protein Data Bank (PDB) ID 6PBC] was used as a reference. The p.(Asp1019Gly), p.(Asp1165Gly), and p.(Asp1165His) variants are predicted to induce destabilizing, with ΔΔG<sup>Stability wt-&gt;mt</sup> values of –0.91 kcal/mol, –1.54 kcal/mol, and –1.59 kcal/mol, respectively, suggesting impaired protein folding or altered conformational dynamics. These results are consistent with their proposed roles in disrupting autoinhibitory interactions (<xref ref-type="bibr" rid="bib35">Hajicek et al., 2013</xref>; <xref ref-type="bibr" rid="bib83">Siraliev-Perez et al., 2022</xref>). The ΔΔG<sup>Stability wt-&gt;mt</sup> value for p.(His380Arg) and the enzymatically inactive p.(His380Arg) are predicted to be –0.22 kcal/mol and –0.13 kcal/mol, respectively. Given that the His380 residue’s influence on the phospholipase activity might not be through the autoinhibition mechanism, the impact of His380 residue variants on the protein folding and stability may not elucidate their effects on protein function. The ΔΔG<sup>Stability wt-&gt;mt</sup> value for p.(Leu597Phe) is predicted to be –1.26 kcal/mol, which is not inconsistent with the potential impact of this variant on interaction between nSH2 domain and RTK activators. However, the p.(Ser1021Phe) variant has a predicted ΔΔG<sup>Stability wt-&gt;mt</sup> value of 0.14 kcal/mol, indicating a slight stabilizing effect. These analyses indicate that the variants may act through various pathogenic mechanisms, but further investigations are needed.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95887-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s3-2"><title>The <italic>PLCG1</italic> variants affect protein function to varying degrees and are associated with variable clinical manifestations</title><p>To better assess the genotype-phenotype relationship of the variants, we summarize the clinical features of affected individuals in <xref ref-type="table" rid="table1">Table 1</xref>, and the phenotypic effects observed in fly assays in <xref ref-type="table" rid="table3">Table 3</xref>. The p.(Asp1019Gly) variant carried by Individual 1 and the p.(Asp1165Gly) variant carried by Individual 3, and their corresponding fly variants induce severe phenotypes across all assays performed. Individuals 1 and 3 share several obvious clinical features including hearing loss and heart septal defect. In contrast, the p.(His380Arg) and p.(Leu597Phe) variants cause mild or partially penetrant phenotypes across different fly assays. Individual 2 who carries the p.(His380Arg) variant does not exhibit hearing impairment or heart defects observed in Individuals 1 and 3, but has eye malformations and neuroinflammation features that are shared with individuals 1 and 3, although the ocular and immunological defects manifest differently among individuals. Interestingly, individuals 4–7 are from the same family and all carry the p.(Leu597Phe) variant but also differ in their phenotypes, yet all share some clinical features with Individuals 1–3 (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Summary of the phenotypes observed in fly assays.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="6">25°C</th><th align="left" valign="bottom" colspan="3">29°C</th></tr><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="2">Lethality when expressed in <italic>sl<sup>T2A</sup>/Y</italic> mutant</th><th align="left" valign="bottom" colspan="2">Lethality when expressed in <italic>sl<sup>T2A</sup>/y w</italic> heterozygous</th><th align="left" valign="bottom" colspan="2">Ca<sup>2+</sup> activity</th><th align="left" valign="bottom" colspan="2">Wing morphology when overexpressed</th><th align="left" valign="bottom">Eye morphology when overexpressed</th></tr><tr><th align="left" valign="bottom"><italic>PLCG1</italic> variants</th><th align="left" valign="bottom">Human variants</th><th align="left" valign="bottom">Fly variants</th><th align="left" valign="bottom">Human variants</th><th align="left" valign="bottom">Fly variants</th><th align="left" valign="bottom">Human variants</th><th align="left" valign="bottom">Fly variants</th><th align="left" valign="bottom">Human variants</th><th align="left" valign="bottom">Fly variants</th><th align="left" valign="bottom">Human variants</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Reference</bold></td><td align="left" valign="bottom">++</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">+</td><td align="char" char="." valign="bottom">+</td><td align="char" char="." valign="bottom">+</td></tr><tr><td align="left" valign="bottom"><bold>H380R</bold></td><td align="left" valign="bottom">+++</td><td align="char" char="." valign="bottom">+++</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">++</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">++</td><td align="char" char="." valign="bottom">++</td><td align="char" char="." valign="bottom">+</td></tr><tr><td align="left" valign="bottom"><bold>D1019G</bold></td><td align="left" valign="bottom">100% lethal</td><td align="char" char="." valign="bottom">100% lethal</td><td align="char" char="." valign="bottom">100% lethal</td><td align="char" char="." valign="bottom">100% lethal</td><td align="char" char="." valign="bottom">+</td><td align="char" char="." valign="bottom">+</td><td align="char" char="." valign="bottom">++++</td><td align="char" char="." valign="bottom">++++</td><td align="char" char="." valign="bottom">+++</td></tr><tr><td align="left" valign="bottom"><bold>D1165G</bold></td><td align="left" valign="bottom">100% lethal</td><td align="char" char="." valign="bottom">100% lethal</td><td align="char" char="." valign="bottom">100% lethal</td><td align="char" char="." valign="bottom">100% lethal</td><td align="char" char="." valign="bottom">+</td><td align="char" char="." valign="bottom">+</td><td align="char" char="." valign="bottom">++++</td><td align="left" valign="bottom">lethal</td><td align="char" char="." valign="bottom">+++</td></tr><tr><td align="left" valign="bottom"><bold>L597F</bold></td><td align="left" valign="bottom">+++</td><td align="char" char="." valign="bottom">++</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">+</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">+++</td><td align="char" char="." valign="bottom">++</td></tr><tr><td align="left" valign="bottom"><bold>H380A</bold></td><td align="left" valign="bottom">+++</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom">(+)</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom"><bold>D1165H</bold></td><td align="left" valign="bottom">100% lethal</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom">100% lethal</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom">+</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">lethal</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">lethal</td></tr><tr><td align="left" valign="bottom"><bold>S1021F</bold></td><td align="left" valign="bottom">++</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom">+</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom">+</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">-</td></tr></tbody></table><table-wrap-foot><fn><p>‘-’: no obvious phenotypes observed.</p></fn><fn><p>‘+’: phenotypes observed, the number of ‘+’ corresponds to the severity of the observed phenotype.</p></fn><fn><p>NA: Not Available.</p></fn></table-wrap-foot></table-wrap><p>The heterogeneity in clinical manifestations may be influenced by additional genetic variants (see <xref ref-type="table" rid="table1">Table 1</xref> legend) and environmental factors. Additionally, the variable expressivity observed in carriers of the same variant may be explained by allelic expression bias through autosomal random monoallelic expression (aRME; <xref ref-type="bibr" rid="bib78">Reinius and Sandberg, 2015</xref>), a phenomenon that is thought to be common among carriers of genetic defects associated with inborn errors of immunity (IEIs). Indeed, these conditions often exhibit non-Mendelian segregation patterns and variable clinical features (<xref ref-type="bibr" rid="bib88">Stewart et al., 2025</xref>). Moreover, the PLCγ1 isozyme is an integral component of multiple signaling pathways, and the consequences of its dysregulation are likely to be context dependent. It is likely that different <italic>PLCG1</italic> variants impact distinct cellular processes across various tissues and cell types, resulting in a spectrum of pathological changes. In summary, the symptoms observed in affected individuals appear to correlate, to some extent, with the severity of the variants as indicated by fly assays. However, the penetrance and expressivity of these phenotypes will require further investigation to better understand the genotype-phenotype associations of <italic>PLCG1</italic> variants.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Recruitment of the probands</title><p>Individuals 1 and 2 were recruited through the Undiagnosed Diseases Network (UDN) and were evaluated through the clinical research protocol of the National Institutes of Health Undiagnosed Diseases (15-HG-0130), which was approved by the National Human Genome Research Institute (NHGRI). Individuals 3–7 were recruited through GeneMatcher. Formal consent for genetic testing and participation, as well as for publication under the Creative Commons Attribution 4.0 International Public License (CC BY 4.0), was obtained from all individuals or their family members.</p></sec><sec id="s4-2"><title>Drosophila husbandry and generation of transgenic flies</title><p>All the flies used in this study were raised and maintained on standard fly food at room temperature unless specified. The <italic>UAS-PLCG1 cDNAs</italic> and <italic>UAS-sl cDNAs</italic> transgenic flies were generated in-house (see Materials and methods below). Other fly strains used in this study were obtained from the Bloomington <italic>Drosophila</italic> Stock Center (BDSC), including: <italic>w<sup>1118</sup></italic> (#3605), <italic>y w</italic> (#1495), <italic>sl<sup>2</sup></italic> (#5735), <italic>sl<sup>KO</sup></italic> (#93748), <italic>sl<sup>T2A</sup></italic> (#81213), <italic>Dp(1;3)DC313</italic> (Genomic Rescue) (#30423), <italic>UAS-Flippase</italic> (#4539), <italic>UAS-mCherry.nls</italic> (#38424), <italic>tub-GAL4</italic> (#5138), <italic>da-GAL4</italic> (#55851), <italic>nub-GAL4</italic> (#86108), <italic>ey-GAL4</italic> (#5534), <italic>tub-GAL80ts</italic> (#7107), <italic>UAS-Empty</italic> (#9750). The <italic>sl<sup>T2A</sup></italic> allele was outcrossed with <italic>w<sup>1118</sup></italic> to clean up the genetic background.</p><p>To generate the <italic>UAS-cDNA</italic> transgenic lines, human <italic>PLCG1</italic> cDNA was obtained from Horizon Discovery (MHS6278-213246131, clone ID 9052656), and fly <italic>sl</italic> cDNA was obtained from Drosophila Genomics Resource Center (DGRC, RE62235). The coding sequence (CDS) of <italic>PLCG1<sup>Reference</sup></italic> and <italic>sl<sup>WT</sup></italic> was amplified using iProof High-Fidelity DNA Polymerase Kit (BioRad, #1725301), purified using QIAEX II Gel Extraction Kit (QIAGEN, #20021), sub-cloned into the Gateway compatible entry vector pDONR223 by BP cloning (BP clonase II, Thermo Fisher Scientific, #11789020) and sequentially cloned into the destination vector pGW-attB-HA by LR cloning (LR clonase II, Thermo Fisher Scientific, #11791100) (<xref ref-type="bibr" rid="bib12">Bischof et al., 2013</xref>). The variants were generated by site-directed mutagenesis strategy using Q5 Hot Start High-Fidelity 2x Master Mix (NEB, #M0494S) and <italic>DpnI</italic> restriction enzyme (NEB, # R0176L). Human <italic>PLCG2</italic> cDNA was obtained from Genescript (clone ID OHu24072) and was cloned into pUAST vector using <italic>NotI</italic> and <italic>XbaI</italic> restriction enzyme sites. All the constructs were Sanger verified and injected and inserted into the VK33 (<italic>PBac{y[+]-attP}VK00033</italic>) docking site using ϕC31 mediated transgenesis (<xref ref-type="bibr" rid="bib97">Venken et al., 2006</xref>; <xref ref-type="bibr" rid="bib11">Bischof et al., 2007</xref>). Primers are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-3"><title>Drosophila behavioral assays</title><p>For the lifespan assay, newly eclosed male flies were collected and maintained at 25°C (10 flies per vial). The flies were transferred to a new vial and the number of dead flies was counted every 2 days.</p><p>For the temperature-shifting related assays, flies were raised at 18°C until eclosion. Newly eclosed males were collected and maintained at 29°C for the lifespan assay and climbing assays conducted at specified ages.</p><p>The climbing assay to examine the negative geotaxis and locomotion ability of the flies was performed as previously described (<xref ref-type="bibr" rid="bib58">Madabattula et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Lu et al., 2022a</xref>) with some modifications. For climbing assay of <italic>sl<sup>T2A</sup></italic> mutant, <italic>sl<sup>WT</sup></italic> rescue, and <italic>w<sup>1118</sup></italic> control flies, 17–22 flies per vial were transferred to an empty plastic vial and given 20 min to rest prior to being tested. The flies were tapped to the bottom of the vial and were allowed to climb for 15 s. The percentage of flies per vial that climbed over 5 cm was calculated. For climbing assay of the flies underwent temperature-shifting, the distance each fly climbed in 15 s were measured. The maximum distance from the bottom to the top is 18.5 cm.</p></sec><sec id="s4-4"><title>Immunostaining</title><p>Fly tissues were dissected in 1x PBS, fixed in 4% paraformaldehyde for 20 min at room temperature, and washed in PBS (3 x 10 min). For antibody staining, samples were treated with PBST (Triton X-100 in PBS, 0.1% for larval tissues, 2% for adult brain), 5% normal goat serum, and incubated in primary antibody overnight at 4°C. Samples were washed with 0.1% PBST (3 x 10 min) and incubated with secondary antibody for 2 hr at room temperature (in darkness) and washed in 0.1% PBST (3 x 10 min). Primary antibodies: rat anti-Drosophila Elav (1:250, DSHB, #7E8A10); mouse anti-Drosophila Repo (1:50, DSHB, #8D12). Secondary antibodies: goat anti-rat-647 (1:250, Jackson ImmunoResearch, #112-605-003), goat anti-mouse-Cy5 (1:250, Invitrogen, #A10524). Larval discs were mounted in Vectashield (Vector Labs #H1200 and #H1000). Larval CNS and adult brain were mounted in Rapiclear (Cedarlane, #RC147001). For adult retinas, flies are reared at 25°C under 12 hr light/dark conditions. Retinas were isolated from 5- to 7-day-old flies. Heads were dissected in PBS and fixed in 3.7% formaldehyde overnight at 4°C. The samples were rinsed with 0.1% PBST, and the retinas were subsequently dissected and incubated with PBST-diluted phalloidin 647 (1:100, Invitrogen, #A22287) for 1 hr. Retinas were washed in 0.1% PBST and mounted in Vectashield. The images were obtained with a confocal microscope (Leica SP8X or Zeiss Airyscan LSM 880) and processed using the ImageJ-FIJI software (<xref ref-type="bibr" rid="bib80">Schneider et al., 2012</xref>).</p></sec><sec id="s4-5"><title>Imaging of adult fly wings and eyes</title><p>To prepare the samples of adult fly wings, the wing blades were dissected and mounted in a glycerol/ethanol 1/1 mixture. Only wings from the same gender were compared to each other since females have larger wings than males when raised in the same conditions. To prepare the samples of adult fly eyes, the flies were frozen and placed onto a double-sided stick tape with one eye facing up. The samples were imaged using bright field Stereomicroscope (Leica MZ16 or Leica Z16 APO). Image Pro Plus 7.0 software was used to create extended depth-of-field images. The image processing and the measurement of the total areas of the wing blades or eyes were conducted using the ImageJ-FIJI software (<xref ref-type="bibr" rid="bib80">Schneider et al., 2012</xref>).</p></sec><sec id="s4-6"><title>Real-time PCR</title><p>Real-time PCR was performed as previously described (<xref ref-type="bibr" rid="bib76">Ravenscroft et al., 2020</xref>) with modifications. All-In-One 5X RT MasterMix (abm, #G592), iTaq Universal SYBR Green Master Mix (BioRad, #1725120) and BioRad C1000 Touch Cycler were used. Primers are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-7"><title>Molecular dynamics simulations</title><p>The three-dimensional structures of the wild-type and variant forms of the PLCG1 protein were predicted using AlphaFold3 (<xref ref-type="bibr" rid="bib1">Abramson et al., 2024</xref>). All simulations were performed using GROMACS (<xref ref-type="bibr" rid="bib74">Pronk et al., 2013</xref>) version 2020.6. Initial PDB files were processed to remove water molecules and hydrogen atoms. The AMBER14SB_parmbsc1 force field (<xref ref-type="bibr" rid="bib59">Maier et al., 2015</xref>) was employed for parameterization. TIP3P water model was used to solvate the system in a cubic box with a minimum distance of 1.0 nm between the protein and box edges. Counterions (Na<sup>+</sup> and Cl⁻) were added to neutralize the system’s net charge. Energy minimization was conducted using the steepest descent algorithm to eliminate unfavorable contacts. Subsequently, the system underwent equilibration in two phases: NVT Equilibration: Maintained at 300 K using the velocity-rescaling thermostat for 100 ps; NPT Equilibration: Pressure was stabilized at 1 bar using the Parrinello-Rahman barostat for 100 ps.</p><p>An unrestrained production MD simulation was carried out for 100 ns under constant temperature (300 K) and pressure (1 bar) conditions. The LINCS algorithm was used to constrain all bonds involving hydrogen atoms, allowing a time step of 2 fs. Long-range electrostatics were treated using the Particle Mesh Ewald (PME) method with a cutoff of 1.0 nm for both Coulomb and van der Waals interactions.</p><p>Post-simulation analyses included root mean square deviation (RMSD) calculations to assess structural stability and radius of gyration (Rg) to evaluate compactness. All analyses were performed using built-in GROMACS tools. The results are plotted by the ggplot2 R package.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Receives revenue from clinical genetic testing completed at Baylor Genetics Laboratories</p></fn><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Resources, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources</p></fn><fn fn-type="con" id="con10"><p>Resources</p></fn><fn fn-type="con" id="con11"><p>Resources</p></fn><fn fn-type="con" id="con12"><p>Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Resources</p></fn><fn fn-type="con" id="con15"><p>Resources</p></fn><fn fn-type="con" id="con16"><p>Data curation</p></fn><fn fn-type="con" id="con17"><p>Formal analysis</p></fn><fn fn-type="con" id="con18"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Resources</p></fn><fn fn-type="con" id="con21"><p>Resources</p></fn><fn fn-type="con" id="con22"><p>Conceptualization, Resources, Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con23"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con24"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con25"><p>Conceptualization, Resources, Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con26"><p>Conceptualization, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con27"><p>Conceptualization, Resources, Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con28"><p>Conceptualization, Resources, Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con29"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Individuals 1 and 2 were recruited through the Undiagnosed Diseases Network (UDN) and were evaluated through the clinical research protocol of the National Institutes of Health Undiagnosed Diseases (15-HG-0130), which was approved by the National Human Genome Research Institute (NHGRI). Individuals 3-7 were recruited through GeneMatcher. Formal written consent for genetic testing and participation, as well as for publication under the Creative Commons Attribution 4.0 International Public License (CC BY 4.0), was obtained from all individuals or their family members.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-95887-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Primers used in this study.</title></caption><media xlink:href="elife-95887-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files; source data files have been provided. All reagents developed in this study are available upon reasonable request.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the individuals and families for their participation in this study. We thank Ms Hongling Pan for helping in the generation of transgenic fly lines. We thank Dr Meisheng Ma for suggestions about protein structure interpretation. We thank Dr Zhandong Liu for providing computational resources for performing the molecular dynamics simulations. We thank the Bloomington Drosophila Stock Center (BDSC) for providing stocks. H J B receives support from the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, the Huffington Foundation, as well as grants from the National Institute of Neurological Disorders and Stroke (NINDS, U54 NS093793) and the National Institutes of Health Office of the Director (R24 OD031447). This work was also supported by the Undiagnosed Diseases Network funded by grants from the National Human Genome Research Institute (NHGRI) and NINDS (U01 HG010233, U01 NS134355, U01 HG007709, U01 HG007942). Sequence data analysis was supported by the University of Washington Center for Rare Disease Research (UW-CRDR) and grants from NHGRI (U01 HG011744, UM1 HG006493, U24 HG011746). Confocal microscopy was performed in the Baylor College of Medicine Intellectual and Developmental Disabilities Research Center (IDDRC) Neurovisualization Core, supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, U54 HD083092). The content of this paper is the sole responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>J</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Dunger</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Willmore</surname><given-names>L</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Bambrick</surname><given-names>J</given-names></name><name><surname>Bodenstein</surname><given-names>SW</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name><name><surname>Hung</surname><given-names>C-C</given-names></name><name><surname>O’Neill</surname><given-names>M</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Žemgulytė</surname><given-names>A</given-names></name><name><surname>Arvaniti</surname><given-names>E</given-names></name><name><surname>Beattie</surname><given-names>C</given-names></name><name><surname>Bertolli</surname><given-names>O</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Cherepanov</surname><given-names>A</given-names></name><name><surname>Congreve</surname><given-names>M</given-names></name><name><surname>Cowen-Rivers</surname><given-names>AI</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>FB</given-names></name><name><surname>Gladman</surname><given-names>H</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>YA</given-names></name><name><surname>Low</surname><given-names>CMR</given-names></name><name><surname>Perlin</surname><given-names>K</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Savy</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Stecula</surname><given-names>A</given-names></name><name><surname>Thillaisundaram</surname><given-names>A</given-names></name><name><surname>Tong</surname><given-names>C</given-names></name><name><surname>Yakneen</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>ED</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Bapst</surname><given-names>V</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Jaderberg</surname><given-names>M</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name><name><surname>Jumper</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Addendum: Accurate structure prediction of biomolecular interactions with AlphaFold 3</article-title><source>Nature</source><volume>636</volume><elocation-id>E4</elocation-id><pub-id pub-id-type="doi">10.1038/s41586-024-08416-7</pub-id><pub-id pub-id-type="pmid">39604737</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arteaga</surname><given-names>CL</given-names></name><name><surname>Johnson</surname><given-names>MD</given-names></name><name><surname>Todderud</surname><given-names>G</given-names></name><name><surname>Coffey</surname><given-names>RJ</given-names></name><name><surname>Carpenter</surname><given-names>G</given-names></name><name><surname>Page</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas</article-title><source>PNAS</source><volume>88</volume><fpage>10435</fpage><lpage>10439</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.23.10435</pub-id><pub-id pub-id-type="pmid">1683701</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>S</given-names></name><name><surname>Maetani</surname><given-names>Y</given-names></name><name><surname>Ago</surname><given-names>Y</given-names></name><name><surname>Kanematsu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Phospholipase C-related catalytically inactive protein enhances cisplatin-induced apoptotic cell death</article-title><source>European Journal of Pharmacology</source><volume>933</volume><elocation-id>175273</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2022.175273</pub-id><pub-id pub-id-type="pmid">36108738</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>JH</given-names></name><name><surname>Lew</surname><given-names>ED</given-names></name><name><surname>Yuzawa</surname><given-names>S</given-names></name><name><surname>Tomé</surname><given-names>F</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site</article-title><source>Cell</source><volume>138</volume><fpage>514</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.05.028</pub-id><pub-id pub-id-type="pmid">19665973</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phosphoinositides: tiny lipids with giant impact on cell regulation</article-title><source>Physiological Reviews</source><volume>93</volume><fpage>1019</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1152/physrev.00028.2012</pub-id><pub-id pub-id-type="pmid">23899561</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayram</surname><given-names>Y</given-names></name><name><surname>Karaca</surname><given-names>E</given-names></name><name><surname>Coban Akdemir</surname><given-names>Z</given-names></name><name><surname>Yilmaz</surname><given-names>EO</given-names></name><name><surname>Tayfun</surname><given-names>GA</given-names></name><name><surname>Aydin</surname><given-names>H</given-names></name><name><surname>Torun</surname><given-names>D</given-names></name><name><surname>Bozdogan</surname><given-names>ST</given-names></name><name><surname>Gezdirici</surname><given-names>A</given-names></name><name><surname>Isikay</surname><given-names>S</given-names></name><name><surname>Atik</surname><given-names>MM</given-names></name><name><surname>Gambin</surname><given-names>T</given-names></name><name><surname>Harel</surname><given-names>T</given-names></name><name><surname>El-Hattab</surname><given-names>AW</given-names></name><name><surname>Charng</surname><given-names>W-L</given-names></name><name><surname>Pehlivan</surname><given-names>D</given-names></name><name><surname>Jhangiani</surname><given-names>SN</given-names></name><name><surname>Muzny</surname><given-names>DM</given-names></name><name><surname>Karaman</surname><given-names>A</given-names></name><name><surname>Celik</surname><given-names>T</given-names></name><name><surname>Yuregir</surname><given-names>OO</given-names></name><name><surname>Yildirim</surname><given-names>T</given-names></name><name><surname>Bayhan</surname><given-names>IA</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Elcioglu</surname><given-names>N</given-names></name><name><surname>Tuysuz</surname><given-names>B</given-names></name><name><surname>Lupski</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular etiology of arthrogryposis in multiple families of mostly Turkish origin</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><fpage>762</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1172/JCI84457</pub-id><pub-id pub-id-type="pmid">26752647</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baysac</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Schmitz</surname><given-names>EG</given-names></name><name><surname>Cruz</surname><given-names>AC</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>AC</given-names></name><collab>PLCG2-Immune Dysregulation Working Group</collab><name><surname>Mace</surname><given-names>E</given-names></name><name><surname>Milner</surname><given-names>JD</given-names></name><name><surname>Ombrello</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>153</volume><fpage>230</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2023.08.036</pub-id><pub-id pub-id-type="pmid">37769878</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behjati</surname><given-names>S</given-names></name><name><surname>Tarpey</surname><given-names>PS</given-names></name><name><surname>Sheldon</surname><given-names>H</given-names></name><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Gundem</surname><given-names>G</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Cooke</surname><given-names>SL</given-names></name><name><surname>Pillay</surname><given-names>N</given-names></name><name><surname>Vollan</surname><given-names>HKM</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Koss</surname><given-names>H</given-names></name><name><surname>Bunney</surname><given-names>TD</given-names></name><name><surname>Hardy</surname><given-names>C</given-names></name><name><surname>Joseph</surname><given-names>OR</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Mudie</surname><given-names>L</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Patil</surname><given-names>M</given-names></name><name><surname>Steers</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Gumbs</surname><given-names>C</given-names></name><name><surname>Ingram</surname><given-names>D</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Little</surname><given-names>L</given-names></name><name><surname>Mahadeshwar</surname><given-names>H</given-names></name><name><surname>Protopopov</surname><given-names>A</given-names></name><name><surname>Al Sannaa</surname><given-names>GA</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ravi</surname><given-names>V</given-names></name><name><surname>Torres</surname><given-names>KE</given-names></name><name><surname>Khatri</surname><given-names>B</given-names></name><name><surname>Halai</surname><given-names>D</given-names></name><name><surname>Roxanis</surname><given-names>I</given-names></name><name><surname>Baumhoer</surname><given-names>D</given-names></name><name><surname>Tirabosco</surname><given-names>R</given-names></name><name><surname>Amary</surname><given-names>MF</given-names></name><name><surname>Boshoff</surname><given-names>C</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Flanagan</surname><given-names>AM</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Recurrent PTPRB and PLCG1 mutations in angiosarcoma</article-title><source>Nature Genetics</source><volume>46</volume><fpage>376</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1038/ng.2921</pub-id><pub-id pub-id-type="pmid">24633157</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berridge</surname><given-names>MJ</given-names></name><name><surname>Irvine</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Inositol trisphosphate, a novel second messenger in cellular signal transduction</article-title><source>Nature</source><volume>312</volume><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1038/312315a0</pub-id><pub-id pub-id-type="pmid">6095092</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berridge</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Inositol trisphosphate and calcium signalling</article-title><source>Nature</source><volume>361</volume><fpage>315</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1038/361315a0</pub-id><pub-id pub-id-type="pmid">8381210</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischof</surname><given-names>J</given-names></name><name><surname>Maeda</surname><given-names>RK</given-names></name><name><surname>Hediger</surname><given-names>M</given-names></name><name><surname>Karch</surname><given-names>F</given-names></name><name><surname>Basler</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>An optimized transgenesis system for Drosophila using germ-line-specific phiC31 integrases</article-title><source>PNAS</source><volume>104</volume><fpage>3312</fpage><lpage>3317</lpage><pub-id pub-id-type="doi">10.1073/pnas.0611511104</pub-id><pub-id pub-id-type="pmid">17360644</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischof</surname><given-names>J</given-names></name><name><surname>Björklund</surname><given-names>M</given-names></name><name><surname>Furger</surname><given-names>E</given-names></name><name><surname>Schertel</surname><given-names>C</given-names></name><name><surname>Taipale</surname><given-names>J</given-names></name><name><surname>Basler</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A versatile platform for creating a comprehensive UAS-ORFeome library in Drosophila</article-title><source>Development</source><volume>140</volume><fpage>2434</fpage><lpage>2442</lpage><pub-id pub-id-type="doi">10.1242/dev.088757</pub-id><pub-id pub-id-type="pmid">23637332</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>AH</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Targeted gene expression as a means of altering cell fates and generating dominant phenotypes</article-title><source>Development</source><volume>118</volume><fpage>401</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1242/dev.118.2.401</pub-id><pub-id pub-id-type="pmid">8223268</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>KR</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Panchal</surname><given-names>R</given-names></name><name><surname>Liao</surname><given-names>C</given-names></name><name><surname>Abderrazzaq</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>R</given-names></name><name><surname>Schultz</surname><given-names>P</given-names></name><name><surname>Compitello</surname><given-names>J</given-names></name><name><surname>Grant</surname><given-names>RH</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Phu</surname><given-names>W</given-names></name><name><surname>Wilson</surname><given-names>MW</given-names></name><name><surname>Laricchia</surname><given-names>KM</given-names></name><name><surname>Goodrich</surname><given-names>JK</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Goldstein</surname><given-names>JI</given-names></name><name><surname>Vittal</surname><given-names>C</given-names></name><name><surname>Poterba</surname><given-names>T</given-names></name><name><surname>Baxter</surname><given-names>S</given-names></name><name><surname>Watts</surname><given-names>NA</given-names></name><name><surname>Solomonson</surname><given-names>M</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>A</given-names></name><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Radivojac</surname><given-names>P</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><collab>gnomAD Consortium</collab></person-group><year iso-8601-date="2024">2024</year><article-title>The Landscape of Regional Missense Mutational Intolerance Quantified from 125,748 Exomes</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.04.11.588920</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocco</surname><given-names>L</given-names></name><name><surname>Follo</surname><given-names>MY</given-names></name><name><surname>Manzoli</surname><given-names>L</given-names></name><name><surname>Suh</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phosphoinositide-specific phospholipase C in health and disease</article-title><source>Journal of Lipid Research</source><volume>56</volume><fpage>1853</fpage><lpage>1860</lpage><pub-id pub-id-type="doi">10.1194/jlr.R057984</pub-id><pub-id pub-id-type="pmid">25821234</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>A</given-names></name><name><surname>Hadler</surname><given-names>J</given-names></name><name><surname>Pointon</surname><given-names>JP</given-names></name><name><surname>Robinson</surname><given-names>PC</given-names></name><name><surname>Karaderi</surname><given-names>T</given-names></name><name><surname>Leo</surname><given-names>P</given-names></name><name><surname>Cremin</surname><given-names>K</given-names></name><name><surname>Pryce</surname><given-names>K</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Joo</surname><given-names>KB</given-names></name><name><surname>Shim</surname><given-names>SC</given-names></name><name><surname>Weisman</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name><name><surname>Chiocchia</surname><given-names>G</given-names></name><name><surname>Nossent</surname><given-names>J</given-names></name><name><surname>Lie</surname><given-names>BA</given-names></name><name><surname>Førre</surname><given-names>Ø</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Laiho</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Bradbury</surname><given-names>LA</given-names></name><name><surname>Elewaut</surname><given-names>D</given-names></name><name><surname>Burgos-Vargas</surname><given-names>R</given-names></name><name><surname>Stebbings</surname><given-names>S</given-names></name><name><surname>Appleton</surname><given-names>L</given-names></name><name><surname>Farrah</surname><given-names>C</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Kenna</surname><given-names>TJ</given-names></name><name><surname>Haroon</surname><given-names>N</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Mulero</surname><given-names>J</given-names></name><name><surname>Fernandez-Sueiro</surname><given-names>JL</given-names></name><name><surname>Gonzalez-Gay</surname><given-names>MA</given-names></name><name><surname>Lopez-Larrea</surname><given-names>C</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name><name><surname>Bowness</surname><given-names>P</given-names></name><name><surname>Gafney</surname><given-names>K</given-names></name><name><surname>Gaston</surname><given-names>H</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Rahman</surname><given-names>P</given-names></name><name><surname>Maksymowych</surname><given-names>WP</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Crusius</surname><given-names>JBA</given-names></name><name><surname>van der Horst-Bruinsma</surname><given-names>IE</given-names></name><name><surname>Chou</surname><given-names>CT</given-names></name><name><surname>Valle-Oñate</surname><given-names>R</given-names></name><name><surname>Romero-Sánchez</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>IM</given-names></name><name><surname>Pimentel-Santos</surname><given-names>FM</given-names></name><name><surname>Inman</surname><given-names>RD</given-names></name><name><surname>Videm</surname><given-names>V</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Breban</surname><given-names>M</given-names></name><name><surname>Reveille</surname><given-names>JD</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Kim</surname><given-names>T-H</given-names></name><name><surname>Wordsworth</surname><given-names>BP</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><collab>International Genetics of Ankylosing Spondylitis Consortium (IGAS)</collab><collab>Australo-Anglo-American Spondyloarthritis Consortium (TASC)</collab><collab>Groupe Française d’Etude Génétique des Spondylarthrites (GFEGS)</collab><collab>Nord-Trøndelag Health Study (HUNT)</collab><collab>Spondyloarthritis Research Consortium of Canada (SPARCC)</collab><collab>Wellcome Trust Case Control Consortium 2 (WTCCC2)</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci</article-title><source>Nature Genetics</source><volume>45</volume><fpage>730</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1038/ng.2667</pub-id><pub-id pub-id-type="pmid">23749187</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalal</surname><given-names>D</given-names></name><name><surname>Molin</surname><given-names>LH</given-names></name><name><surname>Piccini</surname><given-names>J</given-names></name><name><surname>Tichnell</surname><given-names>C</given-names></name><name><surname>James</surname><given-names>C</given-names></name><name><surname>Bomma</surname><given-names>C</given-names></name><name><surname>Prakasa</surname><given-names>K</given-names></name><name><surname>Towbin</surname><given-names>JA</given-names></name><name><surname>Marcus</surname><given-names>FI</given-names></name><name><surname>Spevak</surname><given-names>PJ</given-names></name><name><surname>Bluemke</surname><given-names>DA</given-names></name><name><surname>Abraham</surname><given-names>T</given-names></name><name><surname>Russell</surname><given-names>SD</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Judge</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2</article-title><source>Circulation</source><volume>113</volume><fpage>1641</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.568642</pub-id><pub-id pub-id-type="pmid">16549640</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBell</surname><given-names>K</given-names></name><name><surname>Graham</surname><given-names>L</given-names></name><name><surname>Reischl</surname><given-names>I</given-names></name><name><surname>Serrano</surname><given-names>C</given-names></name><name><surname>Bonvini</surname><given-names>E</given-names></name><name><surname>Rellahan</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Intramolecular regulation of phospholipase C-gamma1 by its C-terminal Src homology 2 domain</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>854</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1128/MCB.01400-06</pub-id><pub-id pub-id-type="pmid">17116690</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>F</given-names></name><name><surname>White</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A novel approach for directing transgene expression in Drosophila: T2A-Gal4 in-frame fusion</article-title><source>Genetics</source><volume>190</volume><fpage>1139</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1534/genetics.111.136291</pub-id><pub-id pub-id-type="pmid">22209908</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>F</given-names></name><name><surname>Ironfield</surname><given-names>H</given-names></name><name><surname>Luan</surname><given-names>H</given-names></name><name><surname>Diao</surname><given-names>F</given-names></name><name><surname>Shropshire</surname><given-names>WC</given-names></name><name><surname>Ewer</surname><given-names>J</given-names></name><name><surname>Marr</surname><given-names>E</given-names></name><name><surname>Potter</surname><given-names>CJ</given-names></name><name><surname>Landgraf</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Plug-and-play genetic access to drosophila cell types using exchangeable exon cassettes</article-title><source>Cell Reports</source><volume>10</volume><fpage>1410</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.059</pub-id><pub-id pub-id-type="pmid">25732830</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>B</given-names></name><name><surname>Hafen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Genetics of signal transduction in invertebrates</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>4</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/0959-437x(94)90092-2</pub-id><pub-id pub-id-type="pmid">8193542</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>MLL</given-names></name><name><surname>Luke</surname><given-names>G</given-names></name><name><surname>Mehrotra</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hughes</surname><given-names>LE</given-names></name><name><surname>Gani</surname><given-names>D</given-names></name><name><surname>Ryan</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of the aphthovirus 2A/2B polyprotein “cleavage” mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal “skip”</article-title><source>The Journal of General Virology</source><volume>82</volume><fpage>1013</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-82-5-1013</pub-id><pub-id pub-id-type="pmid">11297676</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrazeh</surname><given-names>M</given-names></name><name><surname>Ezzatifar</surname><given-names>F</given-names></name><name><surname>Torkamandi</surname><given-names>S</given-names></name><name><surname>Mohammadi</surname><given-names>FS</given-names></name><name><surname>Salimifard</surname><given-names>S</given-names></name><name><surname>Gowhari Shabgah</surname><given-names>A</given-names></name><name><surname>Hemmatzadeh</surname><given-names>M</given-names></name><name><surname>Aslani</surname><given-names>S</given-names></name><name><surname>Babaie</surname><given-names>F</given-names></name><name><surname>Jadidi-Niaragh</surname><given-names>F</given-names></name><name><surname>Gholizadeh Navashenaq</surname><given-names>J</given-names></name><name><surname>Mohammadi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Association of the genetic variants in the endoplasmic reticulum aminopeptidase 2 gene with ankylosing spondylitis susceptibility</article-title><source>International Journal of Rheumatic Diseases</source><volume>24</volume><fpage>567</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1111/1756-185X.14079</pub-id><pub-id pub-id-type="pmid">33550689</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>MV</given-names></name><name><surname>James</surname><given-names>SR</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Downes</surname><given-names>CP</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Catalytic domain of phosphoinositide-specific phospholipase C (PLC). Mutational analysis of residues within the active site and hydrophobic ridge of plcdelta1</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>11650</fpage><lpage>11659</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.19.11650</pub-id><pub-id pub-id-type="pmid">9565585</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Exton</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>36</volume><fpage>481</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1146/annurev.pa.36.040196.002405</pub-id><pub-id pub-id-type="pmid">8725399</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>JA</given-names></name><name><surname>Giniger</surname><given-names>E</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name><name><surname>Ptashne</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>GAL4 activates transcription in Drosophila</article-title><source>Nature</source><volume>332</volume><fpage>853</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1038/332853a0</pub-id><pub-id pub-id-type="pmid">3128741</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foskett</surname><given-names>JK</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Cheung</surname><given-names>K-H</given-names></name><name><surname>Mak</surname><given-names>D-OD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inositol trisphosphate receptor Ca2+ release channels</article-title><source>Physiological Reviews</source><volume>87</volume><fpage>593</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1152/physrev.00035.2006</pub-id><pub-id pub-id-type="pmid">17429043</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>McGovern</surname><given-names>DPB</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Radford-Smith</surname><given-names>GL</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Lees</surname><given-names>CW</given-names></name><name><surname>Balschun</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>CA</given-names></name><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Bumpstead</surname><given-names>S</given-names></name><name><surname>Ellinghaus</surname><given-names>D</given-names></name><name><surname>Festen</surname><given-names>EM</given-names></name><name><surname>Georges</surname><given-names>M</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Haritunians</surname><given-names>T</given-names></name><name><surname>Jostins</surname><given-names>L</given-names></name><name><surname>Latiano</surname><given-names>A</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><name><surname>Montgomery</surname><given-names>GW</given-names></name><name><surname>Prescott</surname><given-names>NJ</given-names></name><name><surname>Raychaudhuri</surname><given-names>S</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Schumm</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>Y</given-names></name><name><surname>Simms</surname><given-names>LA</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Whiteman</surname><given-names>D</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Baldassano</surname><given-names>RN</given-names></name><name><surname>Barclay</surname><given-names>M</given-names></name><name><surname>Bayless</surname><given-names>TM</given-names></name><name><surname>Brand</surname><given-names>S</given-names></name><name><surname>Büning</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>A</given-names></name><name><surname>Colombel</surname><given-names>JF</given-names></name><name><surname>Cottone</surname><given-names>M</given-names></name><name><surname>Stronati</surname><given-names>L</given-names></name><name><surname>Denson</surname><given-names>T</given-names></name><name><surname>De Vos</surname><given-names>M</given-names></name><name><surname>D’Inca</surname><given-names>R</given-names></name><name><surname>Dubinsky</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>C</given-names></name><name><surname>Florin</surname><given-names>T</given-names></name><name><surname>Franchimont</surname><given-names>D</given-names></name><name><surname>Gearry</surname><given-names>R</given-names></name><name><surname>Glas</surname><given-names>J</given-names></name><name><surname>Van Gossum</surname><given-names>A</given-names></name><name><surname>Guthery</surname><given-names>SL</given-names></name><name><surname>Halfvarson</surname><given-names>J</given-names></name><name><surname>Verspaget</surname><given-names>HW</given-names></name><name><surname>Hugot</surname><given-names>JP</given-names></name><name><surname>Karban</surname><given-names>A</given-names></name><name><surname>Laukens</surname><given-names>D</given-names></name><name><surname>Lawrance</surname><given-names>I</given-names></name><name><surname>Lemann</surname><given-names>M</given-names></name><name><surname>Levine</surname><given-names>A</given-names></name><name><surname>Libioulle</surname><given-names>C</given-names></name><name><surname>Louis</surname><given-names>E</given-names></name><name><surname>Mowat</surname><given-names>C</given-names></name><name><surname>Newman</surname><given-names>W</given-names></name><name><surname>Panés</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>A</given-names></name><name><surname>Proctor</surname><given-names>DD</given-names></name><name><surname>Regueiro</surname><given-names>M</given-names></name><name><surname>Russell</surname><given-names>R</given-names></name><name><surname>Rutgeerts</surname><given-names>P</given-names></name><name><surname>Sanderson</surname><given-names>J</given-names></name><name><surname>Sans</surname><given-names>M</given-names></name><name><surname>Seibold</surname><given-names>F</given-names></name><name><surname>Steinhart</surname><given-names>AH</given-names></name><name><surname>Stokkers</surname><given-names>PCF</given-names></name><name><surname>Torkvist</surname><given-names>L</given-names></name><name><surname>Kullak-Ublick</surname><given-names>G</given-names></name><name><surname>Wilson</surname><given-names>D</given-names></name><name><surname>Walters</surname><given-names>T</given-names></name><name><surname>Targan</surname><given-names>SR</given-names></name><name><surname>Brant</surname><given-names>SR</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>D’Amato</surname><given-names>M</given-names></name><name><surname>Weersma</surname><given-names>RK</given-names></name><name><surname>Kugathasan</surname><given-names>S</given-names></name><name><surname>Griffiths</surname><given-names>AM</given-names></name><name><surname>Mansfield</surname><given-names>JC</given-names></name><name><surname>Vermeire</surname><given-names>S</given-names></name><name><surname>Duerr</surname><given-names>RH</given-names></name><name><surname>Silverberg</surname><given-names>MS</given-names></name><name><surname>Satsangi</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Annese</surname><given-names>V</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Parkes</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci</article-title><source>Nature Genetics</source><volume>42</volume><fpage>1118</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1038/ng.717</pub-id><pub-id pub-id-type="pmid">21102463</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye</article-title><source>Cell</source><volume>87</volume><fpage>651</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81385-9</pub-id><pub-id pub-id-type="pmid">8929534</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerull</surname><given-names>B</given-names></name><name><surname>Heuser</surname><given-names>A</given-names></name><name><surname>Wichter</surname><given-names>T</given-names></name><name><surname>Paul</surname><given-names>M</given-names></name><name><surname>Basson</surname><given-names>CT</given-names></name><name><surname>McDermott</surname><given-names>DA</given-names></name><name><surname>Lerman</surname><given-names>BB</given-names></name><name><surname>Markowitz</surname><given-names>SM</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>MacRae</surname><given-names>CA</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Grossmann</surname><given-names>KS</given-names></name><name><surname>Drenckhahn</surname><given-names>J</given-names></name><name><surname>Michely</surname><given-names>B</given-names></name><name><surname>Sasse-Klaassen</surname><given-names>S</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name><name><surname>Dietz</surname><given-names>R</given-names></name><name><surname>Breithardt</surname><given-names>G</given-names></name><name><surname>Schulze-Bahr</surname><given-names>E</given-names></name><name><surname>Thierfelder</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy</article-title><source>Nat Genet</source><volume>36</volume><fpage>1162</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1038/ng1461</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>DA</given-names></name><name><surname>de Miranda</surname><given-names>MC</given-names></name><name><surname>Faria</surname><given-names>JAQA</given-names></name><name><surname>Rodrigues</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The basis of nuclear phospholipase C in cell proliferation</article-title><source>Advances in Biological Regulation</source><volume>82</volume><elocation-id>100834</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbior.2021.100834</pub-id><pub-id pub-id-type="pmid">34710785</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gresset</surname><given-names>A</given-names></name><name><surname>Hicks</surname><given-names>SN</given-names></name><name><surname>Harden</surname><given-names>TK</given-names></name><name><surname>Sondek</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mechanism of phosphorylation-induced activation of phospholipase C-gamma isozymes</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>35836</fpage><lpage>35847</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.166512</pub-id><pub-id pub-id-type="pmid">20807769</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gresset</surname><given-names>A</given-names></name><name><surname>Sondek</surname><given-names>J</given-names></name><name><surname>Harden</surname><given-names>TK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The phospholipase C isozymes and their regulation</article-title><source>Sub-Cellular Biochemistry</source><volume>58</volume><fpage>61</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1007/978-94-007-3012-0_3</pub-id><pub-id pub-id-type="pmid">22403074</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans</article-title><source>Science</source><volume>348</volume><fpage>648</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1126/science.1262110</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajicek</surname><given-names>N</given-names></name><name><surname>Charpentier</surname><given-names>TH</given-names></name><name><surname>Rush</surname><given-names>JR</given-names></name><name><surname>Harden</surname><given-names>TK</given-names></name><name><surname>Sondek</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes</article-title><source>Biochemistry</source><volume>52</volume><fpage>4810</fpage><lpage>4819</lpage><pub-id pub-id-type="doi">10.1021/bi400433b</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajicek</surname><given-names>N</given-names></name><name><surname>Keith</surname><given-names>NC</given-names></name><name><surname>Siraliev-Perez</surname><given-names>E</given-names></name><name><surname>Temple</surname><given-names>BR</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Harden</surname><given-names>TK</given-names></name><name><surname>Sondek</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis for the activation of PLC-γ isozymes by phosphorylation and cancer-associated mutations</article-title><source>eLife</source><volume>8</volume><elocation-id>e51700</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.51700</pub-id><pub-id pub-id-type="pmid">31889510</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakui</surname><given-names>H</given-names></name><name><surname>Kioka</surname><given-names>H</given-names></name><name><surname>Sera</surname><given-names>F</given-names></name><name><surname>Nakamoto</surname><given-names>K</given-names></name><name><surname>Ozu</surname><given-names>K</given-names></name><name><surname>Kuramoto</surname><given-names>Y</given-names></name><name><surname>Miyashita</surname><given-names>Y</given-names></name><name><surname>Ohtani</surname><given-names>T</given-names></name><name><surname>Hikoso</surname><given-names>S</given-names></name><name><surname>Asano</surname><given-names>Y</given-names></name><name><surname>Sakata</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Refractory ventricular arrhythmias in a patient with dilated cardiomyopathy caused by a nonsense mutation in BAG5</article-title><source>Circulation Journal</source><volume>86</volume><elocation-id>220329</elocation-id><pub-id pub-id-type="doi">10.1253/circj.CJ-22-0329</pub-id><pub-id pub-id-type="pmid">36130910</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilgemann</surname><given-names>DW</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Nasuhoglu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The complex and intriguing lives of PIP2 with ion channels and transporters</article-title><source>Science’s STKE</source><volume>2001</volume><elocation-id>re19</elocation-id><pub-id pub-id-type="doi">10.1126/stke.2001.111.re19</pub-id><pub-id pub-id-type="pmid">11734659</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilgemann</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Local PIP(2) signals: when, where, and how?</article-title><source>Pflugers Archiv</source><volume>455</volume><fpage>55</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1007/s00424-007-0280-9</pub-id><pub-id pub-id-type="pmid">17534652</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homma</surname><given-names>Y</given-names></name><name><surname>Takenawa</surname><given-names>T</given-names></name><name><surname>Emori</surname><given-names>Y</given-names></name><name><surname>Sorimachi</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Tissue- and cell type-specific expression of mRNAs for four types of inositol phospholipid-specific phospholipase C</article-title><source>Biochemical and Biophysical Research Communications</source><volume>164</volume><fpage>406</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/0006-291x(89)91734-8</pub-id><pub-id pub-id-type="pmid">2553017</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Comjean</surname><given-names>A</given-names></name><name><surname>Rodiger</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>V</given-names></name><name><surname>Zirin</surname><given-names>J</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name><name><surname>Mohr</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2021 update</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D908</fpage><lpage>D915</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa936</pub-id><pub-id pub-id-type="pmid">33104800</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lemire</surname><given-names>G</given-names></name><name><surname>Briere</surname><given-names>LC</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Wessels</surname><given-names>MW</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Osmond</surname><given-names>M</given-names></name><name><surname>Kanca</surname><given-names>O</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>High</surname><given-names>FA</given-names></name><name><surname>Walker</surname><given-names>MA</given-names></name><name><surname>Rodan</surname><given-names>LH</given-names></name><name><surname>Wangler</surname><given-names>MF</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Kernohan</surname><given-names>KD</given-names></name><name><surname>Sweetser</surname><given-names>DA</given-names></name><name><surname>Boycott</surname><given-names>KM</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>The recurrent de novo c.2011C&gt;T missense variant in MTSS2 causes syndromic intellectual disability</article-title><source>The American Journal of Human Genetics</source><volume>109</volume><fpage>1923</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2022.08.011</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Pehlivan</surname><given-names>D</given-names></name><name><surname>Kanca</surname><given-names>O</given-names></name><name><surname>Un-Candan</surname><given-names>F</given-names></name><name><surname>Shu</surname><given-names>L</given-names></name><name><surname>Akay</surname><given-names>G</given-names></name><name><surname>Mitani</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Candan</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Lupski</surname><given-names>JR</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Novel dominant and recessive variants in human <italic>ROBO1</italic> cause distinct neurodevelopmental defects through different mechanisms</article-title><source>Human Molecular Genetics</source><volume>31</volume><fpage>2751</fpage><lpage>2765</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddac070</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>QS</given-names></name><name><surname>Winnier</surname><given-names>GE</given-names></name><name><surname>Niswender</surname><given-names>KD</given-names></name><name><surname>Horstman</surname><given-names>D</given-names></name><name><surname>Wisdom</surname><given-names>R</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name><name><surname>Carpenter</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development</article-title><source>PNAS</source><volume>94</volume><fpage>2999</fpage><lpage>3003</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.7.2999</pub-id><pub-id pub-id-type="pmid">9096335</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadamur</surname><given-names>G</given-names></name><name><surname>Ross</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mammalian phospholipase C</article-title><source>Annual Review of Physiology</source><volume>75</volume><fpage>127</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-030212-183750</pub-id><pub-id pub-id-type="pmid">23140367</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Francioli</surname><given-names>LC</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Alföldi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Collins</surname><given-names>RL</given-names></name><name><surname>Laricchia</surname><given-names>KM</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Gauthier</surname><given-names>LD</given-names></name><name><surname>Brand</surname><given-names>H</given-names></name><name><surname>Solomonson</surname><given-names>M</given-names></name><name><surname>Watts</surname><given-names>NA</given-names></name><name><surname>Rhodes</surname><given-names>D</given-names></name><name><surname>Singer-Berk</surname><given-names>M</given-names></name><name><surname>England</surname><given-names>EM</given-names></name><name><surname>Seaby</surname><given-names>EG</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Walters</surname><given-names>RK</given-names></name><name><surname>Tashman</surname><given-names>K</given-names></name><name><surname>Farjoun</surname><given-names>Y</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Poterba</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Seed</surname><given-names>C</given-names></name><name><surname>Whiffin</surname><given-names>N</given-names></name><name><surname>Chong</surname><given-names>JX</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Zappala</surname><given-names>Z</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Vittal</surname><given-names>C</given-names></name><name><surname>Armean</surname><given-names>IM</given-names></name><name><surname>Bergelson</surname><given-names>L</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Connolly</surname><given-names>KM</given-names></name><name><surname>Covarrubias</surname><given-names>M</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Ferriera</surname><given-names>S</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Gentry</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Jeandet</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>D</given-names></name><name><surname>Llanwarne</surname><given-names>C</given-names></name><name><surname>Munshi</surname><given-names>R</given-names></name><name><surname>Novod</surname><given-names>S</given-names></name><name><surname>Petrillo</surname><given-names>N</given-names></name><name><surname>Roazen</surname><given-names>D</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Saltzman</surname><given-names>A</given-names></name><name><surname>Schleicher</surname><given-names>M</given-names></name><name><surname>Soto</surname><given-names>J</given-names></name><name><surname>Tibbetts</surname><given-names>K</given-names></name><name><surname>Tolonen</surname><given-names>C</given-names></name><name><surname>Wade</surname><given-names>G</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><collab>Genome Aggregation Database Consortium</collab><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title><source>Nature</source><volume>581</volume><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id><pub-id pub-id-type="pmid">32461654</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katan</surname><given-names>M</given-names></name><name><surname>Cockcroft</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Phospholipase C families: Common themes and versatility in physiology and pathology</article-title><source>Progress in Lipid Research</source><volume>80</volume><elocation-id>101065</elocation-id><pub-id pub-id-type="doi">10.1016/j.plipres.2020.101065</pub-id><pub-id pub-id-type="pmid">32966869</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Kitanaka</surname><given-names>A</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Shimamura</surname><given-names>T</given-names></name><name><surname>Yasunaga</surname><given-names>J-I</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name><name><surname>Sato-Otsubo</surname><given-names>A</given-names></name><name><surname>Nagae</surname><given-names>G</given-names></name><name><surname>Ishii</surname><given-names>R</given-names></name><name><surname>Muto</surname><given-names>S</given-names></name><name><surname>Kotani</surname><given-names>S</given-names></name><name><surname>Watatani</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Shiozawa</surname><given-names>Y</given-names></name><name><surname>Yoshizato</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Makishima</surname><given-names>H</given-names></name><name><surname>Iwanaga</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>G</given-names></name><name><surname>Nosaka</surname><given-names>K</given-names></name><name><surname>Hishizawa</surname><given-names>M</given-names></name><name><surname>Itonaga</surname><given-names>H</given-names></name><name><surname>Imaizumi</surname><given-names>Y</given-names></name><name><surname>Munakata</surname><given-names>W</given-names></name><name><surname>Ogasawara</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Sasai</surname><given-names>K</given-names></name><name><surname>Muramoto</surname><given-names>K</given-names></name><name><surname>Penova</surname><given-names>M</given-names></name><name><surname>Kawaguchi</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Hama</surname><given-names>N</given-names></name><name><surname>Shide</surname><given-names>K</given-names></name><name><surname>Kubuki</surname><given-names>Y</given-names></name><name><surname>Hidaka</surname><given-names>T</given-names></name><name><surname>Kameda</surname><given-names>T</given-names></name><name><surname>Nakamaki</surname><given-names>T</given-names></name><name><surname>Ishiyama</surname><given-names>K</given-names></name><name><surname>Miyawaki</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>S-S</given-names></name><name><surname>Tobinai</surname><given-names>K</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Takaori-Kondo</surname><given-names>A</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Matsuoka</surname><given-names>M</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Shimoda</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Integrated molecular analysis of adult T cell leukemia/lymphoma</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1304</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.1038/ng.3415</pub-id><pub-id pub-id-type="pmid">26437031</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunze</surname><given-names>K</given-names></name><name><surname>Spieker</surname><given-names>T</given-names></name><name><surname>Gamerdinger</surname><given-names>U</given-names></name><name><surname>Nau</surname><given-names>K</given-names></name><name><surname>Berger</surname><given-names>J</given-names></name><name><surname>Dreyer</surname><given-names>T</given-names></name><name><surname>Sindermann</surname><given-names>JR</given-names></name><name><surname>Hoffmeier</surname><given-names>A</given-names></name><name><surname>Gattenlöhner</surname><given-names>S</given-names></name><name><surname>Bräuninger</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A recurrent activating <italic>PLCG1</italic> mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells</article-title><source>Cancer Research</source><volume>74</volume><fpage>6173</fpage><lpage>6183</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1162</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>PT</given-names></name><name><surname>Zirin</surname><given-names>J</given-names></name><name><surname>Kanca</surname><given-names>O</given-names></name><name><surname>Lin</surname><given-names>WW</given-names></name><name><surname>Schulze</surname><given-names>KL</given-names></name><name><surname>Li-Kroeger</surname><given-names>D</given-names></name><name><surname>Tao</surname><given-names>R</given-names></name><name><surname>Devereaux</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>V</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Ge</surname><given-names>M</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Housden</surname><given-names>BE</given-names></name><name><surname>Mohr</surname><given-names>SE</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Levis</surname><given-names>RW</given-names></name><name><surname>Spradling</surname><given-names>AC</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A gene-specific T2A-GAL4 library for Drosophila</article-title><source>eLife</source><volume>7</volume><elocation-id>35574</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.35574</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Huray</surname><given-names>KIP</given-names></name><name><surname>Bunney</surname><given-names>TD</given-names></name><name><surname>Pinotsis</surname><given-names>N</given-names></name><name><surname>Kalli</surname><given-names>AC</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Characterization of the membrane interactions of phospholipase Cγ reveals key features of the active enzyme</article-title><source>Science Advances</source><volume>8</volume><elocation-id>eabp9688</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abp9688</pub-id><pub-id pub-id-type="pmid">35749497</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Hill</surname><given-names>AJ</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Tukiainen</surname><given-names>T</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Duncan</surname><given-names>LE</given-names></name><name><surname>Estrada</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Berghout</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>Deflaux</surname><given-names>N</given-names></name><name><surname>DePristo</surname><given-names>M</given-names></name><name><surname>Do</surname><given-names>R</given-names></name><name><surname>Flannick</surname><given-names>J</given-names></name><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Gauthier</surname><given-names>L</given-names></name><name><surname>Goldstein</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Howrigan</surname><given-names>D</given-names></name><name><surname>Kiezun</surname><given-names>A</given-names></name><name><surname>Kurki</surname><given-names>MI</given-names></name><name><surname>Moonshine</surname><given-names>AL</given-names></name><name><surname>Natarajan</surname><given-names>P</given-names></name><name><surname>Orozco</surname><given-names>L</given-names></name><name><surname>Peloso</surname><given-names>GM</given-names></name><name><surname>Poplin</surname><given-names>R</given-names></name><name><surname>Rivas</surname><given-names>MA</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Rose</surname><given-names>SA</given-names></name><name><surname>Ruderfer</surname><given-names>DM</given-names></name><name><surname>Shakir</surname><given-names>K</given-names></name><name><surname>Stenson</surname><given-names>PD</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>BP</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Tusie-Luna</surname><given-names>MT</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Won</surname><given-names>H-H</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Altshuler</surname><given-names>DM</given-names></name><name><surname>Ardissino</surname><given-names>D</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Elosua</surname><given-names>R</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Glatt</surname><given-names>SJ</given-names></name><name><surname>Hultman</surname><given-names>CM</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>McCarroll</surname><given-names>S</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>McGovern</surname><given-names>D</given-names></name><name><surname>McPherson</surname><given-names>R</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Purcell</surname><given-names>SM</given-names></name><name><surname>Saleheen</surname><given-names>D</given-names></name><name><surname>Scharf</surname><given-names>JM</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Tsuang</surname><given-names>MT</given-names></name><name><surname>Watkins</surname><given-names>HC</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><collab>Exome Aggregation Consortium</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title><source>Nature</source><volume>536</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/nature19057</pub-id><pub-id pub-id-type="pmid">27535533</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>HJ</given-names></name><name><surname>Kume</surname><given-names>T</given-names></name><name><surname>McKay</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>MJ</given-names></name><name><surname>Ihle</surname><given-names>JN</given-names></name><name><surname>Carpenter</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>9335</fpage><lpage>9341</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109955200</pub-id><pub-id pub-id-type="pmid">11744703</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Bunney</surname><given-names>TD</given-names></name><name><surname>Khosa</surname><given-names>S</given-names></name><name><surname>Macé</surname><given-names>K</given-names></name><name><surname>Beckenbauer</surname><given-names>K</given-names></name><name><surname>Askwith</surname><given-names>T</given-names></name><name><surname>Maslen</surname><given-names>S</given-names></name><name><surname>Stubbs</surname><given-names>C</given-names></name><name><surname>de Oliveira</surname><given-names>TM</given-names></name><name><surname>Sader</surname><given-names>K</given-names></name><name><surname>Skehel</surname><given-names>M</given-names></name><name><surname>Gavin</surname><given-names>A-C</given-names></name><name><surname>Phillips</surname><given-names>C</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural insights and activating mutations in diverse pathologies define mechanisms of deregulation for phospholipase C gamma enzymes</article-title><source>EBioMedicine</source><volume>51</volume><elocation-id>102607</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.102607</pub-id><pub-id pub-id-type="pmid">31918402</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Hernan</surname><given-names>R</given-names></name><name><surname>Marcogliese</surname><given-names>PC</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Gertler</surname><given-names>TS</given-names></name><name><surname>Akcaboy</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Oguz</surname><given-names>MM</given-names></name><name><surname>Oztoprak</surname><given-names>U</given-names></name><name><surname>de Baaij</surname><given-names>JHF</given-names></name><name><surname>Ivanisevic</surname><given-names>J</given-names></name><name><surname>McGinnis</surname><given-names>E</given-names></name><name><surname>Guillen Sacoto</surname><given-names>MJ</given-names></name><name><surname>Chung</surname><given-names>WK</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Loss-of-function variants in TIAM1 are associated with developmental delay, intellectual disability, and seizures</article-title><source>The American Journal of Human Genetics</source><volume>109</volume><fpage>571</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2022.01.020</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Bacino</surname><given-names>CA</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Sutton</surname><given-names>VR</given-names></name><name><surname>Bartley</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Beleza-Meireles</surname><given-names>A</given-names></name><name><surname>Chauhan</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Prescott</surname><given-names>K</given-names></name><name><surname>Amin</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>G</given-names></name><name><surname>Wangler</surname><given-names>MF</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>De novo variants in FRMD5 are associated with developmental delay, intellectual disability, ataxia, and abnormalities of eye movement</article-title><source>The American Journal of Human Genetics</source><volume>109</volume><fpage>1932</fpage><lpage>1943</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2022.09.005</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The fly homolog of    <italic>SUPT16H</italic>    , a gene associated with neurodevelopmental disorders, is required in a cell-autonomous fashion for cell survival</article-title><source>Human Molecular Genetics</source><volume>32</volume><fpage>984</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddac259</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madabattula</surname><given-names>ST</given-names></name><name><surname>Strautman</surname><given-names>JC</given-names></name><name><surname>Bysice</surname><given-names>AM</given-names></name><name><surname>O’Sullivan</surname><given-names>JA</given-names></name><name><surname>Androschuk</surname><given-names>A</given-names></name><name><surname>Rosenfelt</surname><given-names>C</given-names></name><name><surname>Doucet</surname><given-names>K</given-names></name><name><surname>Rouleau</surname><given-names>G</given-names></name><name><surname>Bolduc</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Quantitative analysis of climbing defects in a Drosophila model of neurodegenerative disorders</article-title><source>Journal of Visualized Experiments</source><volume>100</volume><elocation-id>52741</elocation-id><pub-id pub-id-type="doi">10.3791/52741</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>JA</given-names></name><name><surname>Martinez</surname><given-names>C</given-names></name><name><surname>Kasavajhala</surname><given-names>K</given-names></name><name><surname>Wickstrom</surname><given-names>L</given-names></name><name><surname>Hauser</surname><given-names>KE</given-names></name><name><surname>Simmerling</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB</article-title><source>Journal of Chemical Theory and Computation</source><volume>11</volume><fpage>3696</fpage><lpage>3713</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.5b00255</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majerus</surname><given-names>PW</given-names></name><name><surname>Connolly</surname><given-names>TM</given-names></name><name><surname>Deckmyn</surname><given-names>H</given-names></name><name><surname>Ross</surname><given-names>TS</given-names></name><name><surname>Bross</surname><given-names>TE</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Bansal</surname><given-names>VS</given-names></name><name><surname>Wilson</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>The metabolism of phosphoinositide-derived messenger molecules</article-title><source>Science</source><volume>234</volume><fpage>1519</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1126/science.3024320</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manso</surname><given-names>R</given-names></name><name><surname>Rodríguez-Pinilla</surname><given-names>SM</given-names></name><name><surname>González-Rincón</surname><given-names>J</given-names></name><name><surname>Gómez</surname><given-names>S</given-names></name><name><surname>Monsalvo</surname><given-names>S</given-names></name><name><surname>Llamas</surname><given-names>P</given-names></name><name><surname>Rojo</surname><given-names>F</given-names></name><name><surname>Pérez-Callejo</surname><given-names>D</given-names></name><name><surname>Cereceda</surname><given-names>L</given-names></name><name><surname>Limeres</surname><given-names>MA</given-names></name><name><surname>Maeso</surname><given-names>C</given-names></name><name><surname>Ferrando</surname><given-names>L</given-names></name><name><surname>Pérez-Seoane</surname><given-names>C</given-names></name><name><surname>Rodríguez</surname><given-names>G</given-names></name><name><surname>Arrinda</surname><given-names>JM</given-names></name><name><surname>García-Bragado</surname><given-names>F</given-names></name><name><surname>Franco</surname><given-names>R</given-names></name><name><surname>Rodriguez-Peralto</surname><given-names>JL</given-names></name><name><surname>González-Carreró</surname><given-names>J</given-names></name><name><surname>Martín-Dávila</surname><given-names>F</given-names></name><name><surname>Piris</surname><given-names>MA</given-names></name><name><surname>Sánchez-Beato</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas</article-title><source>Haematologica</source><volume>100</volume><fpage>e25</fpage><lpage>e27</lpage><pub-id pub-id-type="doi">10.3324/haematol.2014.113696</pub-id><pub-id pub-id-type="pmid">25304611</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuyama</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mapping neural circuits with activity-dependent nuclear import of a transcription factor</article-title><source>Journal of Neurogenetics</source><volume>26</volume><fpage>89</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.3109/01677063.2011.642910</pub-id><pub-id pub-id-type="pmid">22236090</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarkar-Jaiswal</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>PT</given-names></name><name><surname>Campbell</surname><given-names>ME</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Anguiano-Zarate</surname><given-names>S</given-names></name><name><surname>Gutierrez</surname><given-names>MC</given-names></name><name><surname>Busby</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>WW</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Schulze</surname><given-names>KL</given-names></name><name><surname>Booth</surname><given-names>BW</given-names></name><name><surname>Evans-Holm</surname><given-names>M</given-names></name><name><surname>Venken</surname><given-names>KJT</given-names></name><name><surname>Levis</surname><given-names>RW</given-names></name><name><surname>Spradling</surname><given-names>AC</given-names></name><name><surname>Hoskins</surname><given-names>RA</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A library of MiMICs allows tagging of genes and reversible, spatial and temporal knockdown of proteins in <italic>Drosophila</italic></article-title><source>eLife</source><volume>4</volume><elocation-id>e05338</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.05338</pub-id><pub-id pub-id-type="pmid">25824290</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neves</surname><given-names>JF</given-names></name><name><surname>Doffinger</surname><given-names>R</given-names></name><name><surname>Barcena-Morales</surname><given-names>G</given-names></name><name><surname>Martins</surname><given-names>C</given-names></name><name><surname>Papapietro</surname><given-names>O</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Curtis</surname><given-names>J</given-names></name><name><surname>Martins</surname><given-names>M</given-names></name><name><surname>Kumararatne</surname><given-names>D</given-names></name><name><surname>Cordeiro</surname><given-names>AI</given-names></name><name><surname>Neves</surname><given-names>C</given-names></name><name><surname>Borrego</surname><given-names>LM</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name><name><surname>Nejentsev</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Novel <italic>PLCG2</italic> mutation in a patient With APLAID and cutis laxa</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>2863</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02863</pub-id><pub-id pub-id-type="pmid">30619256</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishizuka</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Turnover of inositol phospholipids and signal transduction</article-title><source>Science</source><volume>225</volume><fpage>1365</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1126/science.6147898</pub-id><pub-id pub-id-type="pmid">6147898</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishizuka</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C</article-title><source>Science</source><volume>258</volume><fpage>607</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1126/science.1411571</pub-id><pub-id pub-id-type="pmid">1411571</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noh</surname><given-names>DY</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Ryu</surname><given-names>SH</given-names></name><name><surname>Suh</surname><given-names>PG</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Elevated content of phospholipase C-gamma 1 in colorectal cancer tissues</article-title><source>Cancer</source><volume>73</volume><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19940101)73:1&lt;36::aid-cncr2820730108&gt;3.0.co;2-5</pub-id><pub-id pub-id-type="pmid">8275435</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nosbisch</surname><given-names>JL</given-names></name><name><surname>Bear</surname><given-names>JE</given-names></name><name><surname>Haugh</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A kinetic model of phospholipase C-γ1 linking structure-based insights to dynamics of enzyme autoinhibition and activation</article-title><source>The Journal of Biological Chemistry</source><volume>298</volume><elocation-id>101886</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2022.101886</pub-id><pub-id pub-id-type="pmid">35367415</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oleari</surname><given-names>R</given-names></name><name><surname>André</surname><given-names>V</given-names></name><name><surname>Lettieri</surname><given-names>A</given-names></name><name><surname>Tahir</surname><given-names>S</given-names></name><name><surname>Roth</surname><given-names>L</given-names></name><name><surname>Paganoni</surname><given-names>A</given-names></name><name><surname>Eberini</surname><given-names>I</given-names></name><name><surname>Parravicini</surname><given-names>C</given-names></name><name><surname>Scagliotti</surname><given-names>V</given-names></name><name><surname>Cotellessa</surname><given-names>L</given-names></name><name><surname>Bedogni</surname><given-names>F</given-names></name><name><surname>De Martini</surname><given-names>LB</given-names></name><name><surname>Corridori</surname><given-names>MV</given-names></name><name><surname>Gulli</surname><given-names>S</given-names></name><name><surname>Augustin</surname><given-names>HG</given-names></name><name><surname>Gaston-Massuet</surname><given-names>C</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Cariboni</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A novel SEMA3G mutation in two siblings affected by syndromic GnRH deficiency</article-title><source>Neuroendocrinology</source><volume>111</volume><fpage>421</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1159/000508375</pub-id><pub-id pub-id-type="pmid">32365351</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ombrello</surname><given-names>MJ</given-names></name><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Freeman</surname><given-names>AF</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Torabi-Parizi</surname><given-names>P</given-names></name><name><surname>Subramanian</surname><given-names>N</given-names></name><name><surname>Bunney</surname><given-names>TD</given-names></name><name><surname>Baxendale</surname><given-names>RW</given-names></name><name><surname>Martins</surname><given-names>MS</given-names></name><name><surname>Romberg</surname><given-names>N</given-names></name><name><surname>Komarow</surname><given-names>H</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Ho</surname><given-names>J</given-names></name><name><surname>Cruse</surname><given-names>G</given-names></name><name><surname>Jung</surname><given-names>M-Y</given-names></name><name><surname>Gilfillan</surname><given-names>AM</given-names></name><name><surname>Metcalfe</surname><given-names>DD</given-names></name><name><surname>Nelson</surname><given-names>C</given-names></name><name><surname>O’Brien</surname><given-names>M</given-names></name><name><surname>Wisch</surname><given-names>L</given-names></name><name><surname>Stone</surname><given-names>K</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Gandhi</surname><given-names>C</given-names></name><name><surname>Wanderer</surname><given-names>AA</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>Shianna</surname><given-names>KV</given-names></name><name><surname>Cirulli</surname><given-names>ET</given-names></name><name><surname>Goldstein</surname><given-names>DB</given-names></name><name><surname>Long</surname><given-names>EO</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Meffre</surname><given-names>E</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>HM</given-names></name><name><surname>Milner</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>330</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1102140</pub-id><pub-id pub-id-type="pmid">22236196</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Alvarez</surname><given-names>AN</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Crawford</surname><given-names>MW</given-names></name><name><surname>Briere</surname><given-names>LC</given-names></name><name><surname>Kanca</surname><given-names>O</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Sweetser</surname><given-names>DA</given-names></name><name><surname>Wilson</surname><given-names>JL</given-names></name><name><surname>Napier</surname><given-names>RJ</given-names></name><name><surname>Pruneda</surname><given-names>JN</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Allelic strengths of encephalopathy-associated UBA5 Variants correlate between in vivo and in vitro Assays</article-title><source>eLife</source><volume>12</volume><elocation-id>898911</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.89891.1</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Park</surname><given-names>KJ</given-names></name><name><surname>Noh</surname><given-names>DY</given-names></name><name><surname>Ryu</surname><given-names>SH</given-names></name><name><surname>Suh</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Overexpression of phospholipase C-gamma 1 in familial adenomatous polyposis</article-title><source>Cancer Research</source><volume>54</volume><fpage>2240</fpage><lpage>2244</lpage><pub-id pub-id-type="pmid">8174133</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pronk</surname><given-names>S</given-names></name><name><surname>Páll</surname><given-names>S</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Larsson</surname><given-names>P</given-names></name><name><surname>Bjelkmar</surname><given-names>P</given-names></name><name><surname>Apostolov</surname><given-names>R</given-names></name><name><surname>Shirts</surname><given-names>MR</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name><name><surname>Kasson</surname><given-names>PM</given-names></name><name><surname>van der Spoel</surname><given-names>D</given-names></name><name><surname>Hess</surname><given-names>B</given-names></name><name><surname>Lindahl</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit</article-title><source>Bioinformatics</source><volume>29</volume><fpage>845</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt055</pub-id><pub-id pub-id-type="pmid">23407358</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinodoz</surname><given-names>M</given-names></name><name><surname>Royer-Bertrand</surname><given-names>B</given-names></name><name><surname>Cisarova</surname><given-names>K</given-names></name><name><surname>Di Gioia</surname><given-names>SA</given-names></name><name><surname>Superti-Furga</surname><given-names>A</given-names></name><name><surname>Rivolta</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>DOMINO: Using machine learning to predict genes associated with dominant disorders</article-title><source>American Journal of Human Genetics</source><volume>101</volume><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.09.001</pub-id><pub-id pub-id-type="pmid">28985496</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravenscroft</surname><given-names>TA</given-names></name><name><surname>Janssens</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>PT</given-names></name><name><surname>Tepe</surname><given-names>B</given-names></name><name><surname>Marcogliese</surname><given-names>PC</given-names></name><name><surname>Makhzami</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>TC</given-names></name><name><surname>Aerts</surname><given-names>S</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Drosophila voltage-gated sodium channels are only expressed in active neurons and are localized to distal axonal initial segment-like domains</article-title><source>The Journal of Neuroscience</source><volume>40</volume><fpage>7999</fpage><lpage>8024</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0142-20.2020</pub-id><pub-id pub-id-type="pmid">32928889</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regunathan</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kutlesa</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Malarkannan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Differential and nonredundant roles of phospholipase Cgamma2 and phospholipase Cgamma1 in the terminal maturation of NK cells</article-title><source>Journal of Immunology</source><volume>177</volume><fpage>5365</fpage><lpage>5376</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.8.5365</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinius</surname><given-names>B</given-names></name><name><surname>Sandberg</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Random monoallelic expression of autosomal genes: stochastic transcription and allele-level regulation</article-title><source>Nature Reviews. Genetics</source><volume>16</volume><fpage>653</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1038/nrg3888</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinow</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Characterization and spatial distribution of the ELAV protein during <italic>Drosophila melanogaster</italic> development</article-title><source>Journal of Neurobiology</source><volume>22</volume><fpage>443</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/neu.480220503</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Rasband</surname><given-names>WS</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NIH Image to ImageJ: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweitzer</surname><given-names>R</given-names></name><name><surname>Shilo</surname><given-names>BZ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>A thousand and one roles for the <italic>Drosophila</italic> EGF receptor</article-title><source>Trends in Genetics</source><volume>13</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/s0168-9525(97)01091-3</pub-id><pub-id pub-id-type="pmid">9154002</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepp</surname><given-names>KJ</given-names></name><name><surname>Schulte</surname><given-names>J</given-names></name><name><surname>Auld</surname><given-names>VJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Peripheral glia direct axon guidance across the CNS/PNS transition zone</article-title><source>Developmental Biology</source><volume>238</volume><fpage>47</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1006/dbio.2001.0411</pub-id><pub-id pub-id-type="pmid">11783993</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siraliev-Perez</surname><given-names>E</given-names></name><name><surname>Stariha</surname><given-names>JTB</given-names></name><name><surname>Hoffmann</surname><given-names>RM</given-names></name><name><surname>Temple</surname><given-names>BRS</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Hajicek</surname><given-names>N</given-names></name><name><surname>Jenkins</surname><given-names>ML</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Sondek</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Dynamics of allosteric regulation of the phospholipase C-γ isozymes upon recruitment to membranes</article-title><source>eLife</source><volume>11</volume><elocation-id>e77809</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.77809</pub-id><pub-id pub-id-type="pmid">35708309</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MR</given-names></name><name><surname>Liu</surname><given-names>YL</given-names></name><name><surname>Matthews</surname><given-names>NT</given-names></name><name><surname>Rhee</surname><given-names>SG</given-names></name><name><surname>Sung</surname><given-names>WK</given-names></name><name><surname>Kung</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Phospholipase C-gamma 1 can induce DNA synthesis by a mechanism independent of its lipase activity</article-title><source>PNAS</source><volume>91</volume><fpage>6554</fpage><lpage>6558</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.14.6554</pub-id><pub-id pub-id-type="pmid">8022819</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobreira</surname><given-names>N</given-names></name><name><surname>Schiettecatte</surname><given-names>F</given-names></name><name><surname>Valle</surname><given-names>D</given-names></name><name><surname>Hamosh</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>GeneMatcher: a matching tool for connecting investigators with an interest in the same gene</article-title><source>Human Mutation</source><volume>36</volume><fpage>928</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1002/humu.22844</pub-id><pub-id pub-id-type="pmid">26220891</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Songyang</surname><given-names>Z</given-names></name><name><surname>Shoelson</surname><given-names>SE</given-names></name><name><surname>Chaudhuri</surname><given-names>M</given-names></name><name><surname>Gish</surname><given-names>G</given-names></name><name><surname>Pawson</surname><given-names>T</given-names></name><name><surname>Haser</surname><given-names>WG</given-names></name><name><surname>King</surname><given-names>F</given-names></name><name><surname>Roberts</surname><given-names>T</given-names></name><name><surname>Ratnofsky</surname><given-names>S</given-names></name><name><surname>Lechleider</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>SH2 domains recognize specific phosphopeptide sequences</article-title><source>Cell</source><volume>72</volume><fpage>767</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90404-e</pub-id><pub-id pub-id-type="pmid">7680959</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Splinter</surname><given-names>K</given-names></name><name><surname>Phillips</surname><given-names>JA</given-names></name><name><surname>Adams</surname><given-names>DR</given-names></name><name><surname>Bacino</surname><given-names>CA</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name><name><surname>Phillips</surname><given-names>JA</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Cheatle-Jarvela</surname><given-names>AM</given-names></name><name><surname>Eng</surname><given-names>CM</given-names></name><name><surname>Esteves</surname><given-names>C</given-names></name><name><surname>Gahl</surname><given-names>WA</given-names></name><name><surname>Hamid</surname><given-names>R</given-names></name><name><surname>Jacob</surname><given-names>HJ</given-names></name><name><surname>Kikani</surname><given-names>B</given-names></name><name><surname>Koeller</surname><given-names>DM</given-names></name><name><surname>Kohane</surname><given-names>IS</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>McCray</surname><given-names>AT</given-names></name><name><surname>Metz</surname><given-names>TO</given-names></name><name><surname>Mulvihill</surname><given-names>JJ</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>Palmer</surname><given-names>CGS</given-names></name><name><surname>Pick</surname><given-names>L</given-names></name><name><surname>Postlethwait</surname><given-names>JH</given-names></name><name><surname>Reuter</surname><given-names>C</given-names></name><name><surname>Shashi</surname><given-names>V</given-names></name><name><surname>Sweetser</surname><given-names>DA</given-names></name><name><surname>Tifft</surname><given-names>CJ</given-names></name><name><surname>Walley</surname><given-names>NM</given-names></name><name><surname>Wangler</surname><given-names>MF</given-names></name><name><surname>Westerfield</surname><given-names>M</given-names></name><name><surname>Wheeler</surname><given-names>MT</given-names></name><name><surname>Wise</surname><given-names>AL</given-names></name><name><surname>Worthey</surname><given-names>EA</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><collab>Undiagnosed Diseases Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Effect of genetic diagnosis on patients with previously undiagnosed disease</article-title><source>The New England Journal of Medicine</source><volume>379</volume><fpage>2131</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1714458</pub-id><pub-id pub-id-type="pmid">30304647</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>O</given-names></name><name><surname>Gruber</surname><given-names>C</given-names></name><name><surname>Randolph</surname><given-names>HE</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Ramba</surname><given-names>M</given-names></name><name><surname>Calzoni</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>LH</given-names></name><name><surname>Levy</surname><given-names>J</given-names></name><name><surname>Buta</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Sazeides</surname><given-names>C</given-names></name><name><surname>Prue</surname><given-names>Z</given-names></name><name><surname>Hoytema van Konijnenburg</surname><given-names>DP</given-names></name><name><surname>Chinn</surname><given-names>IK</given-names></name><name><surname>Pedroza</surname><given-names>LA</given-names></name><name><surname>Lupski</surname><given-names>JR</given-names></name><name><surname>Schmitt</surname><given-names>EG</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Puel</surname><given-names>A</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Martin-Fernandez</surname><given-names>M</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Milner</surname><given-names>JD</given-names></name><name><surname>Bogunovic</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Monoallelic expression can govern penetrance of inborn errors of immunity</article-title><source>Nature</source><volume>637</volume><fpage>1186</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-08346-4</pub-id><pub-id pub-id-type="pmid">39743591</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>BC</given-names></name><name><surname>Hille</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>PIP2 is a necessary cofactor for ion channel function: how and why?</article-title><source>Annual Review of Biophysics</source><volume>37</volume><fpage>175</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1146/annurev.biophys.37.032807.125859</pub-id><pub-id pub-id-type="pmid">18573078</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>PG</given-names></name><name><surname>Park</surname><given-names>JI</given-names></name><name><surname>Manzoli</surname><given-names>L</given-names></name><name><surname>Cocco</surname><given-names>L</given-names></name><name><surname>Peak</surname><given-names>JC</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name><name><surname>Fukami</surname><given-names>K</given-names></name><name><surname>Kataoka</surname><given-names>T</given-names></name><name><surname>Yun</surname><given-names>S</given-names></name><name><surname>Ryu</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Multiple roles of phosphoinositide-specific phospholipase C isozymes</article-title><source>BMB Reports</source><volume>41</volume><fpage>415</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.5483/bmbrep.2008.41.6.415</pub-id><pub-id pub-id-type="pmid">18593525</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>KY</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Bao</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Kapoor</surname><given-names>M</given-names></name><name><surname>Backman</surname><given-names>J</given-names></name><name><surname>Joseph</surname><given-names>T</given-names></name><name><surname>Maxwell</surname><given-names>E</given-names></name><name><surname>Mitra</surname><given-names>G</given-names></name><name><surname>Gorovits</surname><given-names>A</given-names></name><name><surname>Mansfield</surname><given-names>A</given-names></name><name><surname>Boutkov</surname><given-names>B</given-names></name><name><surname>Gokhale</surname><given-names>S</given-names></name><name><surname>Habegger</surname><given-names>L</given-names></name><name><surname>Marcketta</surname><given-names>A</given-names></name><name><surname>Locke</surname><given-names>AE</given-names></name><name><surname>Ganel</surname><given-names>L</given-names></name><name><surname>Hawes</surname><given-names>A</given-names></name><name><surname>Kessler</surname><given-names>MD</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Staples</surname><given-names>J</given-names></name><name><surname>Bovijn</surname><given-names>J</given-names></name><name><surname>Gelfman</surname><given-names>S</given-names></name><name><surname>Di Gioia</surname><given-names>A</given-names></name><name><surname>Rajagopal</surname><given-names>VM</given-names></name><name><surname>Lopez</surname><given-names>A</given-names></name><name><surname>Varela</surname><given-names>JR</given-names></name><name><surname>Alegre-Díaz</surname><given-names>J</given-names></name><name><surname>Berumen</surname><given-names>J</given-names></name><name><surname>Tapia-Conyer</surname><given-names>R</given-names></name><name><surname>Kuri-Morales</surname><given-names>P</given-names></name><name><surname>Torres</surname><given-names>J</given-names></name><name><surname>Emberson</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><collab>Regeneron Genetics Center</collab><collab>RGC-ME Cohort Partners</collab><name><surname>Cantor</surname><given-names>M</given-names></name><name><surname>Thornton</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Overton</surname><given-names>JD</given-names></name><name><surname>Shuldiner</surname><given-names>AR</given-names></name><name><surname>Cremona</surname><given-names>ML</given-names></name><name><surname>Nafde</surname><given-names>M</given-names></name><name><surname>Baras</surname><given-names>A</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Marchini</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>JG</given-names></name><name><surname>Salerno</surname><given-names>W</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A deep catalogue of protein-coding variation in 983,578 individuals</article-title><source>Nature</source><volume>631</volume><fpage>583</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07556-0</pub-id><pub-id pub-id-type="pmid">38768635</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>PY</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A gain-of-function variation in PLCG1 causes a new immune dysregulation disease</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>152</volume><fpage>1292</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2023.06.020</pub-id><pub-id pub-id-type="pmid">37422272</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thackeray</surname><given-names>JR</given-names></name><name><surname>Gaines</surname><given-names>PC</given-names></name><name><surname>Ebert</surname><given-names>P</given-names></name><name><surname>Carlson</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>small wing encodes a phospholipase C-(gamma) that acts as a negative regulator of R7 development in Drosophila</article-title><source>Development</source><volume>125</volume><fpage>5033</fpage><lpage>5042</lpage><pub-id pub-id-type="doi">10.1242/dev.125.24.5033</pub-id><pub-id pub-id-type="pmid">9811587</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>D</given-names></name><name><surname>Cm</surname><given-names>V</given-names></name><name><surname>Bisht</surname><given-names>K</given-names></name><name><surname>Janardan</surname><given-names>V</given-names></name><name><surname>Pandit</surname><given-names>A</given-names></name><name><surname>Basak</surname><given-names>B</given-names></name><name><surname>Shwetha</surname><given-names>H</given-names></name><name><surname>Ramesh</surname><given-names>N</given-names></name><name><surname>Raghu</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A genome engineering resource to uncover principles of cellular organization and tissue architecture by lipid signaling</article-title><source>eLife</source><volume>9</volume><elocation-id>55793</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.55793</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaqué</surname><given-names>JP</given-names></name><name><surname>Gómez-López</surname><given-names>G</given-names></name><name><surname>Monsálvez</surname><given-names>V</given-names></name><name><surname>Varela</surname><given-names>I</given-names></name><name><surname>Martínez</surname><given-names>N</given-names></name><name><surname>Pérez</surname><given-names>C</given-names></name><name><surname>Domínguez</surname><given-names>O</given-names></name><name><surname>Graña</surname><given-names>O</given-names></name><name><surname>Rodríguez-Peralto</surname><given-names>JL</given-names></name><name><surname>Rodríguez-Pinilla</surname><given-names>SM</given-names></name><name><surname>González-Vela</surname><given-names>C</given-names></name><name><surname>Rubio-Camarillo</surname><given-names>M</given-names></name><name><surname>Martín-Sánchez</surname><given-names>E</given-names></name><name><surname>Pisano</surname><given-names>DG</given-names></name><name><surname>Papadavid</surname><given-names>E</given-names></name><name><surname>Papadaki</surname><given-names>T</given-names></name><name><surname>Requena</surname><given-names>L</given-names></name><name><surname>García-Marco</surname><given-names>JA</given-names></name><name><surname>Méndez</surname><given-names>M</given-names></name><name><surname>Provencio</surname><given-names>M</given-names></name><name><surname>Hospital</surname><given-names>M</given-names></name><name><surname>Suárez-Massa</surname><given-names>D</given-names></name><name><surname>Postigo</surname><given-names>C</given-names></name><name><surname>San Segundo</surname><given-names>D</given-names></name><name><surname>López-Hoyos</surname><given-names>M</given-names></name><name><surname>Ortiz-Romero</surname><given-names>PL</given-names></name><name><surname>Piris</surname><given-names>MA</given-names></name><name><surname>Sánchez-Beato</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PLCG1 mutations in cutaneous T-cell lymphomas</article-title><source>Blood</source><volume>123</volume><fpage>2034</fpage><lpage>2043</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-05-504308</pub-id><pub-id pub-id-type="pmid">24497536</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venema</surname><given-names>WJ</given-names></name><name><surname>Hiddingh</surname><given-names>S</given-names></name><name><surname>van Loosdregt</surname><given-names>J</given-names></name><name><surname>Bowes</surname><given-names>J</given-names></name><name><surname>Balliu</surname><given-names>B</given-names></name><name><surname>de Boer</surname><given-names>JH</given-names></name><name><surname>Ossewaarde-van Norel</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>SD</given-names></name><name><surname>Langefeld</surname><given-names>CD</given-names></name><name><surname>de Ligt</surname><given-names>A</given-names></name><name><surname>van der Veken</surname><given-names>LT</given-names></name><name><surname>Krijger</surname><given-names>PHL</given-names></name><name><surname>de Laat</surname><given-names>W</given-names></name><name><surname>Kuiper</surname><given-names>JJW</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A cis-regulatory element regulates ERAP2 expression through autoimmune disease risk SNPs</article-title><source>Cell Genomics</source><volume>4</volume><elocation-id>100460</elocation-id><pub-id pub-id-type="doi">10.1016/j.xgen.2023.100460</pub-id><pub-id pub-id-type="pmid">38190099</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venken</surname><given-names>KJT</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Hoskins</surname><given-names>RA</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>P[acman]: a BAC transgenic platform for targeted insertion of large DNA fragments in <italic>D. melanogaster</italic></article-title><source>Science</source><volume>314</volume><fpage>1747</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1126/science.1134426</pub-id><pub-id pub-id-type="pmid">17138868</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venken</surname><given-names>KJT</given-names></name><name><surname>Popodi</surname><given-names>E</given-names></name><name><surname>Holtzman</surname><given-names>SL</given-names></name><name><surname>Schulze</surname><given-names>KL</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Carlson</surname><given-names>JW</given-names></name><name><surname>Hoskins</surname><given-names>RA</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name><name><surname>Kaufman</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A molecularly defined duplication set for the X chromosome of <italic>Drosophila melanogaster</italic></article-title><source>Genetics</source><volume>186</volume><fpage>1111</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1534/genetics.110.121285</pub-id><pub-id pub-id-type="pmid">20876565</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>J</given-names></name><name><surname>Rathnayake</surname><given-names>U</given-names></name><name><surname>Jenkins</surname><given-names>LM</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Appella</surname><given-names>E</given-names></name><name><surname>Randazzo</surname><given-names>PA</given-names></name><name><surname>Samelson</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>In vitro reconstitution reveals cooperative mechanisms of adapter protein-mediated activation of phospholipase C-γ1 in T cells</article-title><source>The Journal of Biological Chemistry</source><volume>298</volume><elocation-id>101680</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2022.101680</pub-id><pub-id pub-id-type="pmid">35124007</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Al-Ouran</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>S-Y</given-names></name><name><surname>Wan</surname><given-names>Y-W</given-names></name><name><surname>Wangler</surname><given-names>MF</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Chao</surname><given-names>H-T</given-names></name><name><surname>Comjean</surname><given-names>A</given-names></name><name><surname>Mohr</surname><given-names>SE</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name><name><surname>Adams</surname><given-names>CJ</given-names></name><name><surname>Adams</surname><given-names>DR</given-names></name><name><surname>Alejandro</surname><given-names>ME</given-names></name><name><surname>Allard</surname><given-names>P</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Azamian</surname><given-names>MS</given-names></name><name><surname>Bacino</surname><given-names>CA</given-names></name><name><surname>Balasubramanyam</surname><given-names>A</given-names></name><name><surname>Barseghyan</surname><given-names>H</given-names></name><name><surname>Beggs</surname><given-names>AH</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Bican</surname><given-names>A</given-names></name><name><surname>Bick</surname><given-names>DP</given-names></name><name><surname>Birch</surname><given-names>CL</given-names></name><name><surname>Boone</surname><given-names>BE</given-names></name><name><surname>Briere</surname><given-names>LC</given-names></name><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Brush</surname><given-names>M</given-names></name><name><surname>Burke</surname><given-names>EA</given-names></name><name><surname>Burrage</surname><given-names>LC</given-names></name><name><surname>Chao</surname><given-names>KR</given-names></name><name><surname>Clark</surname><given-names>GD</given-names></name><name><surname>Cogan</surname><given-names>JD</given-names></name><name><surname>Cooper</surname><given-names>CM</given-names></name><name><surname>Craigen</surname><given-names>WJ</given-names></name><name><surname>Davids</surname><given-names>M</given-names></name><name><surname>Dayal</surname><given-names>JG</given-names></name><name><surname>Dell’Angelica</surname><given-names>EC</given-names></name><name><surname>Dhar</surname><given-names>SU</given-names></name><name><surname>Dipple</surname><given-names>KM</given-names></name><name><surname>Donnell-Fink</surname><given-names>LA</given-names></name><name><surname>Dorrani</surname><given-names>N</given-names></name><name><surname>Dorset</surname><given-names>DC</given-names></name><name><surname>Draper</surname><given-names>DD</given-names></name><name><surname>Dries</surname><given-names>AM</given-names></name><name><surname>Eckstein</surname><given-names>DJ</given-names></name><name><surname>Emrick</surname><given-names>LT</given-names></name><name><surname>Eng</surname><given-names>CM</given-names></name><name><surname>Esteves</surname><given-names>C</given-names></name><name><surname>Estwick</surname><given-names>T</given-names></name><name><surname>Fisher</surname><given-names>PG</given-names></name><name><surname>Frisby</surname><given-names>TS</given-names></name><name><surname>Frost</surname><given-names>K</given-names></name><name><surname>Gahl</surname><given-names>WA</given-names></name><name><surname>Gartner</surname><given-names>V</given-names></name><name><surname>Godfrey</surname><given-names>RA</given-names></name><name><surname>Goheen</surname><given-names>M</given-names></name><name><surname>Golas</surname><given-names>GA</given-names></name><name><surname>Goldstein</surname><given-names>DB</given-names></name><name><surname>Gordon</surname><given-names>MG</given-names></name><name><surname>Gould</surname><given-names>SE</given-names></name><name><surname>Gourdine</surname><given-names>J-PF</given-names></name><name><surname>Graham</surname><given-names>BH</given-names></name><name><surname>Groden</surname><given-names>CA</given-names></name><name><surname>Gropman</surname><given-names>AL</given-names></name><name><surname>Hackbarth</surname><given-names>ME</given-names></name><name><surname>Haendel</surname><given-names>M</given-names></name><name><surname>Hamid</surname><given-names>R</given-names></name><name><surname>Hanchard</surname><given-names>NA</given-names></name><name><surname>Handley</surname><given-names>LH</given-names></name><name><surname>Hardee</surname><given-names>I</given-names></name><name><surname>Herzog</surname><given-names>MR</given-names></name><name><surname>Holm</surname><given-names>IA</given-names></name><name><surname>Howerton</surname><given-names>EM</given-names></name><name><surname>Jacob</surname><given-names>HJ</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Johnston</surname><given-names>JM</given-names></name><name><surname>Jones</surname><given-names>AL</given-names></name><name><surname>Koehler</surname><given-names>AE</given-names></name><name><surname>Koeller</surname><given-names>DM</given-names></name><name><surname>Kohane</surname><given-names>IS</given-names></name><name><surname>Kohler</surname><given-names>JN</given-names></name><name><surname>Krasnewich</surname><given-names>DM</given-names></name><name><surname>Krieg</surname><given-names>EL</given-names></name><name><surname>Krier</surname><given-names>JB</given-names></name><name><surname>Kyle</surname><given-names>JE</given-names></name><name><surname>Lalani</surname><given-names>SR</given-names></name><name><surname>Latham</surname><given-names>L</given-names></name><name><surname>Latour</surname><given-names>YL</given-names></name><name><surname>Lau</surname><given-names>CC</given-names></name><name><surname>Lazar</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>PR</given-names></name><name><surname>Levy</surname><given-names>SE</given-names></name><name><surname>Levy</surname><given-names>DJ</given-names></name><name><surname>Lewis</surname><given-names>RA</given-names></name><name><surname>Liebendorfer</surname><given-names>AP</given-names></name><name><surname>Lincoln</surname><given-names>SA</given-names></name><name><surname>Loomis</surname><given-names>CR</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name><name><surname>Maas</surname><given-names>RL</given-names></name><name><surname>Macnamara</surname><given-names>EF</given-names></name><name><surname>MacRae</surname><given-names>CA</given-names></name><name><surname>Maduro</surname><given-names>VV</given-names></name><name><surname>Malicdan</surname><given-names>MCV</given-names></name><name><surname>Mamounas</surname><given-names>LA</given-names></name><name><surname>Manolio</surname><given-names>TA</given-names></name><name><surname>Markello</surname><given-names>TC</given-names></name><name><surname>Mazur</surname><given-names>P</given-names></name><name><surname>McCarty</surname><given-names>AJ</given-names></name><name><surname>McConkie-Rosell</surname><given-names>A</given-names></name><name><surname>McCray</surname><given-names>AT</given-names></name><name><surname>Metz</surname><given-names>TO</given-names></name><name><surname>Might</surname><given-names>M</given-names></name><name><surname>Moretti</surname><given-names>PM</given-names></name><name><surname>Mulvihill</surname><given-names>JJ</given-names></name><name><surname>Murphy</surname><given-names>JL</given-names></name><name><surname>Muzny</surname><given-names>DM</given-names></name><name><surname>Nehrebecky</surname><given-names>ME</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>Newberry</surname><given-names>JS</given-names></name><name><surname>Newman</surname><given-names>JH</given-names></name><name><surname>Nicholas</surname><given-names>SK</given-names></name><name><surname>Novacic</surname><given-names>D</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Pallais</surname><given-names>JC</given-names></name><name><surname>Palmer</surname><given-names>CGS</given-names></name><name><surname>Papp</surname><given-names>JC</given-names></name><name><surname>Pena</surname><given-names>LDM</given-names></name><name><surname>Phillips</surname><given-names>JA</given-names><suffix>III</suffix></name><name><surname>Posey</surname><given-names>JE</given-names></name><name><surname>Postlethwait</surname><given-names>JH</given-names></name><name><surname>Potocki</surname><given-names>L</given-names></name><name><surname>Pusey</surname><given-names>BN</given-names></name><name><surname>Ramoni</surname><given-names>RB</given-names></name><name><surname>Robertson</surname><given-names>AK</given-names></name><name><surname>Rodan</surname><given-names>LH</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Sadozai</surname><given-names>S</given-names></name><name><surname>Schaffer</surname><given-names>KE</given-names></name><name><surname>Schoch</surname><given-names>K</given-names></name><name><surname>Schroeder</surname><given-names>MC</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Shashi</surname><given-names>V</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name><name><surname>Sinsheimer</surname><given-names>JS</given-names></name><name><surname>Soldatos</surname><given-names>AG</given-names></name><name><surname>Spillmann</surname><given-names>RC</given-names></name><name><surname>Splinter</surname><given-names>K</given-names></name><name><surname>Stoler</surname><given-names>JM</given-names></name><name><surname>Stong</surname><given-names>N</given-names></name><name><surname>Strong</surname><given-names>KA</given-names></name><name><surname>Sullivan</surname><given-names>JA</given-names></name><name><surname>Sweetser</surname><given-names>DA</given-names></name><name><surname>Thomas</surname><given-names>SP</given-names></name><name><surname>Tifft</surname><given-names>CJ</given-names></name><name><surname>Tolman</surname><given-names>NJ</given-names></name><name><surname>Toro</surname><given-names>C</given-names></name><name><surname>Tran</surname><given-names>AA</given-names></name><name><surname>Valivullah</surname><given-names>ZM</given-names></name><name><surname>Vilain</surname><given-names>E</given-names></name><name><surname>Waggott</surname><given-names>DM</given-names></name><name><surname>Wahl</surname><given-names>CE</given-names></name><name><surname>Walley</surname><given-names>NM</given-names></name><name><surname>Walsh</surname><given-names>CA</given-names></name><name><surname>Wangler</surname><given-names>MF</given-names></name><name><surname>Warburton</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name><name><surname>Waters</surname><given-names>KM</given-names></name><name><surname>Webb-Robertson</surname><given-names>B-JM</given-names></name><name><surname>Weech</surname><given-names>AA</given-names></name><name><surname>Westerfield</surname><given-names>M</given-names></name><name><surname>Wheeler</surname><given-names>MT</given-names></name><name><surname>Wise</surname><given-names>AL</given-names></name><name><surname>Wolfe</surname><given-names>LA</given-names></name><name><surname>Worthey</surname><given-names>EA</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Zornio</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MARRVEL: Integration of human and model organism genetic resources to facilitate functional annotation of the human genome</article-title><source>The American Journal of Human Genetics</source><volume>100</volume><fpage>843</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.04.010</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>EY</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>FY</given-names></name><name><surname>Pennypacker</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Phospholipase C-gamma1 is required for the epidermal growth factor receptor-induced squamous cell carcinoma cell mitogenesis</article-title><source>Biochemical and Biophysical Research Communications</source><volume>397</volume><fpage>296</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.05.103</pub-id><pub-id pub-id-type="pmid">20510673</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YR</given-names></name><name><surname>Choi</surname><given-names>JH</given-names></name><name><surname>Chang</surname><given-names>J-S</given-names></name><name><surname>Kwon</surname><given-names>HM</given-names></name><name><surname>Jang</surname><given-names>H-J</given-names></name><name><surname>Ryu</surname><given-names>SH</given-names></name><name><surname>Suh</surname><given-names>P-G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Diverse cellular and physiological roles of phospholipase C-γ1</article-title><source>Advances in Biological Regulation</source><volume>52</volume><fpage>138</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.advenzreg.2011.09.017</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Constien</surname><given-names>R</given-names></name><name><surname>Dear</surname><given-names>N</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name><name><surname>Hanke</surname><given-names>P</given-names></name><name><surname>Bunney</surname><given-names>TD</given-names></name><name><surname>Kunder</surname><given-names>S</given-names></name><name><surname>Quintanilla-Martinez</surname><given-names>L</given-names></name><name><surname>Huffstadt</surname><given-names>U</given-names></name><name><surname>Schröder</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>NP</given-names></name><name><surname>Peters</surname><given-names>T</given-names></name><name><surname>Fuchs</surname><given-names>H</given-names></name><name><surname>Hrabe de Angelis</surname><given-names>M</given-names></name><name><surname>Nehls</surname><given-names>M</given-names></name><name><surname>Grosse</surname><given-names>J</given-names></name><name><surname>Wabnitz</surname><given-names>P</given-names></name><name><surname>Meyer</surname><given-names>TPH</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name><name><surname>Schiemann</surname><given-names>M</given-names></name><name><surname>Schneider-Fresenius</surname><given-names>C</given-names></name><name><surname>Jagla</surname><given-names>W</given-names></name><name><surname>Russ</surname><given-names>A</given-names></name><name><surname>Popp</surname><given-names>A</given-names></name><name><surname>Josephs</surname><given-names>M</given-names></name><name><surname>Marquardt</surname><given-names>A</given-names></name><name><surname>Laufs</surname><given-names>J</given-names></name><name><surname>Schmittwolf</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>H</given-names></name><name><surname>Pfeffer</surname><given-names>K</given-names></name><name><surname>Mudde</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase Cγ2 that specifically increases external Ca2+ entry</article-title><source>Immunity</source><volume>22</volume><fpage>451</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2005.01.018</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>G-S</given-names></name><name><surname>Brady</surname><given-names>J</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Martins</surname><given-names>MS</given-names></name><name><surname>Bunney</surname><given-names>TD</given-names></name><name><surname>Santich</surname><given-names>BH</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Priel</surname><given-names>DAL</given-names></name><name><surname>Ombrello</surname><given-names>A</given-names></name><name><surname>Stone</surname><given-names>D</given-names></name><name><surname>Ombrello</surname><given-names>MJ</given-names></name><name><surname>Khan</surname><given-names>J</given-names></name><name><surname>Milner</surname><given-names>JD</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Aksentijevich</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A hypermorphic missense mutation in PLCG2 , encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency</article-title><source>The American Journal of Human Genetics</source><volume>91</volume><fpage>713</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2012.08.006</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Pires</surname><given-names>DEV</given-names></name><name><surname>Rodrigues</surname><given-names>CHM</given-names></name><name><surname>Ascher</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>DDMut: predicting effects of mutations on protein stability using deep learning</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>W122</fpage><lpage>W128</lpage><pub-id pub-id-type="doi">10.1093/nar/gkad472</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Case Reports</title><sec sec-type="appendix" id="s8-1"><title>Individual 1</title><p>Individual 1 is an 18-year-old male with motor difficulties and multiple congenital anomalies. He failed his newborn hearing screen and was diagnosed with mild congenital hearing loss. He was found to have pyloric stenosis around 2 months of age. He was subsequently diagnosed with multiple joint contractures, Axenfeld-Rieger syndrome with posterior embryotoxon of both eyes, and cardiac septal defects that closed spontaneously. He had chronic joint pain, most severe in his hips. He was found to have bilateral coxa profunda. His motor milestones were delayed due to multiple joint contractures. His speech was also delayed, likely related to mild deafness. No cognitive problems were reported. On physical exam, his weight was 81.2 kg (88<sup>th</sup> percentile), height was 168.4 cm (15<sup>th</sup> percentile), and head circumference was 58.4 cm (90<sup>th</sup> percentile). He had limitation of small joints of the hands and elbows with cubitus valgus. He had limited ability to extend arms above his head. Deep tendon reflexes were normal. His tone was normal in his lower extremities. His muscle strength was normal, although mildly reduced in his hands. His gait was mildly abnormal but significantly improved after his hip surgery. Brain MRI showed stable mild diffuse cerebral and cerebellar vermian volume loss. There was no evidence of neurodegenerative process or progressive cerebellar atrophy process. Spinal MRI showed very mild caudal regression syndrome and Scheuermann’s phenomenon in the midthoracic spine. Reanalysis of the trio whole exome sequencing (WES) identified a <italic>de novo</italic> heterozygous missense variant in <italic>PLCG1</italic>. Optical genome mapping identified an intragenic duplication in <italic>PSD3</italic> duplication, and whole genome sequencing (WGS) was performed to characterize this variant. He also had an <italic>L1CAM</italic> variant reported but a healthy male cousin carries this variant as well, which suggests that the <italic>L1CAM</italic> variant may not be a key player. Chromosomal microarray analysis showed a copy number loss within chromosome band 15q15.3 spanning approximately 0.048 Mb, involving <italic>STRC</italic> and <italic>CATSPER2</italic>, indicating that he was probably a carrier for the autosomal recessive deafness-infertility syndrome [MIM: 611102].</p></sec><sec sec-type="appendix" id="s8-2"><title>Individual 2</title><p>Individual 2 is a 14-year-old female with a history of congenital microphthalmia and blindness of the right eye leading to enucleation, and several episodes of an undifferentiated inflammatory encephalopathy from age of 11 years. She was born at 38 weeks with a right microphthalmia and no useful vision. This anomaly was managed by enucleation at 2 years old with prosthesis placement. She passed her newborn hearing screen. Developmentally, she walked at 2 years old and began talking at 4 years old. She came to our medical attention at the age of 11 years with episodes of inflammatory encephalopathy, which first presented as fever with associated upper respiratory symptoms that later developed into lingering episodes of headache, fatigue, dizziness, and weight loss. Brain MRI imaging showed progressive but symmetrical primarily white matter changes with swelling, particularly of the cerebellum, persistent diffuse T2 hyperintensities (both deep and periventricular white matter), and confluent hyperintensities within the frontoparietal lobes bilaterally. Thus far, this episodic relapsing disorder has been responsive to steroids and intravenous immunoglobulin with relapse on steroid withdrawal. On physical exam, she was noted to have difficulty getting up from the floor without using support from her arms, in addition to weakness of plantar flexion, possibly secondary to chronic steroid administration. Family history is noncontributory, with both parents’ ancestry being Egyptian and no consanguinity reported. Clinical genetic workup included WES, which revealed compound heterozygous variants in <italic>RYR1</italic>, thought to be noncontributory to the phenotype. She was accepted into the Undiagnosed Diseases Network research study in 2021 to pursue additional genetic workup. WGS revealed the genetic findings mentioned in <xref ref-type="table" rid="table1">Table 1</xref>: <italic>PLCG1 de novo</italic> variant, <italic>ERAP2</italic> compound heterozygous variants, and <italic>SEMA3G</italic> compound heterozygous variants, all Sanger confirmed.</p></sec><sec sec-type="appendix" id="s8-3"><title>Individual 3</title><p>Individual 3 is a 9-year-old male born from healthy non-consanguineous parents. During pregnancy, a diagnosis of intrauterine growth retardation was made. At birth, at 39 weeks of gestation, his length was 49 cm (50° centile), weight was 2930 g (25–50° centile) and occipital frontal circumference was 34 cm (50° centile). Newborn audiological screening and the subsequent auditory brainstem response test showed a mild to moderate sensorineural deafness. Echocardiogram revealed a small subaortic ventricular septal defect and a wide atrial septal defect with left to right shunt. For the recurrence of pulmonary infections in the first year of life, he underwent a complete immunological assessment. The immunophenotypic characterization identified an absolute T lymphocytopenia. He had a normal absolute B lymphocyte count and normal IgG subclasses. He had relative macrocephaly and presented with some facial dysmorphisms, such as left eyelid ptosis, downslanting both corners of the mouth, evident venous reticulum of the skull, long and flat philtrum, prominent ears, anteverted nostrils, prognathism, proximally placed thumbs, and evident veins of the scalp. His brain MRI was normal, as was the ophthalmological evaluation with fundus analysis. Trio WES revealed <italic>de novo</italic> heterozygous missense variants in <italic>PKP2</italic> and <italic>PLCG1</italic>.</p></sec><sec sec-type="appendix" id="s8-4"><title>Individuals 4–7</title><p>Individual 4 is an 11-year-old female. She failed her newborn hearing screening and was diagnosed with bilateral congenital sensorineural hearing loss, which has since progressed to profound bilateral hearing impairment. She was also diagnosed with unilateral posterior embryotoxon. She experienced mild motor delay, beginning to walk at 18 months of age, despite normal vestibular test results. On physical examination, her weight, height, and head circumference were within normal ranges. Her medical history includes multiple episodes of joint inflammation, tarsal synovitis, recurrent upper respiratory and lung infections, and inflammatory lymphadenopathy. Her most recent hematologic and immunologic investigations were within normal range. The family history revealed relevant findings in her mother (Individual 5), her brother (Individual 6), and her maternal grandfather (Individual 7).</p><p>Her mother (Individual 5) has a history of severe immunologic disease, beginning at the age of 6 years with idiopathic thrombocytopenic purpura (ITP) (platelet count &lt;2,000 /mm³), treated with corticosteroids and intravenous immunoglobulin therapy for six years, followed by a splenectomy after recurrence of thrombocytopenia. At the age of 20 years, she developed polyarthritis with positive autoimmune antibodies. Immunosuppressive treatment was ineffective and discontinued due to a severe Epstein-Barr virus (EBV) infection. She later developed autoimmune pulmonary fibrosis and multiple episodes of pancytopenia triggered by viral infections. At the age of 33 years, an IgA and IgG2 deficiency was identified. She subsequently experienced pneumococcal sepsis with purpura fulminans. Vaccinations against pneumococcus and meningococcus failed to induce an immune response. At the age of 40 years, she began intravenous immunoglobulin therapy every 3 weeks and takes regular oral antibiotics for recurrent pulmonary infections. Regarding hearing, she experienced an episode of sudden bilateral hearing loss while on corticosteroid therapy. Her sensorineural hearing loss has gradually progressed to moderate bilateral deafness by age of 42 years. She also has a congenital ventricular septal defect and high myopia since adolescence. Her growth parameters are normal, and she does not present with any neurodevelopmental disorders. The 13-year-old brother (Individual 6) has normal hearing. His growth parameters and neuromotor development are within normal ranges. Since early childhood, he had numerous rhinopharyngeal and lung infections. Recent laboratory investigations reveal a mild IgA and IgG2 deficiency. He does not exhibit any joint or ophthalmological symptoms. The maternal grandfather (Individual 7), now 66 years old, presents with moderate bilateral hearing loss that began in adulthood, without any other clinical manifestations upon history-taking. Whole genome sequencing in the 4 individuals revealed a probably pathogenic <italic>PLCG1</italic> variation inherited from Individual 7 (Sanger analysis).</p></sec><sec sec-type="appendix" id="s8-5"><title>Notes for <xref ref-type="fig" rid="fig4">Figure 4</xref></title><p>We assessed if human <italic>PLCG1</italic> could effectively serve as a functional substitute for fly <italic>sl</italic> and rescue the loss-of-function phenotypes observed in <italic>sl</italic> mutant flies. However, as shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>, only a small fraction of the <italic>sl<sup>T2A</sup>/Y</italic> mutant hemizygotes expressing <italic>PLCG1<sup>Reference</sup></italic> can survive to adults, and the escapers die within 1 week. Since overexpression of fly <italic>sl<sup>WT</sup></italic> does not cause viability issues (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), the reduced viability associated with <italic>PLCG1<sup>Reference</sup></italic> in <italic>sl<sup>T2A</sup></italic> mutant male progeny may be due to elevated expression levels of the human proteins.</p><p>To assess the ‘high expression level toxicity’ hypothesis, we raised the flies at different temperatures and tested with various GAL4 drivers. The GAL4-UAS system is highly temperature-dependent since the promoter in the UAS construct contains an Hsp-70 promoter (<xref ref-type="bibr" rid="bib26">Fischer et al., 1988</xref>), and the expression levels increase with higher temperatures and decrease with lower temperatures (<xref ref-type="bibr" rid="bib63">Nagarkar-Jaiswal et al., 2015</xref>). We assessed the viability of the progeny with expression of <italic>PLCG1</italic> or <italic>sl</italic> cDNA in hemizygous mutant flies (<italic>sl<sup>T2A</sup>/Y&gt;UAS-cDNAs</italic>) at 22°C, the survival ratio was increased, but the increase was subtle (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). To avoid the dosage compensation effect that alters the expression level of <italic>sl<sup>T2A</sup></italic> between males or females, we used a ubiquitous GAL4 driver, <italic>Tub-GAL4</italic>, to ectopically drive the expression of <italic>PLCG1<sup>Reference</sup></italic> ubiquitously at different temperatures. As shown in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>, the <italic>Tub-GAL4&gt;UAS-PLCG1<sup>Reference</sup></italic> flies exhibited a high lethality ratio when raised at 29°C (~63% lethal), and the surviving flies die within 1 week. This lethality ratio decreased to ~43% when the flies were raised at 25°C, whereas &gt;90% of the flies were able to eclose as adults at 22°C. This shows that the toxicity is highly dependent on protein levels. Indeed, the expression levels can be further lowered by using a weak ubiquitous GAL4 driver, <italic>da-GAL4</italic>. The <italic>da-GAL4</italic>&gt;<italic>UAS-PLCG1<sup>Reference</sup></italic> flies were viable at the three tested temperatures (29°C, 25°C, and 22°C), but the enclosed adults at 29°C mostly died within 1 week. <italic>da-GAL4&gt;UAS-PLCG1<sup>H380R</sup></italic> or <italic>UAS-PLCG1<sup>L597F</sup></italic> exhibited similar phenotypes. In contrast, <italic>da-GAL4&gt;UAS-PLCG1<sup>D1019G</sup></italic> or <italic>UAS-PLCG1<sup>D1165G</sup></italic> flies were lethal at 29°C, semi-lethal (~80%–85% lethal) at 25°C, and viable at 22°C (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>). The animals that escape lethality at 25°C have smaller pupae (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>) and a reduced adult body size, arguing that growth is impeded. In summary, these data support the hypothesis that elevated expression levels of the human <italic>PLCG1</italic> is toxic in flies.</p><p>In addition to the toxicity, <italic>PLCG1<sup>Reference</sup></italic> fails to rescue the phenotypes observed in the wings or eyes of the <italic>sl</italic> mutant flies <xref ref-type="fig" rid="fig4s3">(Figure 4—figure supplement 3</xref>), which is fully rescued by fly <italic>sl<sup>WT</sup></italic> (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Expression of the <italic>PLCG2</italic> cDNA in <italic>sl<sup>T2A</sup></italic> mutant hemizygous males exhibited similar toxicity (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) and limited ability to rescue the phenotypes caused by loss of <italic>sl</italic>. This suggests that despite their high DIOPT scores, the two human genes encoding PLCγ isozymes cannot fully substitute for the fly PLCγ ortholog. It is possible that during the course of evolution, <italic>PLCG1</italic> has acquired more specialized functions. For example, an essential step for enzymatic activation of mammalian PLCγ is the binding of its nSH2 domain to specific phosphotyrosines on the RTKs through a specific binding motif (<xref ref-type="bibr" rid="bib86">Songyang et al., 1993</xref>). However, Thackeray et al. found that the consensus motif is absent in the intracellular domain of the Drosophila EGF receptor homolog DER (<xref ref-type="bibr" rid="bib93">Thackeray et al., 1998</xref>), one of the three RTKs in Drosophila which is required for wing vein differentiation and photoreceptor formation (<xref ref-type="bibr" rid="bib21">Dickson and Hafen, 1994</xref>; <xref ref-type="bibr" rid="bib29">Freeman, 1996</xref>; <xref ref-type="bibr" rid="bib81">Schweitzer and Shilo, 1997</xref>). Nevertheless, expression of the <italic>PLCG1</italic> variant cDNAs leads to more severely reduced eclosion rate compared to expression of the reference cDNA (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), suggesting that they are detrimental variants.</p></sec><sec sec-type="appendix" id="s8-6"><title>Notes for <xref ref-type="fig" rid="fig5">Figure 5</xref></title><p>To better understand whether the phenotypes caused by the variants in fly models are associated with the enzymatic activity of the PLCγ1 isozyme, we characterized the phenotypes of transgenic flies expressing control constructs: <italic>PLCG1<sup>H380A</sup></italic> (enzymatic dead), <italic>PLCG1<sup>D1165H</sup></italic> (hyperactive) and <italic>PLCG1<sup>S1021F</sup></italic> (hyperactive). Ectopic expression of the enzymatic-dead <italic>PLCG1<sup>H380A</sup></italic> or hyperactive <italic>PLCG1<sup>S1021F</sup></italic> in wings or eyes did not cause obvious morphological abnormalities, whereas expression of the hyperactive <italic>PLCG1<sup>D1165H</sup></italic> caused very severe phenotypes (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2F</xref>). Overexpression of <italic>PLCG1<sup>D1165H</sup></italic> in the eyes or wings causes lethality at 29°C, arguing that it is highly toxic. These flies survive when they are raised at 25°C, yet the wings show severe morphological defects, including notched wing margins, thickened veins as well as reduced wing size (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2E</xref>). These phenotypes are similar to, but more severe than, the defects observed in the wings expressing <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Notably, expression of <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic>, which did not exhibit a hyperactive effect in the <italic>CaLexA</italic> reporter assay compared to <italic>PLCG1<sup>S1021F</sup></italic> (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), caused a partially penetrant wing notching phenotype (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>). Additionally, <italic>PLCG1<sup>L597F</sup></italic> expression led to a reduction in eye size (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2D</xref>). These observations suggest that the morphological phenotypes in wings and eyes are not directly correlated with the enzymatic activity of the PLCγ1 isozyme, but may instead be associated with neomorphic effects. Similarly, the increased lethality observed in <italic>sl<sup>T2A</sup></italic>-driven expression of cDNAs may also be associated with neomorphic effect. As shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>, when driven by <italic>sl<sup>T2A</sup></italic>, <italic>PLCG1<sup>H380A</sup></italic> led to reduced viability in hemizygous mutant flies but not in heterozygous ones, whereas <italic>PLCG1<sup>D1165H</sup></italic> caused 100% lethality in both genotypes. However, the hyperactive <italic>PLCG1<sup>S1021F</sup></italic> did not show distinguishable phenotypes compared to <italic>PLCG1<sup>Reference</sup></italic> in this assay. In summary, the <italic>PLCG1</italic> variants identified in this study exhibit neomorphic effects with variable degrees of severity, whereas the p.(Asp1019Gly) and p.(Asp1165Gly) variants are hyperactive and also cause neomorphic phenotypes.</p></sec><sec sec-type="appendix" id="s8-7"><title>The Undiagnosed Diseases Network Consortia (Version 3.31.25)</title><p>Alyssa A. Tran, Arjun Tarakad, Ashok Balasubramanyam, Brendan H. Lee, Carlos A. Bacino, Daryl A. Scott, Elaine Seto, Gary D. Clark, Hongzheng Dai, Hsiao-Tuan Chao, Ivan Chinn, James P. Orengo, Jennifer E. Posey, Jill A. Rosenfeld, Kim Worley, Lindsay C. Burrage, Lisa T. Emrick, Lorraine Potocki, Monika Weisz Hubshman, Richard A. Lewis, Ronit Marom, Seema R. Lalani, Shamika Ketkar, Tiphanie P. Vogel, William J. Craigen, Jared Sninsky, Lauren Blieden, Sandesh Nagamani, Hugo J. Bellen, Michael F. Wangler, Oguz Kanca, Shinya Yamamoto, Christine M. Eng, Patricia A. Ward, Pengfei Liu, Adeline Vanderver, Cara Skraban, Edward Behrens, Gonench Kilich, Kathleen Sullivan, Kelly Hassey, Ramakrishnan Rajagopalan, Rebecca Ganetzky, Vishnu Cuddapah, Anna Raper, Daniel J. Rader, Giorgio Sirugo, Vaidehi Jobanputra, Allyn McConkie-Rosell, Kelly Schoch, Mohamad Mikati, Nicole M. Walley, Rebecca C. Spillmann, Vandana Shashi, Alan H. Beggs, Calum A. MacRae, David A. Sweetser, Deepak A. Rao, Edwin K. Silverman, Elizabeth L. Fieg, Frances High, Gerard T. Berry, Ingrid A. Holm, J. Carl Pallais, Joan M. Stoler, Joseph Loscalzo, Lance H. Rodan, Laurel A. Cobban, Lauren C. Briere, Matthew Coggins, Melissa Walker, Richard L. Maas, Susan Korrick, Jessica Douglas, Cecilia Esteves, Emily Glanton, Isaac S. Kohane, Kimberly LeBlanc, Rachel Mahoney, Shamil R. Sunyaev, Shilpa N. Kobren, Brett H. Graham, Erin Conboy, Francesco Vetrini, Kayla M. Treat, Khurram Liaqat, Lili Mantcheva, Stephanie M. Ware, Breanna Mitchell, Brendan C. Lanpher, Devin Oglesbee, Eric Klee, Filippo Pinto e Vairo, Ian R. Lanza, Kahlen Darr, Lindsay Mulvihill, Lisa Schimmenti, Queenie Tan, Surendra Dasari, Abdul Elkadri, Brett Bordini, Donald Basel, James Verbsky, Julie McCarrier, Michael Muriello, Michael Zimmermann, Adriana Rebelo, Carson A. Smith, Deborah Barbouth, Guney Bademci, Joanna M. Gonzalez, Kumarie Latchman, LéShon Peart, Mustafa Tekin, Nicholas Borja, Stephan Zuchner, Stephanie Bivona, Willa Thorson, Herman Taylor, Rakale C. Quarells, Ayuko Iverson, Bruce Gelb, Charlotte Cunningham-Rundles, Eric Gayle, Joanna Jen, Louise Bier, Mafalda Barbosa, Manisha Balwani, Mariya Shadrina, Rachel Evard, Saskia Shuman, Susan Shin, Andrea Gropman, Barbara N. Pusey Swerdzewski, Camilo Toro, Colleen E. Wahl, Donna Novacic, Ellen F. Macnamara, John J. Mulvihill, Maria T. Acosta, Precilla D'Souza, Valerie V. Maduro, Ben Afzali, Ben Solomon, Cynthia J. Tifft, David R. Adams, Elizabeth A. Burke, Francis Rossignol, Heidi Wood, Jiayu Fu, Joie Davis, Leoyklang Petcharet, Lynne A. Wolfe, Margaret Delgado, Marie Morimoto, Marla Sabaii, MayChristine V. Malicdan, Neil Hanchard, Orpa Jean-Marie, Wendy Introne, William A. Gahl, Yan Huang, Andrew Stergachis, Danny Miller, Elisabeth Rosenthal, Elizabeth Blue, Elsa Balton, Emily Shelkowitz, Eric Allenspach, Fuki M. Hisama, Gail P. Jarvik, Ghayda Mirzaa, Ian Glass, Kathleen A. Leppig, Katrina Dipple, Mark Wener, Martha Horike-Pyne, Michael Bamshad, Peter Byers, Runjun Kumar, Seth Perlman, Sirisak Chanprasert, Virginia Sybert, Wendy Raskind, Nitsuh K. Dargie, Chun-Hung Chan, Dr. Francisco Bustos velasq, Isum Ward, Jason Schend, Jennifer Morgan, Megan Bell, Miranda Leitheiser, Mohamad Saifeddine, Paul Berger, Rachel Li, Taylor Beagle, Alexander Miller, Beatriz Anguiano, Beth A. Martin, Brianna Tucker, Chloe M. Reuter, Devon Bonner, Elijah Kravets, Hector Rodrigo Mendez, Holly K. Tabor, Jacinda B. Sampson, Jason Hom, Jennefer N. Kohler, Jennifer Schymick, John E. Gorzynski, Jonathan A. Bernstein, Kevin S. Smith, Laura Keehan, Laurens Wiel, Matthew T. Wheeler, Meghan C. Halley, Mia Levanto, Page C. Goddard, Paul G. Fisher, Rachel A. Ungar, Raquel L. Alvarez, Sara Emami, Shruti Marwaha, Stephen B Montgomery, Suha Bachir, Tanner D Jensen, Taylor Maurer, Terra R. Coakley, Euan A. Ashley, Ali Al-Beshri, Anna Hurst, Brandon M Wilk, Bruce Korf, Elizabeth A Worthey, Kaitlin Callaway, Martin Rodriguez, Tammi Skelton, Tarun KK Mamidi, Andrew B. Crouse, Jordan Whitlock, Mariko Nakano-Okuno, Matthew Might, William E. Byrd, Albert R. La Spada, Changrui Xiao, Elizabeth C. Chao, Eric Vilain, Jose Abdenur, Kirsten Blanco, Maija-Rikka Steenari, Rebekah Barrick, Richard Chang, Sanaz Attaripour, Suzanne Sandmeyer, Tahseen Mozaffar, Alden Huang, Andres Vargas, Bianca E. Russell, Brent L. Fogel, Esteban C. Dell'Angelica, George Carvalho, Julian A. Martínez-Agosto, Layal F. Abi Farraj, Manish J. Butte, Martin G. Martin, Naghmeh Dorrani, Neil H. Parker, Rosario I. Corona, Stanley F. Nelson, Yigit Karasozen, Aaron Quinlan, Alistair Ward, Ashley Andrews, Corrine K. Welt, Dave Viskochil, Erin E. Baldwin, John Carey, Justin Alvey, Laura Pace, Lorenzo Botto, Nicola Longo, Paolo Moretti, Rebecca Overbury, Russell Butterfield, Steven Boyden, Thomas J. Nicholas, Matt Velinder, Gabor Marth, Pinar Bayrak-Toydemir, Rong Mao, Monte Westerfield, Brian Corner, John A. Phillips III, Kimberly Ezell, Lynette Rives, Rizwan Hamid, Serena Neumann, Ashley McMinn, Joy D. Cogan, Thomas Cassini, Alex Paul, Dana Kiley, Daniel Wegner, Erin McRoy, Jennifer Wambach, Kathy Sisco, Patricia Dickson, F. Sessions Cole, Dustin Baldridge, Jimann Shin, Lilianna Solnica-Krezel, Stephen C. Pak, Timothy Schedl, Allen Bale, Carol Oladele, Caroline Hendry, Emily Wang, Hua Xu, Hui Zhang, Lauren Jeffries, María José Ortuño Romero, Mark Gerstein, Michele Spencer-Manzon, Monkol Lek, Nada Derar, Odelya Kaufman, Shrikant Mane, Teodoro Jerves Serrano, Vasilis Vasiliou, Winston Halstead, Yong-Hui Jiang</p></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95887.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nahmad</surname><given-names>Marcos</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Center for Research and Advanced Studies of the National Polytechnic Institute</institution><country>Mexico</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study reveals how Drosophila may be used to investigate the role of missense variants in the PLCG1 phospholipase gene in human diseases. The experimental evidence is <bold>compelling</bold> and brings together rigorous analysis of clinical and model organism phenotypes with a structural analysis of the PLCG1 protein.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95887.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The manuscript by Ma et al. reports the identification of three unrelated people who are heterozygous for de novo missense variants in PLCG1, which encodes phospholipase C-gamma 1, a key signaling protein. These individuals present with partially overlapping phenotypes, including hearing loss, ocular pathology, cardiac defects, abnormal brain imaging results, and immune defects. None of the patients present with all of the above phenotypes. PLCG1 has also been implicated as a possible driver for cell proliferation in cancer.</p><p>The three missense variants found in the patients result in the following amino acid substitutions: His380Arg, Asp1019Gly, and Asp1165Gly. PLCG1 (and the closely related PLCG2) have a single Drosophila ortholog called small wing (sl). sl-null flies are viable but have small wings with ectopic wing veins and supernumerary photoreceptors in the eye. As all three amino acids affected in the patients are conserved in the fly protein, in this work Ma et al. tested whether they are pathogenic by expressing either reference or patient variant fly or human genes in Drosophila and determining the phenotypes produced by doing so.</p><p>Expression in Drosophila of the variant forms of PLCG1 found in these three patients is toxic; highly so for Asp1019Gly and Asp1165Gly, much more modestly for His380Arg. Another variant, Asp1165His which was identified in lymphoma samples and shown by others to be hyperactive, was also found to be toxic in the Drosophila assays. However, a final variant, Ser1021Phe, identified by others in an individual with severe immune dysregulation, produced no phenotype upon expression in flies.</p><p>Based on these results, the authors conclude that the PLCG1 variants found in patients are pathogenic, producing gain-of-function phenotypes through hyperactivity. In my view, the data supporting this conclusion are robust, despite the lack of a detectable phenotype with Ser1021Phe, and I have no concerns about the core experiments that comprise the paper.</p><p>Fig. 6, the last in the paper, provides information about PLCG1 structure and how the different variants would affect it. It shows that His380, Asp1019 and Asp1165 all lie within catalytic domains or intramolecular interfaces, and that variants in the latter two affect residues essential for autoinhibition. It also shows that Ser1021 falls outside the key interface occupied by Asp1019, but more could have been said about the potential effects of Ser1021Phe.</p><p>Overall, I believe the authors fully achieved the aims of their study. The work will have a substantial impact because it reports the identification of novel disease-linked genes, and because it further demonstrates the high value of the Drosophila model for finding and understanding gene-disease linkages.</p><p>Comments on revisions:</p><p>The single recommendation I made on the original version, which was to further examine H380 mutants, has been satisfactorily addressed in the revised version.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95887.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Mengqi</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Yiming</given-names></name><role specific-use="author">Author</role><aff><institution>Xiamen University</institution><addr-line><named-content content-type="city">Xiamen</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Mingxi</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Shenzhao</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Xueyang</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Xi</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Etoundi</surname><given-names>Michelle</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Li-Kroeger</surname><given-names>David</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Worley</surname><given-names>Kim C</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Burrage</surname><given-names>Lindsay C</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Blieden</surname><given-names>Lauren S</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Allworth</surname><given-names>Aimee</given-names></name><role specific-use="author">Author</role><aff><institution>Invitae Corporation</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Wei-Liang</given-names></name><role specific-use="author">Author</role><aff><institution>Children's National Medical Center and George Washington University</institution><addr-line><named-content content-type="city">Washington DC</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Merla</surname><given-names>Giuseppe</given-names></name><role specific-use="author">Author</role><aff><institution>University of Naples Federico II</institution><addr-line><named-content content-type="city">Foggia</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Mandriani</surname><given-names>Barbara</given-names></name><role specific-use="author">Author</role><aff><institution>University of Bari &quot;Aldo Moro&quot;</institution><addr-line><named-content content-type="city">Bari</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Otten</surname><given-names>Catherine E</given-names></name><role specific-use="author">Author</role><aff><institution>University of Washington and Seattle Children's Hospital Seattle</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Blanc</surname><given-names>Pierre</given-names></name><role specific-use="author">Author</role><aff><institution>10. SeqOIA Genomics Platform, Assistance Publique-Hôpitaux de Paris (AP-HP)</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Rosenfeld</surname><given-names>Jill A</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Dutta</surname><given-names>Debdeep</given-names></name><role specific-use="author">Author</role><aff><institution>Indian Institute of Technology Kanpur</institution><addr-line><named-content content-type="city">Kanpur</named-content></addr-line><country>India</country></aff></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Shinya</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wangler</surname><given-names>Michael</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Glass</surname><given-names>Ian A</given-names></name><role specific-use="author">Author</role><aff><institution>University of Washington</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jingheng</given-names></name><role specific-use="author">Author</role><aff><institution>University of Washington School of Medicine</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Blue</surname><given-names>Elizabeth</given-names></name><role specific-use="author">Author</role><aff><institution>University of Washington</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Prontera</surname><given-names>Paolo</given-names></name><role specific-use="author">Author</role><aff><institution>Medical Genetics Unit, Hospital of Perugia</institution><addr-line><named-content content-type="city">Perugia</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Rosain</surname><given-names>Jeremie</given-names></name><role specific-use="author">Author</role><aff><institution>Necker Hospital for Sick Children</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Marlin</surname><given-names>Sandrine</given-names></name><role specific-use="author">Author</role><aff><institution>Necker-Enfants Malades Hospital</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Lalani</surname><given-names>Seema R</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Bellen</surname><given-names>Hugo J</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>This manuscript provides an initial characterization of three new missense variants of the PLCG1 gene associated with diverse disease phenotypes, utilizing a Drosophila model to investigate their molecular effects in vivo. Through the meticulous creation of genetic tools, the study assesses the small wing (sl) phenotype - the fly's ortholog of PLCG1 - across an array of phenotypes from longevity to behavior in both sl null mutants and variants. The findings indicate that the Drosophila PLCG1 ortholog displays aberrant functions. Notably, it is demonstrated that overexpression of both human and Drosophila PLCG1 variants in fly tissue leads to toxicity, underscoring their pathogenic potential in vivo.</p><p>Strengths:</p><p>The research effectively highlights the physiological significance of sl in Drosophila. In addition, the study establishes the in vivo toxicity of disease-associated variants of both human PLCG1 and Drosophila sl.</p><p>Weaknesses:</p><p>The study's limitations include the human PLCG1 transgene's inability to compensate for the Drosophila sl null mutant phenotype, suggesting potential functional divergence between the species. This discrepancy signals the need for additional exploration into the mechanistic nuances of PLCG1 variant pathogenesis, especially regarding their gain-of-function effects in vivo.</p><p>Overall:</p><p>The study offers compelling evidence for the pathogenicity of newly discovered disease-related PLCG1 variants, manifesting as toxicity in a Drosophila in vivo model, which substantiates the main claim by the authors. Nevertheless, a deeper inquiry into the specific in vivo mechanisms driving the toxicity caused by these variants in Drosophila could significantly enhance the study's impact.</p><p><bold>Reviewer #2 (Public Review):</bold></p><p>The manuscript by Ma et al. reports the identification of three unrelated people who are heterozygous for de novo missense variants in PLCG1, which encodes phospholipase C-gamma 1, a key signaling protein. These individuals present with partially overlapping phenotypes including hearing loss, ocular pathology, cardiac defects, abnormal brain imaging results, and immune defects. None of the patients present with all of the above phenotypes. PLCG1 has also been implicated as a possible driver for cell proliferation in cancer.</p><p>The three missense variants found in the patients result in the following amino acid substitutions: His380Arg, Asp1019Gly, and Asp1165Gly. PLCG1 (and the closely related PLCG2) have a single Drosophila ortholog called small wing (sl). sl-null flies are viable but have small wings with ectopic wing veins and supernumerary photoreceptors in the eye. As all three amino acids affected in the patients are conserved in the fly protein, in this work Ma et al. tested whether they are pathogenic by expressing either reference or patient variant fly or human genes in Drosophila and determining the phenotypes produced by doing so.</p><p>Expression in Drosophila of the variant forms of PLCG1 found in these three patients is toxic; highly so for Asp1019Gly and Asp1165Gly, much more modestly for His380Arg. Another variant, Asp1165His which was identified in lymphoma samples and shown by others to be hyperactive, was also found to be toxic in the Drosophila assays. However, a final variant, Ser1021Phe, identified by others in an individual with severe immune dysregulation, produced no phenotype upon expression in flies.</p><p>Based on these results, the authors conclude that the PLCG1 variants found in patients are pathogenic, producing gain-of-function phenotypes through hyperactivity. In my view, the data supporting this conclusion are robust, despite the lack of a detectable phenotype with Ser1021Phe, and I have no concerns about the core experiments that comprise the paper.</p><p>Figure 6, the last in the paper, provides information about PLCG1 structure and how the different variants would affect it. It shows that the His380, Asp1019, and Asp1165 all lie within catalytic domains or intramolecular interfaces and that variants in the latter two affect residues essential for autoinhibition. It also shows that Ser1021 falls outside the key interface occupied by Asp1019, but more could have been said about the potential effects of Ser1021Phe.</p><p>Overall, I believe the authors fully achieved the aims of their study. The work will have a substantial impact because it reports the identification of novel disease-linked genes, and because it further demonstrates the high value of the Drosophila model for finding and understanding gene-disease linkages.</p><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>The paper attempts to model the functional significance of variants of PLCG2 in a set of patients with variable clinical manifestations.</p><p>Strengths:</p><p>A study attempting to use the Drosophila system to test the function of variants reported from human patients.</p><p>Weaknesses:</p><p>Additional experiments are needed to shore up the claims in the paper. These are listed below.</p><p>Major Comments:</p><p>(1) Does the pLI/ missense constraint Z score prediction algorithm take into consideration whether the gene exhibits monoallelic or biallelic expression?</p></disp-quote><p>To our knowledge, pLI and missense Z don't consider monoallelic or biallelic expression. Instead, they reflect sequence constraint and are calculated based on the observed versus expected variant frequencies in population databases.</p><disp-quote content-type="editor-comment"><p>(2) Figure 1B: Include human PLCG2 in the alignment that displays the species-wide conserved variant residues.</p></disp-quote><p>We have updated Figure 1B and incorporated the alignment of PLCG2.</p><disp-quote content-type="editor-comment"><p>(3) Figure 4A:</p><p>Given that</p><p>(i) sl is predicted to be the fly ortholog for both mammalian PLCγ isozymes: PLCG1 and PLCG2 [Line 62]</p><p>(ii) they are shown to have non-redundant roles in mammals [Line 71]</p><p>(iii) reconstituting PLCG1 is highly toxic in flies, leading to increased lethality.</p><p>This raises questions about whether sl mutant phenotypes are specifically caused by the absence of PLCG1 or PLCG2 functions in flies. Can hPLCG2 reconstitution in sl mutants be used as a negative control to rule out the possibility of the same?</p></disp-quote><p>The studies about the non-redundant roles of PLCG1 and PLCG2 mainly concern the immune system.</p><p>We have assessed the phenotypes in the <italic>sl<sup>T2A</sup>/Y; UAS-hPLCG2</italic> flies. Expression of human PLCG2 in flies is also toxic and leads to severely reduced eclosion rate.</p><p>We have updated the manuscript with these results, and included the eclosion rate of <italic>sl<sup>T2A</sup>/Y; UAS-hPLCG2</italic> flies in the new Figure 4B.</p><disp-quote content-type="editor-comment"><p>(4) Do slT2A/Y; UAS-PLCG1Reference flies survive when grown at 22{degree sign}C? Since transgenic fly expressing PLCG1 cDNA when driven under ubiquitous gal4s, Tubulin and Da, can result in viable progeny at 22{degree sign}C, the survival of slT2A/Y; UAS-PLCG1Reference should be possible.</p></disp-quote><p>The eclosion rate of <italic>sl<sup>T2A</sup>/Y &gt;PLCG1<sup>Reference</sup></italic> flies at 22°C is slightly higher than at 25°C, but remains severely reduced compared to the UAS-Empty control. We have presented these results in the updated Figure 4 - figure supplement 2.</p><disp-quote content-type="editor-comment"><p>and similarly</p><p>Does slT2A flies exhibit the phenotypes of (i) reduced eclosion rate (ii) reduced wing size and ectopic wing veins and (iii) extra R7 photoreceptor in the fly eye at 22{degree sign}C?</p></disp-quote><p>The mutant phenotypes are still observed at 22 °C.</p><disp-quote content-type="editor-comment"><p>If so, will it be possible to get a complete rescue of the slT2A mutant phenotypes with the hPLCG1 cDNA at 22{degree sign}C? This dataset is essential to establish Drosophila as an ideal model to study the PLCG1 de novo variants.</p></disp-quote><p>Thank you for the suggestion. It is difficult to directly assess the rescue ability of the <italic>PLCG1</italic> cDNAs due to the toxicity. However, our ectopic expression assays show that the variants are more toxic than the reference with variable severities, suggesting that the variants are deleterious.</p><p>The ectopic expression strategy has been used to evaluate the consequence of genetic variants and has significantly contributed to the interpretation of their pathogenicity in many cases (reviewed in Her et al., Genome, 2024, PMID: 38412472).</p><disp-quote content-type="editor-comment"><p>(5) Localisation and western blot assays to check if the introduction of the de novo mutations can have an impact on the sub-cellular targeting of the protein or protein stability respectively.</p></disp-quote><p>Thank you for the suggestion.</p><p>We expressed <italic>PLCG1</italic> cDNAs in the larval salivary glands and performed antibody staining (rabbit anti-Human PLCG1; 1:100, Cell Signaling Technology, #5690). The larval salivary gland are composed of large columnar epithelia cells that are ideal for analyzing subcellular localization of proteins. The PLCG1 proteins are cytoplasmic and localize near the cell surface, with some enrichment in the plasma membrane region. The variant proteins are detected, and did not show significant difference in expression level or subcellular distribution compared to the reference. We did not include this data.</p><disp-quote content-type="editor-comment"><p>(6) Analysing the nature of the reported gain of function (experimental proof for the same is missing in the manuscript) variants:</p><p>Instead of directly showing the effect of introducing the de novo variant transgenes in the Drosophila model especially when the full-length PLCG1 is not able to completely rescue the slT2A phenotype;</p><p>(i) Show that the gain-of-function variants can have an impact on the protein function or signalling via one of the three signalling outputs in the mammalian cell culture system: (i) inositol-1,4,5-trisphosphate production, (ii) intracellular Ca2+ release or (iii) increased phosphorylation of extracellular signal-related kinase, p65, and p38.</p></disp-quote><p>We appreciate the reviewer’s suggestion. We utilized the CaLexA (calcium-dependent nuclear import of LexA) system (Masuyama et al., J Neurogenet, 2012, PMID: 22236090) to assess the intracellular Ca<sup>2+</sup> change associated with the expression of PLCG1 cDNAs in fly wing discs. The results show that, compared to the reference, expression of the D1019G or D1165G variants leads to elevated intracellular Ca<sup>2+</sup> levels, similar to the hyperactive S1021F and D1165H variants. However, the H380R or L597F variants did not show a detectable phenotype in this assay. These results suggest that D1019G and D1165G are hyperactive variants, whereas H380R and L597F variant are not, or their effect is too mild to be detected in this assay. We have updated the related sections in the manuscript and Figures 5A and Figure 5 - figure supplement 1.</p><disp-quote content-type="editor-comment"><p>OR</p><p>(ii) Run a molecular simulation to demonstrate how the protein's auto-inhibited state can be disrupted and basal lipase activity increased by introducing D1019G and D1165G, which destabilise the association between the C2 and cSH2 domains. The H380R variant may also exhibit characteristics similar to the previously documented H335A mutation which leaves the protein catalytically inactive as the residue is important to coordinate the incoming water molecule required for PIP2 hydrolysis.</p></disp-quote><p>We utilized the DDMut platform, which predicts changes in the Gibbs Free Energy (ΔΔG) upon single and multiple point mutations (Zhou et al., Nucleic Acid Res, 2023, PMID: 37283042), to gain insight into the molecular dynamics changes of variants. The results are now presented in Figure S7.</p><p>Additionally, we performed Molecular dynamics (MD) simulations. The results show that, similar to the hyperactive D1165H variant, the D1019G and D1165G variants exhibit increased disorganization, with a higher root mean square deviations (RMSD) compared to the reference PLCG1. The data are also presented in the updated Figure 6 figure supplement 1.</p><disp-quote content-type="editor-comment"><p>(7) Clarify the reason for carrying out the wing-specific and eye-specific experiments using nub-gal4 and eyless-gal4 at 29°C despite the high gal4 toxicity at this temperature.</p></disp-quote><p>We used high temperature and high expression level to see if the mild H380R and L597F variants could show phenotypes in this condition.</p><p>The toxicity of the two strong variants (D1019G and D1165G) has been consistently confirmed in multiple assays at different temperatures.</p><disp-quote content-type="editor-comment"><p>(8) For the sake of completeness the authors should also report other variants identified in the genomes of these patients that could also contribute to the clinical features.</p></disp-quote><p>Thank you!</p><p>The additional variants and their potential contributions to the clinical features are listed and discussed in Table 1 and its legend.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>The manuscript's significant contribution is tempered by a lack of comprehensive analysis using the generated genetic reagents in Drosophila. To enhance our understanding of the PLCG1 orthologs, I suggest the following:</p><p>(1) A more detailed molecular analysis to distinguish the actions of sl variants from the wild-type could be very informative. For example, utilizing the HA-epitope tag within the current UAS-transgenes could reveal more about the cellular dynamics and abundance of these variants, potentially elucidating mechanisms beyond gain-of-function.</p></disp-quote><p>We appreciate the reviewer’s suggestion. The <italic>UAS-sl</italic> cDNA constructs contain stop codon and do not express an HA-epitope tag. Alternatively, we utilized commercially available antibodies against human PLCG1 antibodies to assess the subcellular localization and protein stability by expressing the reference and variant PLCG1 cDNAs in Drosophila larval salivary glands. The reference proteins are cytoplasmic with some enrichment along the plasma membrane. However, we did not observe significant differences between the reference and variant proteins in this assay. We did not include this data.</p><disp-quote content-type="editor-comment"><p>(2) I suggest further investigating the relative contributions of developmental processes and acute (Adult) effects on the sl-variant phenotypes observed. For example, employing systems that allow for precise temporal control of gene expression, such as the temperature-sensitive Gal80, could differentiate between these effects, shedding light on the mechanisms that affect longevity and locomotion. This knowledge would be vital for a deeper understanding of the corresponding human disorders and for developing therapeutic interventions.</p></disp-quote><p>We appreciate the reviewer’s suggestion. We utilized <italic>Tub-GAL4, Tub-GAL80ts</italic> to drive the expression of <italic>sl</italic> wild-type or variant cDNAs, and performed temperature shifts after eclosion to induce expression of the cDNAs only in adult flies. The <italic>sl<sup>D1184G</sup></italic> variant (corresponding to <italic>PLCG1<sup>D1165G</sup></italic>) caused severely reduced lifespan and the flies mostly die within 10 days. The <italic>sl<sup>D1041G</sup></italic> variant (corresponding to <italic>PLCG1<sup>D1019G</sup></italic>) led to reduced longevity and locomotion. The <italic>sl<sup>H384R</sup></italic> variant (corresponding to <italic>PLCG1<sup>H380R</sup></italic>) showed only a mild effect on longevity and no significant effect on climbing ability. These results suggest that the two strong variants (<italic>sl<sup>D1041G</sup></italic> and <italic>sl<sup>D1184G</sup></italic>) contribute to both developmental and acute effects while the H384R variant mainly contributes to developmental stages.</p><disp-quote content-type="editor-comment"><p>I also suggest a more refined analysis of overexpression toxicity. Rather than solely focusing on ubiquitous transgene expression, overexpressing transgene in endogenous pattern using sl-t2a-Gal4 may yield a more nuanced understanding of the pathogenic mechanisms of gain-of-function mutations, particularly in the pathogenesis associated with these variants exclusively located in the coding regions.</p></disp-quote><p>We appreciate the reviewer’s suggestion. We therefore performed the experiments using <italic>sl<sup>T2A</sup></italic> to drive overexpression of <italic>PLCG1</italic> cDNAs in heterozygous female progeny with one copy of wild-type <italic>sl+ (sl<sup>T2A</sup>/ yw &gt; UAS-cDNAs)</italic>. In this context, expression of <italic>PLCG1<sup>Reference</sup></italic>, <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic> is viable whereas expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> is lethal, suggesting that the <italic>PLCG1<sup>D1019G</sup></italic> and <italic>PLCG1<sup>D1165G</sup></italic> variants exert a strong dominant toxic effect while the <italic>PLCG1<sup>H380R</sup></italic> and <italic>PLCG1<sup>L597F</sup></italic> are comparatively milder. Similar patterns have been consistently observed in other ectopic expression assays with varying degrees of severity. These results are updated in the manuscript and figures.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>The work in the paper could be usefully extended by determining the effects of expressing His380Phe and His380Ala in flies. These variants suppress PLCG1 activity, so their phenotype, if any, would be predicted not to be the same as His380Arg. Determining this would add further strength to the conclusions of the paper.</p></disp-quote><p>We thank the reviewer for the constructive suggestions! We have tested the enzymatic-dead H380A variant, which still exhibits toxicity when expressed in <italic>sl<sup>T2A</sup>/Y</italic> hemizygous flies, but it is not toxic in heterozygous females suggesting that the reduced eclosion rate is likely not directly associated with enzymatic activity. We have updated the manuscript and figures accordingly.</p></body></sub-article></article>